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CHAPTER I

BACKGROUND

1.1.

Introduction
T lymphocytes are critical components of adaptive immunity that are found

only in the vertebrate family of organisms. They are characterized by the surface
expression of a multimeric protein complex, historically called the T3 complex is referred
to as the cluster of differentiation 3 (CD3). T cells are known for their role in providing
activation, proliferation, and differentiation signals to immune cells through the release of
a wide variety of cytokines, a class of small proteins that are important in cell signaling. Tcell-mediated responses are also known as cellular immunity or cell-mediated responses.
T cells offer antigen-specificity via a cell-surface dimeric protein called the T cell receptor
(TCR). Like the B-cell receptors (BCRs), TCRs also belong to the immunoglobulin
superfamily.
The T lymphocytes originate from the bone marrow and migrate to the thymus
to undergo maturation. While immature T cells express both the co-receptors, CD4 and
CD8, mature T cells express only one of them. The CD4 and CD8, respectively, recognize
the major histocompatibility complex (MHC) class II (MHC-II) and MHC-I proteins on
the host cells during T cell activation (Figure 1.1). While all nucleated cells express MHCI (Gütgemann et al. 2015), only the thymic epithelial cells (TECs) and antigen-presenting
cells (APCs) such as B cells, macrophages, and dendritic cells express MHC-II (Reith,
LeibundGut-Landmann, and Waldburger 2005). As a result, the CD8+ T cells can kill the
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infected cells by directly engaging with them. On the contrary, the CD4+ T cells cannot kill
the infected cells but secrete cytokines and aid in the growth and differentiation of many
other immune cell types, including T cells. Therefore, CD4+ T cells are also known as T
helper cells (Th), and CD8+ T cells as T cytotoxic cells (Tc).

Figure 1.1: The interaction between TCR and MHC-bound antigenic peptides in CD4+ and
CD8+ T cells. (Majumdar, Pathak, and Nandi 2018). Used with Permission.

Unlike B Lymphocytes, T cells do not directly bind to antigens. Instead, with
TCRs' help, the naïve T (TN) cells bind and recognize MHC-bound antigenic peptides
displayed on APCs (Figure 1.1). The formation of such a tertiary complex provides the
primary activation signal to the T cells. However, to activate fully, the T cells require an
additional signal. The ligation of costimulatory molecules on the surface of T cells with
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their counterparts on APCs provides the second activation signal. Such TCR-mediated
activation has profound effects on the behavior of T cells.
T cells secrete various cytokines after activation, undergo clonal expansion, and
differentiate into memory or effector T cells. Memory T cells have a longer lifespan than
does effector T cells. After the clearance of pathogen-infected cells, most effector T cells
get eliminated by an apoptotic pathway mediated by Fas (CD95) and Fas ligand (FasL or
CD95L), known as the activation-induced cell death (AICD). Memory T-cell responses
are more rapid and effective than the primary responses. The population size of these
memory T-cell clones is much larger than that of the original clone in the TN population,
usually between 100-1000 fold. The population size of these clones gets further expanded
when the memory cells are restimulated with a particular antigen and differentiate into
effector T cells.
TN cells express specific adhesion molecules and chemokine receptors that
govern their migration into a particular tissue. For example, TN cells are known to express
high levels of the lymph-node homing receptors, CD62L (L-selectin) (Mahnke et al. 2013;
Brinkman et al. 2013) and C-C Motif chemokine receptor (CCR7) (Brinkman et al. 2013).
A subset of memory cells called effector memory (TEM) cells downregulates L-selectin &
CCR7 while upregulating specific molecules that allow them to migrate to the peripheral
tissues. Hence, TEM cells are generally defined as CD62- CCR7- T cells.
Besides CD4+ and CD8+ T cells, a subset of T cells that do not express either
CD4 or CD8, referred to as double-negative (DN) T cells, exists. The DN T cells are a
small population in humans' peripheral blood and lymphoid organs (Juvet and Zhang
2012). Unlike most mature T cells whose TCR comprises  and  polypeptide chains, a
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subset of T cells uses the  and  polypeptide chains to form a TCR. This subset, called the

 T cells, is found at the mucosal epithelial sites and the skin. Another subset of T cells
called the NKT cells express a TCR, a natural killer cell marker (NK1.1), and other
molecules typical to NK cells. In the intestines' lamina propria, NKT cells recognize and
respond to the lipid and glycolipid antigens.
Naïve Th cells differentiate into various Th subsets based on the cytokine
stimulation they have received (Figure 1.2). For example, a naïve Th cell receiving
transforming growth factor-beta (TGF-) and Interleukin-2 (IL-2) together will
differentiate into a T regulatory (Treg) cell. However, if the naïve Th cell instead receives
IL-4 and TGF-, it differentiates into a T helper 9 (Th9) cell.
During the late 1980s, Mossman and Coffman helped distinguish different Th
clones based on their cytokine secretions. Since then, the Th1 cells have been characterized
by the secretion of Interferon-gamma (IFN-) and the tumor necrosis factor-alpha (TNF),
and Th2 cells by the secretion of IL-4, IL-5, and IL-13 (Berger 2000; Raphael et al. 2015;
Golubovskaya and Wu 2016). Consequently, Th1 and Th2 cells have unique roles in
mediating protection. Th1 cells are responsible for cell-mediated responses while the Th2
for humoral-mediated immunity. However, not too far in the future, after understanding
the dichotomy of Th1 and Th2 cells, researchers discovered new Th subsets (Figure 1.2),
which too are characterized based on their cytokine profile. For example, the Th17 cells
secrete IL-17, the Th9 cells produce IL-9, Th22 cells release IL-22, and the T follicular
helper cells (Tfh) secrete IL-21 (Raphael et al. 2015; Golubovskaya and Wu 2016). In
addition, the Tregs secrete and IL-10 (a cytokine with an immunosuppressive role) and
TGF- (Golubovskaya and Wu 2016).
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Figure 1.2: Subsets of CD4+ T Lymphocytes. (Golubovskaya and Wu 2016). Used with
Permission.
Upon interacting with the MHC-I-bound antigenic peptide, CD8+ T cells are
activated and become Cytotoxic T Lymphocytes (CTLs). CTLs can kill the target cells by
stimulating two apoptotic pathways. In the first pathway (believed to be the predominant
one) of killing target cells, CTLs release granular molecules called perforins which form
pores on the target cell membrane. Subsequently, CTLs release granzymes - a class of
serine proteases - which pass through the pores formed by the perforins and interact with
target cell components triggering apoptosis. In the second pathway, the interaction between
Fas protein expressed on the target cells and FasL expressed on the CTLs, activates
apoptosis in the target cells.
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1.2.

Scope and Aims
Tc cells or CD8+ T cells are crucial members of cell-mediated immunity. The

activated Tc cells i.e., the effector CTLs detect and eliminate the infected cells or cancer
cells. However, some cancer cells escape such recognition in what is known as Immune
Evasion. Cancer cells evade immunity by lowering their cell surface expression of MHCI protein, thereby rendering T-cells to remain unactivated (Labanieh, Majzner, and Mackall
2018). However, the surface antigens that are expressed by cancer cells can be recognized
by mature B-lymphocytes in an MHC-independent manner. This detection is possible due
to surface immunoglobulins, commonly known as BCRs. However, B cells cannot kill
cancer cells by themselves.

Figure 1.3: Structure and design of Chimeric Antigen Receptors (CARs). (A) Essential
components of CARs and (B) Developments in the design of CARs. “scFv” refers to singlechain variable fragment, “VH” and “VL” refers to the heavy-chain variable fragment and
the light-chain variable fragment of an antibody, respectively, “Fc” refers to the
Crystallizable fragment of an antibody, “ITAM” refers to the immunoreceptor tyrosinebased activation motif. (Chang and Chen 2017). Used with Permission.
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The inability of primary T-cells to be activated directly by MHC-Ilow cancer cells
and the ability of B-cells to recognize cancer cell’s surface antigens have led to the
development of Chimeric Antigen Receptors (CARs). CARs are fusion proteins comprising
well-defined functional domains – an antigen-binding ectodomain, a spacer arm,
transmembrane domain, and cytosolic signaling domain (Figure 1.3) (X. Liu, Zhang, and
Shi 2017; Chang and Chen 2017; Olden et al. 2018; Feldmann et al. 2019; Bloemberg et
al. 2020). In its first generation, CARs are composed of the antigen-specific single-chain
variable fragment (scFv), a transmembrane domain, and the cytoplasmic domain of
CD3 (Huang et al. 2017). The scFv functions as a BCR on B-cell while the cytoplasmic
domain transmits an activation signal to T-cell upon antigen recognition by scFv (Ren and
Zhao 2017). To make the CARs more effective, a second-generation CAR protein was
developed by including either of the cytoplasmic domains of T-cell costimulatory proteins
- CD28 and 4-1BB (CD137) (Rupp et al. 2017; Huang et al. 2017). Currently, thirdgeneration CARs are available that contain an additional cytoplasmic domain from either
of the costimulatory proteins - Inducible T-cell COStimulator (ICOS or CD278) or a tumor
necrosis factor receptor superfamily member 4 (TNFRSF4 or OX40 or CD134) (Feldmann
et al. 2019; Benmebarek et al. 2019).
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Figure 1.4: Methods in adoptive T cell therapy. (a) Tumor-infiltrating lymphocytes (TILs)
and (b) Engineering of tumor non-responsive T cells. (Schaar et al. 2019). Used with
Permission.

T lymphocytes are routinely used in cancer immunotherapy. In adoptive T cell
therapy (Figure 1.4), tumor-infiltrating lymphocytes (TILs) are taken from the patient’s
tumor microenvironment and tested whether they contain any T cells reactive to the tumor.
If no T cells are reacting to the tumor cells, they are engineered with transgenes encoding
either a tumor antigen-specific CAR or a processed antigen-specific TCR. The tumorreactive T cells (Figure 1.4a) or the engineered T cells (Figure 1.4b) are expanded in vitro
and then are infused into the patient.
Genetic engineering of T-cells with CAR transgenes is a highly sought-after
endeavor in T-cell immunotherapy. The CAR-T cell therapy has already achieved
remarkable success in the field of cancer immunotherapy due to the promising clinical
outcomes that were observed in the case of the hematological malignancies, which led to
the approval of KymriahTM and YescartaTM by the food and drug administration (FDA) for
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Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (R/R ALL) in pediatric &
young adults and adult patients with Large B cell Lymphoma, respectively (Dwivedi et al.
2019).
Currently, the introduction of transgenes into T cells is carried out by the viral
transductions using either the lentiviruses or the adenoviruses. However, viral
transductions have several disadvantages or limitations. These include limitations in the
size of nucleic acids to package, unwanted immune responses, immune clearance of the
viral formulations, safety concerns, high manufacturing costs, and most importantly the in
vivo incompatibility due to off-targeting issues. Therefore, the use and development of nonviral vectors are being investigated for transfections. Non-viral vectors such as
Polyethyleneimine (PEI) and Poly(L-Lysine) (PLL) are excellent choices for the
complexation of nucleic acids as they do not display any size limitations. Besides, they are
reported to be biocompatible and display low immune recognition. Nevertheless, these
carriers need functionalization to be used specifically for T cell transfections.
Our general goal is to develop methods to engineer and functionally modulate
the T cells for immune therapy. For this, we have asked a few biological questions each
having a separate hypothesis and/or motivation. T cell-specific transfections can be
achieved by functionalizing the nucleic acid complexes with T-cell-specific receptor
ligands. T cell-specific receptors such as CD3 have previously been targeted. However,
significant transfection efficiencies have not been achieved via the CD3 although stable
genomic integration of the transgene was achieved. Therefore, we intend to target the
Interleukin-2 (IL-2) receptor (IL-2R) which would allow us to predominantly deliver
transgenes to activated T cells and Tregs and also to verify whether the IL-2R can offer
higher transfection efficiencies.
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Functionalizing the cationic polymer and nucleic acid complexes (polyplexes)
with IL-2 is an attractive strategy to achieve T-cell transfections (Chapter V) via the IL-2R
as the naïve T cells do not express significant amounts of the IL-2R subunits. To
systematically study whether the IL-2R can be targeted for T cell-specific transfections,
first, we must understand the endocytic abilities of the IL-2R (Chapter IV). A previous
scientific report had shown the successful targeting of the IL-2R and delivered
nanocapsules of hydrodynamic size ~ 215 nm to activated human T cells (Frick et al. 2016).
In our study, we hypothesized that the IL-2-functionalized nanomaterials would be
endocytosed by the activated T cells up to a certain core-size limit. To verify this
hypothesis, we have functionalized the iron-oxide nanoparticles of different core sizes (50,
100, and 200 nm) with IL-2 and tested them on the activated T cells (Chapter IV).
Second, non-specific bioconjugation techniques used in the functionalization of
IL-2 may result in inconsistent transfection or delivery efficiencies. Therefore, site-specific
bioconjugation techniques must be used or developed to conjugate IL-2 and polymer of
interest or any other foreign material to properly evaluate the potency of the developed
formulation to transfect or deliver cargo to T cells via the IL-2R. In this motivation-driven
study (Chapter III), we aim to express and produce a mouse IL-2 molecule with an Nterminal Cysteine to allow the site-specific bioconjugation of sulfhydryl-reactive foreign
materials. This work is of critical importance because there are no commercially available
Cysteine-accessible IL-2 molecules for site-specific bioconjugation studies. Besides,
although a C-terminally biotinylated IL-2 is commercially available, the bioconjugation
strategy cannot be used in all designs, specifically due to the addition of streptavidin as an
adapter molecule whose involvement could change the physicochemical or transfection
properties of the reagent.
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Third, due to the heavy dependence on the ability of a polymer such as PEI to
carry the nucleic acids to T cells, one must understand their dynamics in transfections. It is
widely known in the field of genetic engineering that T cells are hard-to-transfect.
Therefore, enhancement of transfection efficiency in T cells, in general, is a necessity
(Chapter II). It is known that calcium chloride as an additive (Lam and Cullis 2000; S.-X.
Xie et al. 2018) and calcium phosphate in the form of nucleic acid particles (Ying Xie et
al. 2014) can enhance the transfection efficiency and be directly used as a transfection
reagent respectively. Fortunately, since calcium is not a cell-type-specific reagent and
appears to have a ubiquitous role in transfections, we hypothesized that the addition of
calcium chloride to the culture medium during the PEI-mediated transfections would
enhance the transfection potency in a model T cell line – Jurkat (Chapter II). To access the
transfection efficiency, we would be using a Green Fluorescent Protein (GFP)-expression
plasmid.
Lastly, It is of high importance in the field of T cell therapy that the in vitro
maintenance, optimization, and potency evaluation of engineered T cells is achieved
(Chapter VI). Therefore, the generation of cheaper synthetic tools such as acellular antigenpresenting cells is needed as natural APCs derived from the patient are difficult to maintain
in vitro. We developed a method to coat the superparamagnetic iron-oxide microparticles
of size 2.8 micron mimicking the size of a smaller APC with antigens available on HER2positive cancer cells (Chapter VI). These artificial APCs would be used in the optimization
of the activation levels and to evaluate the potency of HER2-specific CAR-expressing T
cells.
These studies collectively would be useful in the design and development of
engineering and functional modulations in the field of T cell therapy.
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CHAPTER II

ENHANCEMENT OF TRANSFECTION EFFICIENCY IN T LYMPHOCYTES
USING CALCIUM CHLORIDE IN POLYETHYLENEIMINE-MEDIATED
TRANSFECTIONS
Contents of this chapter (significance to conclusion) are derived from the publication
DOI: 10.1080/10717544.2020.1770371 (Authors: V. S. S. Abhinav Ayyadevara, Kyung-Ho Roh)

2.1.

Background and Significance

2.1.1.

Gene Transfer: Techniques and Limitations
The introduction of exogenous nucleic acids into target cells has many implications.

Exogenous genes encode either naturally absent proteins in the target cell or an engineered
(mutated) form of a host protein. On the other hand, an exogenous siRNA pool can
translationally silence the host’s gene expression. Over the last three decades, gene transfer
technology has improved dramatically with the advent of polymerase chain reaction (PCR)
by Kary Mullis. There are three mainstream methods by which gene transfers can be
achieved. In transduction, viral particles are used for the delivery and expression of
transgenes. In electroporation, host cells are subjected to high-voltage electrical shocks to
form pores on the cell membrane through which the nucleic acids enter the cells (Potter
2003). In the third, called transfection, non-viral vectors introduce exogenous genes into
host cells (Kim and Eberwine 2010). In transduction, nucleic acids are packaged into an
attenuated viral particle. In contrast, they are packaged into either a polyplex or a lipoplex
in transfection using cationic polymers or cationic liposomes, respectively. Interestingly,
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in electroporation, naked DNA can be introduced directly into the host cell (Shi et al.
2018b).
In transduction, all viral genomes are modified by deleting some areas of the genes
responsible for replication. However, other potentially harmful effects of transduction still
exist. These include marked immunogenicity, toxin production, insertional mutagenesis,
and limitation in the size of the nucleic acids to be packaged (Nayerossadat, Ali, and
Maedeh 2012).
Electroporation, also known as electropermeabilization, is defined as the transient
loss of semi-permeability of plasma membrane due to the supply of electrical pulses, and
thus - according to Tsong - leads to “ion leakage, escape of metabolites, and increased
uptake by cells of drugs, molecular probes, and DNA” (Tsong 1991; Shi et al. 2018a). This
seemingly simple physical method of nucleic acid delivery has limitations, such as
irreversible damage to plasma membranes leading to cell death and ineffectiveness on
some cell types.
2.1.2.

Transfection
Due to many disadvantages and safety concerns working with electroporation and

transduction strategies, many researchers have long been focused on improving the
transfection methods using non-viral vectors. Polyplexes or lipoplexes form by
electrostatic interactions between the negatively charged nucleic acids and positively
charged polymers or liposomes, respectively (Figure 2.1).
Transfection, in general, could be divided into a few consecutive steps (Figure 2.1);
i) Endocytosis: the polyplex/lipoplexes must bind to the cell membrane to be internalized
by the cells; ii) Endosomal escape: the polyplexes/lipoplexes need to escape the
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endolysosome (acidic compartments) before they are degraded; iii) Disassembly: the
nucleic acids need to be separated from the cationic polymers/liposomes; iv)
Translocation: the nucleic acids must migrate into the nucleus; and finally v) Expression:
transcription of exogenous DNA and translation of mRNA transcripts encoding a proteinof-interest.

Figure 2.1: Basic mechanism of transfection via cationic polymers and liposomes. (Wu et
al. 2018). Used with Permission.

Various internalization routes, such as the clathrin-dependent pathway, caveolaemediated pathway, micropinocytosis, or a combination of these are involved in the
endocytosis of polyplexes (Ingle, Xue, and Reineke 2013; Rejman, Bragonzi, and Conese
2005; Z. ur Rehman et al. 2012; Reilly, Larsen, and Sullivan 2012). Few of these pathways
are reported to display an upper particle size limit of ~ 200 nm for effective internalization
(Pandey and Sawant 2016).
14

Figure 2.2: Mechanism of the polyplex escape out of the endolysosome explained in three
steps. (Bus, Traeger, and Schubert 2018). Used with Permission.

Perhaps the most critical step after the intracellular entry, the endosomal escape of
polyplexes or nucleic acids, is an absolute necessity for expressing protein-of-interest. It is
widely believed that polycations such as PEI can aid in such escape in what is known as
the “proton-sponge” effect (Figure 2.2). Due to the fusion of endosome and lysosome and
the eventual decrease in the pH to an acidic environment, the activity of H-ATPase triggers
the protonation of amines (Figure 2.2a) in PEI. At the same time, the abundant inflow of
protons generates an influx of water molecules besides calcium counter ions to neutralize
the charges (Figure 2.2b), ultimately leading to the endosomal rupture (Figure 2.2c) (Akinc
et al. 2005; Benjaminsen et al. 2013; Z. U. Rehman, Hoekstra, and Zuhorn 2013; Klauber
et al. 2016).
The pDNA that escapes the endosome remains in the cytoplasm until the cell
undergoes division, during which they enter the nucleus and begin expressing the
exogenous gene. However, alternatively, transcription factors that contain the nuclear
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localization signals (NLS, an amino acid sequence) electrostatically bind to specific
sequences on pDNA and help in the nuclear import (Vacik et al. 1999; Zanta, BelguiseValladier, and Behr 1999). In support, the NLS peptide - PKKKRKVEDPYC was reported
to enhance the transgene expression from 10- to 1000-folds when the transgene tagged with
a single NLS peptide is delivered into target cells (Zanta, Belguise-Valladier, and Behr
1999). Furthermore, a recent study reported using a microtubule-associated sequence
(MTAS) and NLS in functionalizing the polymer to promote rapid nuclear entry of
complexed DNA via the microtubule transport machinery (T. T. Smith et al. 2017b).
Therefore, the use of NLS and MTAS is of great importance, particularly when transfecting
cells that grow and replicate slowly.

Figure 2.3: A comparative representation of Stable (a) vs. transient (b) gene expression.
(Kim and Eberwine 2010). Used with Permission.
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In the transient expression system (Figure 2.3b), the transgene expression
diminishes as the cells divide (Wang et al. 2016) because non-viral plasmids do not
replicate in mammalian cells and thus seem to be eliminated in subsequent cell cycles.
Therefore, stable expression (Figure 2.3a) of transgenes is desired and can be achieved
either by stably integrating the transgene into the genomic DNA or using a replicating
plasmid DNA (pDNA).
Fortunately, it is reported that a non-viral plasmid containing the binding sites for
Epstein-Barr Virus (EBV) nuclear antigen-1 protein (EBNA1) enhances the retention of
pDNA in mammalian cells that expresses EBNA1 (Middleton and Sugden 1994).
Currently, in line with the same principle, we have replicating plasmid vectors known as
Episomal Expression Vectors (EEV) from System Biosciences, Inc. EEVs include the
origin of replication from EBV (oriP-EBNA1) and the gene that encodes EBNA1.
2.1.3. Significance
While there has been some progress in transfecting a human T cell line - Jurkat, the
25 kDa bPEI is observed to be ineffective in transfecting primary T cells without
alterations. Polycations such as PEI, PLL, and PDMAEMA are efficient carriers of nucleic
acids, yet they are ineffective in transfecting certain cell types. Therefore, in recent times,
many researchers have been focusing on the enhancers of transfection. It is known that the
lysosomotropic agent chloroquine has been an enhancer of polycation-mediated
transfections (Erbacher et al. 1996; Wolfert and Seymour 1998).
In a different line of function, many divalent cations such as Ca2+, Mg2+, Mn2+, and
Ba2+ have been demonstrated to have major roles in transfections (Kulkarni et al. 2006). It
is known that the phosphate-binding molecules stabilize the DNA’s double-helical
structure (Zhou, Saran, and Liu 2017) while the base-binding molecules destabilize them
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(Eichhorn, Butzow, and Shin 1985). This is because the negative charges of phosphates are
masked and therefore repulsions between the DNA molecules are prevented. On the other
hand, base-binders compete with the hydrogens in the hydrogen bonds for the electron
donor sites on the nucleobases (Eichhorn, Butzow, and Shin 1985). Therefore, the
transfection methods involving these metal ions rely heavily on their nature to form ionic
complexes with the phosphate backbone and thereby impart stability to DNA structures
(Kulkarni et al. 2006). The simple addition of calcium in the form of calcium chloride to
the stabilized plasmid-lipid particles (SPLP) in culture media enhanced the transfection
potency up to 60- to 100-folds in BHK cells (Sandhu et al. 2005). In addition, calcium
phosphate with or without viral and non-viral vectors displayed a positive effect on gene
delivery when it is used in a colloidal particulate system (Kulkarni et al. 2006). Calcium
chloride has been reported to be a potential enhancer of transfection when plasmid DNA
(pDNA) was delivered using low molecular weight PEI (800 Da) or PLL in A549 - human
lung carcinoma cell line (S.-X. Xie et al. 2018). In this study, calcium chloride was used
during DNA complexation. Interestingly, in this study, the high molecular weight 25 kDa
PEI did not enhance the transfection efficiency.
Calcium is known to play an important role in endocytosis (Kulkarni et al. 2006).
Due to its excellent biocompatibility and having a high binding affinity with a variety of
molecules, calcium phosphate is used in the manufacture of various forms of implants, and
as a delivery vehicle for various proteins (Kulkarni et al. 2006). Most importantly, calcium
in the form of calcium phosphate and plasmid particles can help in the endosomal escape
of nucleic acids as it displays acid sensitivity (Ying Xie et al. 2014). This could particularly
enhance the PEI-based transfections as the endosomal escape can be aided not only by the
PEI-driven proton-sponge effect but also by calcium. It is also reported that excessive
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calcium in calcium phosphate particles in the cytoplasm can assist the nuclear entry of
DNA through nuclear pore complexes (Ying Xie et al. 2014). However, none of these
enhancers have been reported to significantly enhance the potency of non-viral vectormediated transfections in T cells. Therefore, we intended to test different candidate
enhancers of polycation-mediated transfections in T cells. However, out of the candidate
enhancers, we intended to first delineate the enhancing capability of CaCl2 in PEI-mediated
T cell transfection. For this, we chose a model T cell, Jurkat – a human leukemia T cell
line, and a 25 kDa PEI as a pDNA carrier. Our study is significantly different from others
in mainly three factors. One, 25 kDa PEI-based DNA complexes have not been reported to
enhance transfection in the presence of calcium. Second, we simply add calcium chloride
to the culture media just before plating the transfection samples while other studies have
either used the reagent while preparing DNA complexes or directly to the prepared
complexes. Third, increase in the transfection efficiency in Jurkat using PEI-based
formulation has not been previously reported.
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2.2. Materials and Methods
2.1.4.

Materials
Potassium phosphate (KH2PO4), magnesium chloride (MgCl2) (EMD Millipore

Corp), potassium chloride (KCl), calcium chloride (CaCl2), dibasic sodium phosphate
(Na2HPO4), sodium chloride (NaCl), 25 kDa branched PEI (Sigma-Aldrich), 4%
Paraformaldehyde (PFA) (ThermoFisher Scientific), and 1M HEPES solution (Fisher
Scientific), and the restriction enzymes – HindIII-HF, SalI-HF, XhoI, SacI-HF, BglII, and
BamHI (NewEngland Biolabs) were used as purchased from manufacturers.
2.1.5.

Buffers
1X Phosphate buffered saline or PBS (137 mM NaCl, 1 mM CaCl2, 10 mM

Na2HPO4, 2.7 mM KCl, 1.8 mM KH2PO4, and 0.5 mM MgCl2, pH 7.4) was prepared in
sterile water. 1X HEPES buffered saline, or HBS (30 mM HEPES, 150 mM NaCl, pH 7.5),
was prepared in sterile water.
2.1.6.

Plasmids
pDNA expressing the Green Fluorescent Protein (GFP) (pAcGFP1-N3, hereafter

“pGFP”) was initially purchased from Clontech Laboratories, Inc. pDNA expressing a
Gaussia luciferase enzyme (pCMV-Gaussia-Dura-Luc, hereafter “pLuc”) was purchased
from Thermo Scientific. pUC18 - a control plasmid for general bacterial transformations was purchased was Agilent Technologies, Inc. The plasmids - pGFP, pLuc, and pUC18
were separately amplified in an overnight culture of transformed XL1-Blue competent cells
(Agilent Technologies, Inc.) in Luria-Bertani (LB) media and were later isolated using
GeneJET Plasmid Maxiprep Kit (Thermo Scientific). The extracted plasmids were
subjected to quality tests using spectrophotometry and agarose gel electrophoresis (Figure
2.4). The A260/280 (a purity indicator) of the extracted plasmids was within 1.8 and 2.0.
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2.1.7.

CD19 CAR-encoding pDNA (pCAR) amplification
An agar stab of NEB Stable strain of E. Coli supplied by Addgene, Inc. was used to

grow overnight in an 8 mL LB media containing 50 g/mL of tetracycline. Then, the 8 mL
culture was used for a miniprep plasmid extraction kit (Thermo Scientific). Following the
manufacturer’s protocol, pCAR was isolated and checked in agarose gel.
2.1.8.

Primer Reconstitution
Lyophilized primers (Eurofins Genomics, LLC) were dissolved in 10 X TE buffer

(100 mM Tris and 1 mM EDTA), aliquots of 5 M were made for each primer in which
the buffer was diluted to 0.5 X TE buffer and stored in -20 0C until further use.
2.1.9.

Restriction Digestions
Before performing any double digestion reactions, the compatibility of buffers and

restriction enzymes in a single reaction was verified on the NEB Cloner webtool. The
HindIII and SalI digestions were performed separately or together (compatible with each
other in a single reaction) in a thermal cycler using a program comprising 37 0C for 30
minutes, 80 0C for 20 minutes, and hold at 4 0C. Briefly, 500 ng of pDNA was digested
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with 10 units of HindIII and/or 10 units of SalI in a 1X buffer (10 X Cutsmart buffer
supplied along with enzyme by manufacturer) in a 20 l reaction volume. The enzyme
concentration and reaction volume were increased with an increase in pDNA quantity
following the manufacturer’s recommended protocol. For double digestions involving
HindIII and XhoI, 20 units of each enzyme were used for approximately 2 g of pDNA in
a 50 l reaction at the conditions mentioned above. For SalI and SacI digestions, 50-60
units of each enzyme were used for approximately 2-5 g of pDNA in 50 l reaction
volume at the same reaction conditions mentioned above. For double digestions involving
BamHI and BglII, 40 units of BamHI and 20 units of BglII were used for approximately 2
g of pDNA in a 50 l reaction at the conditions mentioned above.
2.1.10. Ligation Reactions
Briefly, 500 ng of the gel-extracted double digested plasmid (pGFP, pIRES-GFP,
p1s-2A-GFP or p2A-GFP) with five molar excess of the gel-extracted double digested
insert (CAR or CARsf) were ligated using five units of T4 DNA Ligase in 1 X ligase buffer
(10 X T4 DNA Ligase buffer supplied by the manufacturer) in a 100 l reaction. Reactions
were performed for 60-85 minutes at room temperature (or 22 0C in thermal cycler) for
ligation and then at 70 0C for 5 minutes in a water bath (or 65 0C for 10 minutes in thermal
cycler) to inactivate the ligase.
2.1.11. Bacterial Transformations
Ampicillin (100 mg/ml) and Chloramphenicol (10 mg/ml) solutions were used as
purchased from manufacturers. A 50 mg/ml stock of Kanamycin was prepared by
dissolving 99 mg in 10 ml of 0.9 % NaCl solution and stored in 4 0C until further use.
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Approximately 100 ng of the ligation samples or intact pDNA is used to transform
XL-1 Blue (Agilent Technologies, Inc) competent cells by following the manufacturer’s
recommended protocol. The success of transformations was analyzed on appropriate
antibiotic-resistant LB agar plates left in a 37 0C incubator for 18-48 hours posttransformation. After plating the transformation sample, the leftover sample was allowed
to grow in a 14 mL culture tube for overnight in 8mL of antibiotic-containing LB media at
37 0C at 250 rpm. Later, the overnight culture was used to extract pDNA using the miniprep
plasmid extraction kit (Thermo Scientific), and the quality of plasmids was analyzed on 1
% agarose gel.
2.1.12. Polymerase Chain Reaction
Briefly, a 1 X reaction mixture was prepared using 2.5 M of forward and reverse
primers, 17.5 ng/l of template DNA, 3 % DMSO, and 1 X Phusion Green Hot Start II
High-Fidelity PCR Master Mix containing 1.5 mM MgCl2 (Thermo Scientific). In the
negative sample, nuclease-free water was added instead of DNA. Next, the samples were
placed in a gradient temperature capable thermal cycler (Applied Biosystems) and run for
98 0C for 30 seconds, 35 cycles of {98 0C for 10 seconds, 65 0C for 10 seconds, and 72 0C
for 60 seconds}, 72 0C for 7.5 minutes, and hold at 4 0C.
2.1.13. Cell Culture
Jurkat cells (American Type Culture Collection, Manassas, VA) were cultured in
RPMI complete media without antibiotics supplemented with 10 % Fetal Bovine Serum
(FBS). Cells were cultured at 37 oC and 5 % CO2 in the Heracell VIOS 160i CO2 incubator.
After every three days, cells were split into 0.5 - 1 x 106 cells/ml in a T25 culture flask and
supplemented with fresh RPMI complete media. The Jurkat cells' density was not allowed

23

to increase beyond 3 x 106 cells/ml for regular maintenance. For transfection experiments,
cells were grown to nearly 2.5 x 106 cells/ml.
2.1.14. Preparation of Lipoplexes
All lipoplex formulations were prepared using Lipofectamine 3000 (LF3000)
following the manufacturer’s (Invitrogen) recommended protocol. Briefly, we first
prepared the two solutions: 3.6 l of LF3000 reagent mixed into 60 l of Opti-MEMTM
(Fisher Scientific) (Solution 1), and 4.8 l of P3000 reagent along with 2.4 g of pGFP
mixed into 60 l of Opti-MEMTM (Solution 2). Lipoplexes were prepared by mixing
solutions 1 and 2 using a pipette, followed by incubation for 15 minutes at room
temperature just before use.
2.1.15. Preparation of Polyplexes
A weight ratio of 2:1 (PEI:pGFP) was used for all transfection experiments for
polyplex formation. Typically, 2.4 g of pGFP and 4.8 g of PEI were mixed in 80 l of
pure water and incubated for 15 minutes at room temperature just before use.
2.1.16. SyBr Exclusion Assay
A mixture of 3.6 g of pGFP and 7.2 g of PEI in 120 l of water was incubated
for 15 minutes at room temperature to prepare polyplexes. Next, each 10 l of this solution
was mixed with 290 l of CaCl2 solution at different concentrations to obtain the indicated
final concentrations. This is followed by mixing 3 l of 100 X SyBr Safe (Invitrogen)
solution with 300 l of the polyplex solution. Triplicates for each condition (i.e., three wells
of 100 ng pGFP each) were prepared in a MicroFluor black 96-well plate (Thermo
Scientific). The samples’ fluorescence intensity was measured using BioTek Synergy HTX
Multi-mode Reader (with 485/20 excitation filter and 528/20 emission filter).
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2.1.17. DNA labeling
After purification from E. coli XL-1 Blue, pGFP was labeled with Cy5 at a targeted
density of one dye molecule for every 60 bps using Mirus Label-ITR Nucleic acid labeling
Kit following the manufacturer’s (Mirus Bio) recommended protocol.
2.1.18. DLS measurements
Polyplexes were prepared in ultra-pure water or the indicated buffers. Polyplexes'
z-average size (hydrodynamic diameter in nm) and zeta potential (net surface charge in
mV) were measured using a Malvern Zetasizer Nano for three cycles per measurement.
2.1.19. Cell Viability and Transfection Studies
Each formulation is typically made in bulk to take measurements at four different
time points, three replicates per time point (total 12 replicates/formulation). 800 l of
culture medium was mixed with freshly prepared polyplexes (10 l) or lipoplexes (120 l).
To this mixture, CaCl2 (stock concentration 5 M) or MgCl2 (stock concentration 1M), or
NaCl (stock conc. 3 M) were added to make the indicated final concentrations. Finally, 1.2
x 105 Jurkat cells suspended in the culture media were added to the mixture to a final
volume of 1,200 l. This solution was aliquoted into 12 wells (100 l each) in a 96-well
plate (Corning CoStar). A similar protocol was followed for all experiments with
proportional scaling of components for a smaller number of samples/formulations. The
plates were incubated in a Heracell VIOS 160i CO2 incubator at 5 % CO2 and 37 oC until
the GFP expression were examined by flow cytometry at the indicated time points. Culture
media was not replaced or added at any point of the transfection experiment.
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2.1.20. Flow Cytometry
At each time point, all cells from each well were collected in 5 ml polypropylene
tubes and washed with 3 ml FACS buffer (1X PBS, 0.5 % BSA, 2 mM EDTA) by
centrifuging for 5 minutes at 400 g and 4 oC. After discarding the supernatant, the tubes
were blotted on KimwipesTM to remove any residual fluid. Later, cell pellets were
resuspended in 300 l of FACS buffer. A total of 200 l of each sample was analyzed using
acoustic focusing cytometry (Attune NxT Flow Cytometer, Invitrogen).
2.1.21. Confocal Microscopy
Cells were retrieved at the indicated time-points and fixed by 2% PFA for 20
minutes at room temperature. For imaging of GFP expression, fixed cells were washed
three times with 1X PBS and twice with Tris Buffered Saline (TBS); cells were
permeabilized with 0.1% Triton-X 100 in TBS for 15 minutes at room temperature by
gentle shaking; after washing thrice with TBS, cells were then blocked with 2% goat serum
suspended in 0.1% Tween-20 in TBS (TBST) for 30 minutes; to stain the actin filaments,
cells were stained with Alexa Fluor 594 Phalloidin (ThermoFisher Scientific) for 30 min
in TBST, and finally the cells were washed thrice in TBS.
For examining polyplex association with Jurkat cells, fixed cells were washed twice
with 1 X PBS. Fixed samples were centrifuged at 400 g for 5 minutes at 4 oC. The cell
pellets were resuspended in a mixture of 1X PBS and Prolong diamond antifade with DAPI
(Molecular Probes), mounted on a glass slide, and covered with a coverslip. Slides were
cured for 24 hours at room temperature in the dark before being examined under Zeiss
LSM 700 confocal microscope (with 405, 488, 555, and 639 nm excitation lasers).
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2.1.22. Graphical Representation and Statistical Analysis
Scatter plots and histograms were plotted using v10.0 FlowJo software. All
statistical analyses were performed, bar and line graphs were plotted using v8.0 Prism
software (GraphPad). We employed a 1-way or 2-way ANOVA analysis with Dunnett’s
multiple comparisons to validate the statistical significance.
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2.2.

Results

2.2.1.

Optimization of polyplex formulation
PEI is available in two structural forms: linear PEI (lPEI) and branched PEI (bPEI).

However, the 25 kDa bPEI is superior to 25 kDa lPEI in HeLa, HEK293, COS7, and
HepG2 cell lines (Intra and Salem 2008). Interestingly, 22 kDa lPEI was reported to outperform 25 kDa and 50 kDa bPEI in transfection experiments in vitro and in vivo (Wiseman
et al. 2003). Moreover, the bPEI outperforms lPEI at an N/P ratio of 3, and the difference
is trivial at a higher N/P ratio of 10 (Dai et al. 2011). Hence, we decided to use 25 kDa
bPEI (hereafter just “PEI” unless otherwise mentioned) for all experiments to keep our

Table 1:
Ionic strength
of various solutions and buffers used. Debyestudy design
straightforward.
Huckel formula was used to calculate ionic strength.
Solution / Buffer

Concentration

Ionic strength (mM)

CaCl2

1 mM

3

2 mM

6

5 mM

15

10 mM

30

25 mM

75

10 mM

30

25 mM

75

20 mM

12.5

50 mM

25

PBS

1X

176

HBS

1X

150

MgCl2

NaCl

Table 2.1: Ionic strength of various solutions and buffers used. The ionic strength was
calculated using the Debye-Huckel formula.
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Figure 2.5: Optimization of pGFP polyplex formulation. (a-c) Degree of complexation
analyzed by SyBr exclusion assay (a), size and polydispersity index (PDI) (b), and net
surface charge (c) of the polyplexes at indicated weight ratio on each graph. (d) Size and
PDI of polyplex prepared at w:w of 2 in different suspension mediums. Polyplexes were
either originally prepared in 1,300 l of pure “Water”, 1X “PBS”, or 1X “HBS”, or first
prepared in 100 l of pure water and then diluted to a final volume of 1,300 l using the
indicated suspension mediums for “Water/Water”, “Water/PBS, or “Water/HBS” samples.
Results in the figure are represented as mean ± standard deviation (n = 3).

We first attempted to optimize the mixing ratio of PEI and pGFP for stable
complexation. From the SyBr exclusion assay, it is revealed that a PEI/pGFP weight ratio
(w/w) of just 0.5 (N/P 3.83) was enough to form a complex and that higher w/w may not
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be necessary (Figure 2.5a). This result agrees with previous reports, which showed that
nearly all pDNA could be complexed with PEI at an N/P ratio of 3 ~ 4 (Ogris et al. 1999;
Erbacher et al. 1999). However, from the agarose gel, it was clear that polyplexes made at
a weight ratio of 0.5 might not be stable and that a weight ratio of 2 or higher is necessary
for tighter complexation (Figure 2.4). Indeed, the average hydrodynamic diameters (in nm)
of these complexes decreased as the weight ratio was changed from 0.5 (407.27 ± 5.2, mean
± SD) to 1 (138.27 ± 0.91) to 2 (97.55 ± 1.21). The polydispersity index (PDI) of the
complexes made at weight ratio of 0.5 (0.229 ± 0.02) were marginally higher than those
made at weight ratio of 1 (0.165 ± 0.01, mean ± SD) or 2 (0.173 ± 0.01) (Figure 2.5b).
Besides the size and compactness, the net surface charge of the polyplexes is an important
factor that affects transfection efficiency and cytotoxicity. It was earlier shown that as the
weight ratio increases, more fraction of PEI exists free without participating in
complexation. This free PEI fraction significantly enhances cytotoxicity and transfection
efficiency (Boeckle et al. 2004; Yue et al. 2011). Not surprisingly, the net surface-charge
of polyplexes increased as w/w changed from 0.5 (22.4 ± 0.53, mean ± SD) to 1 (36.93 ±
0.87) to 2 (42.57 ± 1.21 mV) (Figure 2.5c).
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In our earliest experiments, polyplexes prepared at w/w 1 were ineffective in
transfecting Jurkat cells, while those at 2 showed minimal efficiency (Figure 2.6). In
summary, we decided that w/w 2 is the optimal formula for our investigations.
As polyplex formation is a result of electrostatic interactions between polycations
(PEI) and polyanions (DNA), salt concentrations and pH values of the suspension buffers
can influence the physicochemical properties of the resulting polyplex (Raup et al. 2016;
Sang et al. 2015). To test the sole effect of Ca2+ during transfection, we attempted to
prepare polyplex formulations that are the most stable and resistant to ionic strength.
Earlier, pure water or buffers such as PBS and HBS have been employed for complexation
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to yield significantly variable polyplex sizes (Sang et al. 2013). First, we prepared the
polyplexes in 1.3 ml of pure water, PBS, or HBS to check how ionic strength (Table 2.1)
would alter the polyplex formation. The polyplexes made in pure water had a relatively
minimal hydrodynamic diameter and narrowest PDI, whereas, in PBS, the largest
polyplexes with broad peaks were formed (Figure 2.5d, Table 2.2).

Table 2.2: Size and PDI values of polyplexes (PEI/pDNA weight ratio of 2) shown in
Figure 1d. Polyplexes were made either in one medium (1.3 ml of water, PBS, or HBS) or
100 μl pure water and then diluted in another medium (final volume 1.3 ml).

Furthermore, we tested how the polyplex’s size changes when prepared in 100 l
of pure water before diluting (1:13) in pure water, PBS, or HBS. Although the dilutions
somewhat increased the size and PDI values, it was clear that the polyplexes prepared first
in water and diluted into PBS or HBS are smaller than the polyplexes prepared originally
in PBS or HBS, respectively (Figure 2.5d, Table 2.2). We aimed to keep the polyplex
formation as simple as possible (i.e., without the involvement of other metal ions) and the
size of the polyplex as minimal & stable as possible. Therefore, we prepared all polyplex
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formulations first in pure water followed by dilution in the indicated condition for
transfection in further studies.
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Lastly, we attempted to optimize the polyplex dose for the study. It is well
established that an increase in the dose of polyplex enhances transfection efficiency and
cytotoxicity. To optimize the dose for the transfection of Jurkat cells, we tested three
different doses – 10, 20, and 50 pg per cell of pGFP condensed with 20, 40, and 100 pg per
cell of PEI respectively. The data regarding the growth curve of Jurkat cells for four days
and the transfection efficiency measured by the size of the GFP+ cell population
demonstrated that both cytotoxicity and transfection efficiency is dose-dependent (Figure
2.7). We, therefore, chose polyplexes prepared using 40 pg/cell PEI and 20 pg/cell pGFP
as an optimal formulation for further investigations with Jurkat cells.
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2.2.2.

Effect of CaCl2 on size, stability, and charge of polyplexes
First, we evaluated the effect of CaCl2 on the stability of polyplexes made in ultra-

pure water. In Sybr exclusion assay, pDNA was increasingly accessible to intercalation by
Sybr green dye with an increase in the concentration of CaCl2 (Figure 2.8a). This result
indicates potential partial dissociation and loose complexation. In contrast, the polyplex
sizes measured by DLS were uniform at around 175 nm (PDI ~ 0.150) without being
significantly affected by CaCl2 at concentrations up to 50 mM (Figure 2.8b). However,
both size and PDI have wildly fluctuated at 100 mM and above (Figure 2.8b).

Figure 2.8: Effect of calcium chloride on the stability of polyplexes (weight ratio of 2)
analyzed by SyBr exclusion assay; hydrodynamic size and net surface charge of polyplexes
analyzed by DLS. Polyplexes were prepared in ultra-pure water. (a) All comparisons were
made with the “0” condition. Results in the figure are represented as mean ± standard
deviation (n=3; (a) one-way ANOVA with Dunnett’s multiple comparisons, ** p = 0.0064,
*** p = .0007, **** p < .0001, ** p = 0.0035).

The net surface charge of the polyplex remained at around 35 mV up to 10 mM
CaCl2. Still, it decreased steadily at concentrations of 25 mM and above (Figure 2.8c),
indicating an increased exposure of pDNA on the surface of polyplexes. Altogether, while
CaCl2 did not significantly deteriorate the stability of complexes up to 1 M, tighter
complexation of PEI and pDNA with monodisperse and small sizes are maintained only
up to a smaller concentration threshold within 10 - 25 mM.
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2.2.3.

Tolerance of Jurkat on varying concentrations of CaCl2
Next, we examined the ability of Jurkat cells to withstand varying concentrations

of CaCl2 for two days. For CaCl2 concentrations up to 10 mM, the numbers of viable Jurkat
cells increased over time (Figure 2.9). It is noteworthy that there is no significant difference
in the number of live cells up to a concentration of 10 mM. However, there was no cell
growth (in number) in conditions with 25 mM and 50 mM CaCl2, while cell number started
to decrease even at the earliest tested time point (4-hours post-plating) at 100 mM. Indeed,
all Jurkat cells with CaCl2 concentrations above 250 mM were dead by 8 hours post-plating.
Hence, we decided to limit our investigations with CaCl2 at concentrations only up to 25
mM.

Figure 2.9: Effect of CaCl2 (mM) on Jurkat cell viability analyzed by flow cytometer. All
comparisons (48-hour) are made with the “0” group. Results in the figure are represented
as mean ± standard deviation (n=3; two-way ANOVA with Dunnett’s multiple comparisons
for 48-hour groups, **** p < .0001).
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2.2.4.

Effects of CaCl2 in transfecting Jurkat Cells
To evaluate the effects of calcium chloride in the transfection of Jurkat cells, we

added CaCl2 to the culture media. Compared to the cell-only (CO) group, PEI polyplex
without any CaCl2 (0 mM) induced GFP expression in a tiny population, around 0.6%
(Figure 2.10a and 2.10e). Intriguingly, Jurkat cell populations displayed a slight positive
shift in the fluorescence signals of the green emission channel when they were treated with
polyplexes, and the size of this low-level fluorescence shift further increased with the
addition of calcium chloride (Figure 2.11a). Nevertheless, this increase in low-level
fluorescence was invariably observed when a bacterial expression vector, pUC18, was used
in place of pGFP (Figure 2.11b). Meanwhile, the addition of CaCl2 itself without any
polyplex did not induce any shift in the signals of the green emission channel from Jurkat
cells (Figure 2.11c). Thus, we determined that this low-level green signal does not
represent the GFP expression. Consequently, to precisely quantify the GFP expression, we
employed the Jurkat cells treated with pUC18 polyplexes and 10 mM CaCl2 for proper
gating control or a similarly stringent gating strategy henceforth.

Figure 2.10: Effect of calcium chloride on the pGFP transfection of Jurkat cells analyzed
at 96 hpt by flow cytometer. “CO” is control with cells alone. “0”, “1”, “2”, “5”, “10”, and
“25” (numbers on the x-axis) are the polyplex controls with 0-, 1-, 2-, 5-, 10-, & 25 mM
calcium chloride, respectively. (a) Transfection efficiency, (b) GFP expression level, (c)
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Cell viability, (d) Split view of a Jurkat cell expressing GFP from “10” captured with at
100X using confocal laser scanning microscope (Scale bar is 1 m), and (e) Transfection
efficiency and GFP expression levels represented at once using an area plot with forward
scattering (FSC) on the y-axis and GFP channel on the x-axis; control code and their
respective GFP+ % (shown in red) are indicated in each square box. (a, b, c) All
comparisons are made with “0” group and results are presented as mean ± standard
deviation (n=3; one-way ANOVA with Dunnett’s multiple comparisons, * p = 0.0258, ***
p = .0009, **** p < .0001).

Figure 2.11: Enhancement in low-level GFP fluorescence analyzed by flow cytometry. (a)
Effect of the combination of calcium and pGFP polyplexes on low-level GFP signal at 96
hpt. (b) Impact of an empty bacterial expression vector at 96 hpt. (c) Effect of calcium
chloride in polyplex-free culture media at 48-hours post-plating.
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Under this gating tactic, the percentage of GFP+ cells marginally decreased at
concentrations 1, 2, and 5 mM. Still, it significantly increased at higher concentrations, i.e.,
at 10- and 25-mM than the 0 mM (no additional CaCl2) control (Figure 2.10a and 2.10e).
Notably, a broad spectrum of GFP expression levels appeared only in 10- and 25-mM
groups (Figure 2.10e), which was verified by the statistically significant increase in their
respective mean fluorescence intensity (MFI) values (Figure 2.10b). The GFP expression
in Jurkat cells was examined by imaging at high resolution in a confocal microscope
(Figure 2.10d). It is noteworthy that the number of viable cells decreased in 10 mM and 25
mM groups, apparently due to the combined cytotoxicity of CaCl2 and polyplex
formulation (Figure 2.10c). Nonetheless, it is demonstrated that adding CaCl2 at
concentrations of 10 mM or above can boost the transfection efficiency of PEI/pDNA
complexes on otherwise hard-to-transfect Jurkat cells.
2.2.5.

Effect of other metal ions in the transfection of Jurkat cells
We tested whether other metal ions can act as functional analogs of calcium. For

this, we simply replaced calcium chloride with either magnesium chloride or sodium
chloride in our transfection experiments. To normalize the experimentation by matching
the ionic density, we used identical concentrations of MgCl2 to CaCl2 but double the
concentrations of NaCl.
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Figure 2.12: Effects of different cations in the transfection of Jurkat cells and their direct
comparison to lipoplex formulation analyzed at 96-hpt using flow cytometer. “CO” is
control with cell alone; “0” is a polyplex control without any added salt; “10 Ca” and “25
Ca” are polyplex controls with 10- and 25 mM calcium chloride, respectively; “10 Mg”
and “25 Mg” are polyplex controls with 10- and 25 mM magnesium chloride, respectively;
“20 Na” and “50 Na” are polyplex controls with 20- and 50 mM sodium chloride,
respectively; and “LF” is a control with lipofectamine 3000 based formulation. (a)
Transfection efficiency and GFP expression levels are represented at once using an area
plot with forward scattering (FSC) on the y-axis and GFP channel on the x-axis; control
codes and their respective transfection efficiencies (shown in red) are indicated in each
square box. (b, c) All comparisons are made with the “0” group and results are presented
as mean ± standard deviation (n=3; one-way ANOVA with Dunnett’s multiple
comparisons, ** p = .0017 to 0.005, **** p < .0001).
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In direct comparisons, MgCl2 groups did not show any effect in transfection
compared to polyplex-only control (0 mM). In contrast, the addition of NaCl at indicated
concentrations reduced the size of the GFP+ population (Figure 2.12a and 2.12b).
Contrasting the broad spectrum of GFP expression levels observed in the CaCl2 groups,
most of the GFP+ cells in the MgCl2 groups are similar to the low-level GFP expression of
0 mM control (Figure 2.12a and 2.12c). Altogether, calcium ions instead of chloride ions
appear to be responsible for the augmentation of polyplex transfection efficiency, while the
candidate functional analogs, Mg2+ and Na+, were ineffective.
2.2.6.

A comparison between polyplex and lipoplex formulations in transfection
We tested whether the calcium-assisted polyplex formulation can outperform

Lipofectamine 3000 (LF), a commercially available state-of-the-art cationic liposomebased transfection reagent. Hence, the complexes of LF and pDNA are called lipoplexes.
In a transfection assay that prolonged 96 hours, the size of the GFP+ population of the LF
group is significantly larger than the polyplex without any calcium (0 mM) control (Figure
2.12a and 2.12b). Nevertheless, polyplexes outperformed in terms of transfection
efficiency when calcium was added at 10- or 25-mM concentrations. However, in terms of
MFI values, the LF group was in a dominant position over polyplex with 10 mM calcium
(Figure 2.12c) due to the difference in levels of GFP expression among GFP+ cells (Figure
2.12a).

40

Figure 2.13: Effects of calcium ions on transfection using Lipofectamine 3000 analyzed at
96-hpt by flow cytometer. The numbers “0”, “1”, “2”, “5”, “10”, and “25” on the x-axis
are lipoplex formulations with final concentrations of 0-, 1-, 2-, 5-, 10-, and 25- mM
calcium chloride, respectively. (a, b) Unlabeled (unmodified) pGFP was used to measure
the GFP expression. (c) Cy5-labeled pGFP was used only to measure the number of Cy5stained cells. All comparisons are made with “0”. Results in the figure are represented as
mean ± standard deviation (n=3; two-way ANOVA with Dunnett’s multiple comparisons,
* p = 0.0105 ** p = 0.0014 and 0.0052, *** p = .0004, **** p < .0001).

We further tested the effects of calcium ions on the liposome-mediated transfection
in Jurkat cells. Interestingly, calcium ions did not enhance the transfection efficiency but
were detrimental in GFP+ cell % and MFI (Figure 2.13a and 2.13b). This glaring difference
in transfection behaviors between calcium-assisted polyplexes and lipoplexes might be
derived from the underlying difference in their mechanism of action (Z. U. Rehman,
Hoekstra, and Zuhorn 2013; Cohen et al. 2009), which warrants additional investigation.
2.2.7.

Effects of CaCl2 in the interaction of polyplex or lipoplex with Jurkat cells
To comprehend the role of calcium in enhancing transfection, we examined the

association pattern of polyplex and Jurkat cells using Cy5-labelled pGFP. Jurkat cells were
initially examined under the confocal microscope with a maximum intensity projection
(MIP) view after 6- and 24-hours post-plating (hpp) (Figure 2.14a). More pGFP polyplexes
were associated with Jurkat cells in the presence of CaCl2 as early as 6-hpp, relative to the
polyplex-only control (“0” in Figure 2.14). Such improvement was not observed in the
magnesium groups. The quantitative analysis using flow cytometry also clearly confirmed
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that calcium but not magnesium boosts the interaction of polyplexes with Jurkat cells in
terms of the size of the polyplex-associated population (Cy5+ cells, Figure 2.14b) and the
amount of polyplexes per cell (MFI, Figure 2.14c). The multi-fold growth in the MFI of
the calcium-assisted controls indicates that the increased association perhaps had induced
the intracellular delivery of significantly higher copy numbers of pGFP through
endocytosis.

Figure 2.14: Effect of calcium chloride on the association of Cy5-labeled pGFP polyplexes
and Jurkat cells in a 48-hour culture analyzed by confocal microscope and flow cytometer.
“CO” is control with cells alone; “0” is a polyplex control without added salts; “10 Ca”
and “25 Ca” are polyplex controls with 10- and 25 mM calcium chloride, respectively; “10
Mg” and “25 Mg” are polyplex controls with 10- and 25 mM magnesium chloride,
respectively; and ”LF” is a lipoplex only control. (a) Maximum intensity projection (MIP)
image of Jurkat cells associated with polyplexes; Scale bar is 2 m; Nucleus is stained with
DAPI (blue), and polyplexes are stained with Cy5 (red). (b, c) All comparisons are made
with the “0” group of respective time points; Results are presented as mean ± standard
deviation (n=3; one-way ANOVA with Dunnett’s multiple comparisons, **** p < .0001,
*** p = 0.0005 and 0.0009).

42

In a direct comparison, the LF group displayed similar MFI as the polyplex without
any added calcium (0 mM control) (Figure 2.14b). At the same time, only about 35 % of
total cells were associated with lipoplexes. This implies that the copy number of pGFP per
lipoplex could be significantly greater than that of the polyplex.
More intriguingly, adding calcium instead reduced the association between lipoplex
and Jurkat cells (Figure 2.14c). This phenomenon partially explains the detrimental effect
of calcium on the lipoplex-mediated transfection on Jurkat cells (Figure 2.13a and 2.13b).
Calcium played a significant role in the association of the non-viral vectors with
Jurkat cells, differently for polyplex and lipoplex: Ca2+ enhances the association of
polyplexes but reduces the association of lipoplexes. These Ca2+ effects on the association
of either non-viral vectors would directly impact the number of copies of pDNA to be
delivered and thereby the transfection efficiency. There is likely a significant difference
in the mechanism of association and uptake of polyplex and lipoplex onto Jurkat cells.
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2.3.

Discussion
Polyplex is formed by complexation between cationic polymers (e.g., PEI) and

anionic nucleic acids (e.g., pDNA) via charge-charge interactions. For transfections to be
successful, the polyplexes must have a net positive surface-charge to interact with the
anionic cell membrane (Raup et al. 2016). Therefore, an excess of polycation is preferable
for transfection. Finding an optimal ratio of polymer to pDNA is necessary as the former
also contributes to cytotoxicity. Here, we found a weight ratio of 2 (N/P ~ 15) as optimum.
Different endocytic pathways, such as the clathrin-dependent, caveolae-mediated,
micropinocytosis, or their combinations are known to be involved in the uptake of
polyplexes (Ingle, Xue, and Reineke 2013; Rejman, Bragonzi, and Conese 2005; Z. ur
Rehman et al. 2012; Reilly, Larsen, and Sullivan 2012). Fortunately, some of these
pathways were reported to display an upper cargo size limit of around 200 nm for effective
internalization (Pandey and Sawant 2016). Hence, keeping the polyplex size small and
monodisperse during transfections may be beneficial.
It is reported that the hydrodynamic size of polyplexes increases in higher ion
concentrations (Sang et al. 2013), and evidently, the polyplexes made in PBS were
significantly bigger than those made in pure water (Figure 2.5d, Table 2.2). Moreover, once
the polyplexes were prepared in pure water, the complexes gained a certain resistance level
to change in ionic strength (Figure 2.5d, Table 2.2). Therefore, we first prepared the
polyplex in pure water and then added them to the cell culture medium, similarly to others
(Ingle, Hexum, and Reineke 2020; Rejman, Bragonzi, and Conese 2005). Our study is
noteworthy from other previous efforts to evaluate the effects of salt concentrations during
the polyplex formation on the polyplex's final physicochemical and biological properties
(Raup et al. 2016; Sang et al. 2015). Here we normalized all formulation parameters by
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employing uniform doses and formulations made at a single defined preparation condition
to study the sole effect of added calcium.
Before performing transfections, we investigated the concentration-dependent
effects of CaCl2 on the physiochemical properties of polyplexes. While the hydrodynamic
sizes measured by DLS did not significantly change up to 50 mM, the polyplexes seemed
to have substantially loosened at above 10 mM, which was revealed by an increase in the
intercalation of Sybr-dye into the pDNA and decrease in net surface-charge. Interestingly,
the tolerance threshold for CaCl2 concentration of Jurkat cells coincided at about 10 mM,
i.e., the CaCl2 starts to affect the cellular growth at 25 mM or more adversely. Hence, we
were able to investigate the effect of CaCl2 on the transfection efficiency up to 25 mM,
without significant cytotoxicity. In this framework, calcium could have participated in one
or more transfection steps to enhance polyplex transfection.
To study the detailed roles of calcium, we investigated the effect of Ca2+ on the
association and endocytosis of polyplexes. The flow cytometer data showing the
association of dye-labeled pDNA and Jurkat cells demonstrated that Ca2+ enhances the
interaction significantly at 10mM and 25 mM. How exactly divalent cations contribute to
the association between cationic polyplexes and the anionic cell membrane is not clear. It
is noteworthy that a significant portion of the Jurkat cell population associates with
polyplexes even without calcium (over 75 %). Still, only 0.403 ± 0.05 % (mean ± SD, from
3 experiments) cells eventually show GFP expression mainly in a low level. Furthermore,
although nearly all cells are associated with polyplexes at 10- and 25-mM Ca2+, only 3.36
± 0.43 % & 4.81 ± 0.52 % of them, respectively, had expressed the transgene (GFP). Thus,
it is likely that a tiny fraction of the many polyplexes that initially associate with the Jurkat
cells would overcome all the barriers mentioned above to contribute to the gene expression.
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In our study, calcium chloride was added to the culture media (with polyplexes
made in pure water, and Jurkat cells) just before plating the transfection samples. In such
an experimental setup, at 96-hpt, 10 mM and 25 mM calcium controls displayed an increase
in the expression level of GFP by 7.23 and 18.35 folds relative to 0 mM control. However,
in a similar study (S.-X. Xie et al. 2018) where PEI-based polyplexes of a luciferase
expression plasmid were prepared in the presence of calcium chloride, the relative
luminescence units (RLU) per ug protein of 46.9 mM CaCl2 control was approximately
1,000-folds higher than the 0 mM control for 800 Da PEI. More importantly, their study
did not use Jurkat cells but A549 lung carcinoma cells. Interestingly, in the same study, 25
kDa PEI did not enhance the expression level (in terms of RLU/ug protein) of the luciferase
enzyme within 0-750 mM calcium chloride. It must be noted that both studies used
different methods and cell lines to access transfection efficiency and therefore the
enhancement of model protein expression cannot be directly compared. However, a
qualitative comparison can be made. In a direct comparison between the 25 kDa PEI
conditions between these two studies, we understand that 25 kDa PEI-mediated
transfection efficiencies can be enhanced by adding calcium chloride to the culture media
and not during polyplexation (complexation). Besides, the authors of the luciferase study
reported that calcium chloride is perhaps helping in the unpacking of the polyplexes while
we report that calcium chloride is enhancing the association of polyplexes with Jurkat cells.
Therefore, due to the differences in the transfection methodology, explanation of function,
and reported results between these two studies, the findings we reported in this study are
novel.
Nonetheless, the quantity of internalized & membrane-bound polyplexes (MFI in
pDNA label, Cy5) was significantly enhanced in extra Ca2+ (Figure 2.14a and 2.14c),
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directly affecting GFP+ % and MFI in the GFP channel. A previous study showed that the
polyplexes bind to cell membrane within a relatively short period (10 min ~ 7 hours) postplating, and their internalization follows a more extended period (up to 30 hours)
(Delafosse, Xu, and Durocher 2016), and these two steps are inevitably related. Even if we
do not know precisely at which step Ca2+ played a role, it is clear that Ca2+ enhanced the
overall association between the polyplex and Jurkat cells.
Adversely, the combined cytotoxicity of Ca2+ and PEI-based polyplexes (Figure
2.10c) makes applying the current method to real applications difficult. Further
optimization in the dose of calcium & polyplex and the exchange of polyplex formulation
with less cytotoxic counterparts would be an imminent future investigation.
A comparison between the polyplex and lipoplex formulations provided fascinating
insights. The commercial state-of-the-art lipoplex reagent (LF) showed similar transfection
efficiency to the polyplex group assisted with 10 mM Ca2+ (Figure 2.11). However, in
terms of pDNA delivery, the LF group was inferior to polyplex groups assisted with 10
mM calcium (Figure 2.14b and 2.14c). This result supports previous findings that involved
highlighting the differences between polyplexes and lipoplexes. First, it was demonstrated
that the pDNA from lipoplexes are more efficiently expressed than those from polyplexes,
perhaps due to better unpacking (dissociation) of pDNA from lipoplexes than from
polyplexes (Cohen et al. 2009). Additionally, when a similar number of lipoplexes and
polyplexes are delivered to a cell, many more lipoplexes can deliver nucleic acids out of
endolysosomes than polyplexes due to the inherent differences in their mechanism and
kinetics of endosomal escape (Z. U. Rehman, Hoekstra, and Zuhorn 2013).
Furthermore, in our current study, the addition of calcium enhanced the association
of only the polyplex on Jurkat cells and transfection of the transgene, but not the lipoplex.
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Indeed, Ca2+ showed adverse effects on the performance of lipoplexes. Altogether, the
results presented in this study claim further studies on the difference in the mechanism of
action of polyplex and lipoplex employed for the transfection of different cell types.
The functional analog assay validated that Ca2+ has an exclusive (within the tested
groups) ability to augment polyplexes' transfection efficiency by enhancing interactions
between polyplexes and Jurkat cells, which is not displayed by other tested cations - sodium
or magnesium. This result tentatively suggests that there may not be a universally
applicable common critical feature for enhancing transfection among different positively
charged ions. It is known that different metals ions interact with DNA in different ways
mainly due to the differences in their size and pKa values (Zhou, Saran, and Liu 2017).
Metals ions, Mg2+, and Ca2+ have an ionic radius (from Pauling diameter, Dp) of 0.65 Å
and 0.99 Å respectively (Zhou, Saran, and Liu 2017). Metal ions like magnesium and
calcium can bind to the phosphate backbone of DNA in two ways – Inner-sphere
coordination or direct metal binding and Outer-sphere coordination or water-mediated
binding (Zhou, Saran, and Liu 2017). Metals ions, Mg2+, and Ca2+ may interact with DNA
more so in a water-mediated binding and direct metal-binding respectively (Ahmad,
Arakawa, and Tajmir-Riahi 2003). This is because, for the metals ions that fall within the
same group in the periodic table, heavier ions (Ca2+) have a lower charge density than the
lighter ions (Mg2+) (Zhou, Saran, and Liu 2017). Therefore, Ca2+ will have a smaller
hydrated size than does Mg2+. Besides, metal ions having a lower pKa can interact more
with water and lead to hydrolysis. The pKa of Mg2+ and Ca2+ are 11.42 and 12.7. Therefore,
magnesium (bigger hydrated size and lower pKa) relative to calcium can interact more
strongly with water and cause hydrolysis. Thus, the hydrolysis reactions can decrease the
charge of the metals ions. Due to these differences between Mg2+ and Ca2+, calcium retains
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a higher DNA-binding ability than magnesium (Ahmad, Arakawa, and Tajmir-Riahi 2003)
and is significant enough that the enhanced stability is causing the increase in the
transfection efficiency.
It is worth reviewing that Ca2+ has a unique potential to contribute to the transgene
expression by enhancing other physiological processes. For example, it is known that the
endoplasmic reticulum (ER) - a landmark for protein biosynthesis in eukaryotes - functions
as a Ca2+ storing organelle by trapping most of them on the ER surface proteins (CarrerasSureda, Pihán and Hetz 2018). ER-localized chaperones such as calnexin & calreticulin,
which display high calcium-binding capacity, bind to Ca2+ with low affinity for their
activity (Carreras-Sureda, Pihán, and Hetz 2018; Ashby and Tepikin 2001). Thus, Ca2+
may enhance the expression of the exogenous gene (GFP) in Jurkat cells by improving the
function of ER. Additionally, in many cell types, including T and B cells, a process known
as the ‘Store-Operated Calcium Entry’ (SOCE) occurs in which depletion of Ca2+ in the
ER leads to initiation of Ca2+ influx from the extracellular space (Marshall et al. 2015).
Therefore, the role of SOCE in the enhancement of endocytosis has not yet been fully
explored. Besides, further investigations are warranted to precisely delineate the functional
features of calcium in transgenes transfection and possibly utilize this strategy as a
universal transfection enhancer for non-viral vectors.
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2.4.

Conclusion
Here, we report that the transfection efficiency of PEI-based pDNA polyplexes can

be enhanced by Ca2+, a physiologically relevant divalent cation. Even though PEI is widely
adopted as one of the main polycationic non-viral gene delivery vehicles, the transfection
efficiency of PEI-based polyplexes is not significant enough to be utilized in the
transfection of specific cell types such as Jurkat, which are intrinsically resistant to uptake
foreign materials. Therefore, it is inspiring to observe that the transfection of Jurkat cells
using PEI-based polyplexes was effectively improved by the simple addition of Ca2+ into
the transfection medium. With further investigation, mainly to reduce the cytotoxicity
while augmenting the efficiency of the current formulation, the findings of this study will
potentially be applied for the primary human T cell engineering with transgenes such as
chimeric antigen receptors (CARs) for T cell therapy. Nonetheless, further studies are
warranted on the role of calcium as a potential transfection enhancer in non-viral gene
deliveries.
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2.5.

Future Directions

2.5.1.

Other enhancers
Polycationic polymers are an excellent choice for complexing nucleic acids.

Besides, PEI, poly(L-Lysine) (PLL), Polyornithine, Polyarginine, and Histones, Protamine
sulfate (from Salmon Sperm is also known as Salmine) have an excellent ability to
condense DNA (Pandey and Sawant 2016). Protamine sulfate (also known as protamine)
is another known enhancer of transfection (Wagstaff and Jans 2007; Homann et al. 2017;
Ni, Feng, and Chau 2019) in mammalian cells. Protamine sulfate, an arginine-rich protein,
has multiple roles. One, it can complex DNA and become a DNA carrier. And two, it has
a natural peptide sequence (PKKKRKV) resembling the Nuclear Localization Sequence
(NLS). Protamine is a small protein with a molecular weight of 10-14 kDa and contains 4
NLS sequences that facilitate nucleic acids' entry into the nucleus. Protamine has also been
used to enhance the stability of polyplexes (Ni, Feng, and Chau 2019). Most interestingly,
a fusion protein consisting of protamine and HIV-specific antibody fragment was reported
to specifically deliver siRNA to HIV-infected cells (Song et al. 2005; Lostalé-Seijo and
Montenegro 2018).

Figure 2.15: Structure. Numbers in red indicate the molecular weight (in base pairs) of the
DNA ladder. Lane numbers are indicated in green. Electrophoretic run by Ms. Eva Barck.
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Taking benefit from this multi-functional protein, protamine, we have developed a
strategy to enhance the pDNA transfection efficiency in Jurkat or CTLL-2 cell lines.
Briefly, first, pDNA is complexed with protamine and then with PEI resulting in a tight
complex. After the endosomal escape of the nucleic acids from the polyplexes due to the
characteristic feature “proton-sponge” effect of PEI, the pDNA will be assisted in
translocation to the nucleus by protamine. This approach will improve the transfection
efficiency by promoting the gene expression by skipping the wait time of the pDNA to
translocate into the nucleus during cell division. A similar strategy has been previously
attempted in a liposome formulation (Wagstaff and Jans 2007).
We tested different combinations of protamine and PEI to complex pGFP and
analyzed them in a 1 % agarose gel (Figure 2.15). We found that protamine's lower weight
ratios to pGFP were optimal for a weight ratio of 1 or 2 of PEI-to-pGFP to condense pGFP
efficiently. Interestingly, any tested amounts of protamine by themselves were not enough
to condense pGFP (Figure 2.15). Therefore, we intend to use weight ratios of 0.1 and 0.25
of protamine-to-pGFP and a weight ratio of 1 or 2 of PEI-to-pGFP as a formulation in
future investigations.
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2.5.2.
2.5.2.1.

Generation of a CD19 CAR model mouse T cell line
Construction of pDNAs with CAR and anti-PD1 shRNA

Figure 2.16: Retroviral pDNA containing a second-generation CAR construct against
mouse CD19. The CAR protein translation is displayed as an orange arrow running from
position 1,825 (near HindIII) to 3,255 (near SalI) bps. pDNA sequence is obtained from
the Addgene, Inc. website, and the map is generated with additional features in v5.3
Snapgene Viewer.
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Figure 2.17: Quality of the extracted plasmids - pCAR (6,941 bps, Lane 3) in comparison
to pLuc (5,482 bps, Lane 1) and pGFP (4,722 bps, Lane 2) analyzed by agarose gel
electrophoresis. Numbers in red indicate the molecular weight (in base pairs) of the DNA
ladder. Lane numbers are indicated in green.

We aimed to generate a mouse CAR-T model cell line to recognize and kill CD19expressing mouse cells, potentially cancer cells. For this, we purchased a retroviral pDNA
that contained a second-generation CAR (1D3-28Z) against mouse CD19 (“MSGV-1D328Z All ITAMs intact” from Addgene, Inc., hereafter just “pCAR”, Figure 2.16). The main
components of this CAR construct include an scFv fragment comprising the variable light
chain (VL) followed by a variable heavy chain (VH) of the 1D3 (clone) antibody (against
mouse CD19), a portion of the sequence from mouse CD28 (costimulatory molecule), and
the cytoplasmic tail of the mouse CD3- (a T cell marker) (Kochenderfer et al. 2010). We
amplified the bacterial strain (“NEB Stable” supplied by Addgene, Inc.) that contained
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pCAR overnight and isolated pCAR using a miniprep plasmid isolation kit (Thermo
Scientific). We tested the quality of the extracted pCAR on a 1 % agarose gel (Figure 2.17).

Figure 2.18: p1s-2A-GFP vector containing a U6-shRNA construct (235 to 556) and a
P2A-GFP construct (1267 to 2022). pDNA sequence is obtained from Creative Biolabs,
Inc., and the map is generated with additional features in v5.3 Snapgene Viewer.

An immune checkpoint protein known as the programmed death-ligand 1 (PD-L1
or B7-H1 or CD274) is expressed on immune regulatory cells and some cancer cells. PDL1 binds to its partner programmed cell death protein 1 (PD1 or PDCD1 or CD279)
expressed on the surface of T cell. The interaction between PD1 and PD-L1 counters the
positive signals provided by the TCR and CD28 (Sharpe and Pauken 2018), rendering the
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T cells inactive. Since this interaction is detrimental in CAR-T cell therapy, the
downregulation or complete silencing of pdcd1 expression is suggested. Therefore, to
facilitate the CAR-T function, we wanted to silence the expression of pdcd1 by delivering
a pDNA encoding shRNA against moue PD1.
2.5.2.1.1.

Designing the anti-PD1 shRNA construct in a GFP-expressing pDNA

We, along with the scientists at Creative Biolabs, Inc. (Manufacturer), designed an
shRNA construct (Figure 2.18) that expresses under the U6 promoter. The U6-shRNA
construct at the BamHI site, and a CMV promoter-driven P2A-GFP construct between
XhoI and XbaI were inserted into the original pcDNA3.1(+) plasmid giving rise to
pcDNA3.1(+)-shRNA-CMV-2A-GFP (hereafter “p1s-2A-GFP”, Figure 2.18). P2A
(ATNFS LLKQA GDVEE NPG’P), like T2A and F2A, is a self-cleaving peptide. In
eukaryotic translation, ribosomes are known to skip the formation of the glycyl-prolyl
peptide bonds (Z. Liu et al. 2017). Therefore, a P2A DNA sequence between two ORFs
generates the first protein with 18-residues on the C-terminus and the second protein with
a Proline on its N-terminus. We designed this plasmid such that any ORF inserted upstream
of the P2A sequence would translationally express GFP separately and not in fusion.
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Figure 2.19: Design of the stop-free CAR primers. (a) Forward primer indicated in red in
5’-3’ direction. (b) Reverse primer indicated in magenta excluding the stop codon in green
in 3’-5’ direction. Source: Extracted from pCAR DNA sequence generated in v5.3
Snapgene Viewer.

2.5.2.1.2.

Generation of a stop-free CAR DNA

Because of a stop codon in the CAR ORF of pCAR, we generated a stop-free CAR
(CARsf) PCR product of size 1,464 bps by designing stop codon removing PCR primers
(forward primer: 5'- CTC GAG AAG CTT GCC ACC ATG GGT GTC CCT A -3', length
= 31 bases, melting temperature (Tm) = 74.2 0C, reverse primer: 5'- GGT ACC GTC GAC
TCT GGG GGC CAG GGT CTG CAT -3', length = 33 bases, Tm = 78.1 0C). The primers
were designed (Figure 2.19) such that the PCR product generated would have XhoI (C’TC
GAG) followed by HindIII (A’AG CTT) restriction sites on the 5’-end and a SalI restriction
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site (G’TC GAC) on the 3’-end. The complementary sequence to the stop codon (TGA),
i.e., TCA (reverse complementary), is removed from the reverse primer. Such deletion
causes a looped structure of the DNA-primer hybrid or an unhybridized portion of primer
onto the DNA during the annealing step of the PCR. Nonetheless, due to the hybridization
of most bases at the 5’-end of the reverse primer onto the pDNA, amplification of the CAR
ORF without the stop codon is expected.

Figure 2.20: Quality of the amplified stop-free CAR (CARsf) ORF from pCAR using stop
codon removing PCR primers analyzed by agarose gel electrophoresis. Numbers in red
indicate the molecular weight (in base pairs) of the DNA ladder. Lane numbers are
indicated in green. Lane 1-3 are the replicates of negative control in which pCAR was not
supplied. Lane 4-9 are the replicates of test control in which pCAR was supplied.

CARsf ORF was amplified using the primers, pCAR, and Phusion Green Hot Start
II High-Fidelity PCR Master Mix (Thermo Scientific). Later, the quality of the amplified
PCR product was checked on a 1 % agarose gel (Figure 2.20). It is demonstrated that the
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CARsf ORF (estimated to be 1,464 bps) was amplified (bands between 1,000 and 1,500
bps markers in Lanes 4-9 of Figure 2.20).

Figure 2.21: Quality of the gel-extracted stop-free CAR (Lane 2) DNA compared to pCAR
(Lane 1) analyzed by agarose gel electrophoresis. Numbers in red indicate the molecular
weight (in base pairs) of the DNA ladder. Lane numbers are indicated in green.

Next, the agarose gel with bands within 1,000 and 1,500 bps markers were cut using
a scalpel, digested, and DNA was extracted using Agarose Gel DNA Extraction Kit
(Thermo Scientific). The quality of the agarose gel extracted CARsf DNA was verified in
a 1 % agarose gel (Figure 2.21).
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2.5.2.1.3.

Construction of CAR pDNAs without the anti-PD1 shRNA construct

Figure 2.22: pAcGFP1-N3 (pGFP) vector. pDNA sequence is obtained from Takara, Inc.,
and the map is generated with additional features in v5.3 Snapgene Viewer.

Figure 2.23: Quality of HindIII and SalI double digests analyzed by agarose gel
electrophoresis. (a) pGFP (Lane 1) with its double digest (Lane 2). (b) CARsf (Lane 1)
with its double digest (Lane 2). Numbers in red indicate the molecular weight (in base
pairs) of the DNA ladder. Lane numbers are indicated in green.
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Figure 2.24: pIRES2-AcGFP1 (pIRES-GFP) vector. pDNA sequence is obtained from
Takara, Inc., and the map is generated with additional features in v5.3 Snapgene Viewer.

Figure 2.25: Quality of double digests analyzed by agarose gel electrophoresis. (a) pIRESGFP (Lane 1) with its SacI and SalI double digest (Lane 2). (b) pCAR (Lane 1) with its
HindIII and SalI double digest (Lane 2). Numbers in red indicate the molecular weight (in
base pairs) of the DNA ladder. Lane numbers are indicated in green.
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First, pGFP (Figure 2.22, kanamycin-resistant) and CARsf PCR product were
double digested with HindIII and Sal I and analyzed the extent of digestion in 1 % agarose
gel (Figure 2.23). Next, single major bands of the double digests were excised from the
agarose gel, and the DNA was purified using a gel extraction kit. Later, the pCARsf-GFP
vector containing a CARsf ORF upstream of GFP was constructed by ligating the double
digests of pGFP and CARsf using T4 DNA Ligase. This plasmid serves as a CAR construct
whose protein expression level is supposedly equivalent to that of GFP. Similarly, pIRESGFP (Figure 2.24, kanamycin-resistant) and pCAR were double digested with SacI & SalI
and HindIII & SalI, respectively. The extent of digestion was analyzed on a 1 % agarose
gel (Figure 2.25). Next, the double digests were excised from the agarose gel, and its DNA
was extracted using a gel extraction kit. The pCAR-IRES-GFP vector containing a native
CAR ORF upstream of the IRES-GFP was constructed by ligating the gel-extracted double
digest of pIRES-GFP and HindIII-CAR-SalI fragment using T4 DNA Ligase. This plasmid
serves as an alternative CAR construct whose protein expression level is supposedly
different from the IRES-driven GFP. The ligates were then used to separately transform E.
Coli XL-1 Blue competent cells (Agilent Technologies, Inc), giving rise to XL-1 Blue
pCARsf-GFP and XL-1 Blue pCAR-IRES-GFP strains, respectively.
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Figure 2.26: Quality of constructed plasmids analyzed by agarose gel electrophoresis.
Numbers in red indicate the molecular weight (in base pairs) of the DNA ladder. Lane
numbers are indicated in green. (a) Verification of pCARsf-GFP clones of even numbers,
Lane 1: pGFP, Lane 2: pCARsf-GFP from colony #2, Lane 3: pCARsf-GFP from colony
#4, Lane 4: pCARsf-GFP from colony #6, Lane 5: pCARsf-GFP from colony #8, Lane 6:
pCARsf-GFP from colony #10, Lane 7: pIRES-GFP, and Lane 8: pCAR-IRES-GFP from
colony #10. (b) Verification of pCAR-IRES-GFP clones of even numbers, Lane 1: pIRESGFP, Lane 2: pCAR-IRES-GFP from colony #2, Lane 3: pCAR-IRES-GFP from colony
#4, Lane 4: pCAR-IRES-GFP from colony #6, and Lane 5: pCAR-IRES-GFP from colony
#8.

We selected ten clones of each bacterial strain from kanamycin containing LB agar
plates. First, we analyzed the even-numbered clones on a 1 % agarose gel (Figure 2.26).
63

From the gel, it appears that pCAR-IRES-GFP colonies 2, 4, 6 (Lanes 2, 3, 4 in Figure
2.26b), and 10 (Lane 8 in Figure 2.26a) have a CAR construct in them as the bands are
above the pIRES-GFP ones. However, pCAR-IRES-GFP from colony 4 (Lane 3 in Figure
2.26b) seemed to have more distinct bands characteristic of a pure plasmid without
contaminants. Similarly, all even-numbered colonies of pCARsf-GFP appear to have a
CARsf construct in them as the bands are above the pGFP ones. Nonetheless, all these
plasmids must be verified by double digestions and analyzed by agarose gel.
2.5.2.1.4.

Construction of CAR pDNAs with the anti-PD1 shRNA construct

Figure 2.27: Quality of amplified and constructed plasmids analyzed by agarose gel
electrophoresis. Numbers in red indicate the molecular weight (in base pairs) of the DNA
ladder. Lane numbers are indicated in green. Lane 1: p1s-2A-GFP from manufacturer’s
stock, Lane 2: HindIII and XhoI double digest of p1s-2A-GFP from manufacturer’s stock,
Lane 3: p1s-2A-GFP from ampicillin-containing media, Lane 4: p1s-2A-GFP from
ampicillin and tetracycline-containing media, and Lane 5: p1s-CARsf-2A-GFP from
ampicillin media (transformation sample grown overnight and not from a single colony).

We transformed the tetracycline-resistant XL-1 Blue competent cells with the
Creative Biolabs, Inc. supplied ampicillin-resistant p1s-2A-GFP and grown them in
ampicillin only and ampicillin & tetracycline containing LB media overnight and tested
the quality of pDNAs extracted using a miniprep kit on a 1 % agarose gel. We found that

64

p1s-2A-GFP from either antibiotic LB media could yield pure plasmid (Lane 3 and 4 in
Figure 2.27). Next, we double digested the p1s-2A-GFP (Lane 1 in Figure 2.27) with
HindIII and XhoI (Lane 2 in Figure 2.27). We then ligated the HindIII-CARsf-SalI
fragment with HindIII & XhoI double digested p1s-2A-GFP using T4 DNA Ligase. It must
be noted that the cohesive ends of XhoI and SalI are compatible with each other, and hence
ligation is possible. The ligation sample was quickly used to transform XL-1 Blue
competent cells. The transformed cells were grown overnight in ampicillin-containing LB
media, and pDNA was extracted using a miniprep kit. From the gel, it appears that ligation
and transformation successfully gave us the p1s-CARsf-2A-GFP vector (Lane 5 in Figure
2.27).

Figure 2.28: Quality of p1s-CARsf-2A-GFP plasmid clones analyzed by HindIII and SalI
double digestions in agarose gel electrophoresis. Numbers in red indicate the molecular
weight (in base pairs) of the DNA ladder. Lane numbers are indicated in green. Lane 1:
p1s-2A-GFP (manufacturer’s stock), Lane 2: p1s-2A-GFP (ampicillin grown, not from a
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colony), Lane 3: p1s-2A-GFP (ampicillin and tetracycline grown, not from a colony), Lane
4: p1s-CARsf-2A-GFP (ampicillin grown, not from a colony), Lane 5: p1s-CARsf-2AGFP from colony #1, Lane 6: p1s-CARsf-2A-GFP from colony #3, Lane 7: p1s-CARsf2A-GFP from colony #5, Lane 8: p1s-CARsf-2A-GFP from colony #7, and Lane 9: p1sCARsf-2A-GFP from colony #9. Arrows in red indicate the appropriate band showing the
difference between non-inserted and inserted constructs. The arrow in green indicates nonligated fragments.

We wanted to select a p1s-CARsf-2A-GFP from a single clone, and therefore 10
colonies were picked from ampicillin and tetracycline-containing LB agar plates. The oddnumbered colonies were tested on a 1 % agarose gel after double digestions with HindIII
and SalI. Typically, since there are two SalI and only one HindIII site in the p1s-2A-GFP
vector, double digestion with both corresponding enzymes should display three bands
corresponding to fragments of length 3,031 (4,259-1,228), 2,185 (6,444-4,259), and 1,230
(6,444-1,228) bps (Figure 2.18). These three bands are clearly shown at the exact positions
in Lane 1 and Lane 3 of Figure 2.28. However, although it is supposed to be the same
plasmid, Lane 2 appears to have contamination, and therefore the corresponding sample
was never used for further investigation. If the CARsf construct was successfully inserted
into the major band, i.e., the 3,031 bps band, it should displace the 3,031 band to 4,495
(3,031 + 1,464) bps (shown in Lane 5 of Figure 2.28), and the other bands should not
displace as they are not supposed to have any insert in them. The bands in the gel indicate
complete digestion. Therefore, only clone #1 of p1s-CARsf-2A-GFP has the pure plasmid
with the right construct.
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Figure 2.29: Quality of p1s-2A-GFP, p2A-GFP, and p1s-CARsf-2A-GFP plasmids
analyzed by HindIII and SalI double digestions in agarose gel electrophoresis. Numbers in
red indicate the molecular weight (in base pairs) of the DNA ladder. Lane numbers are
indicated in green. Lane 1: p1s-2A-GFP (ampicillin and tetracycline grown, not from a
colony), Lane 2: double digest of Lane 1 plasmid, Lane 3: p1s-2A-GFP from colony #1,
Lane 4: double digest of Lane 3 plasmid, Lane 5: p2A-GFP (ampicillin grown, not from a
colony), Lane 6: double digest of Lane 5 plasmid, Lane 7: p1s-CARsf-2A-GFP from
colony #1, and Lane 8: double digest of Lane 7 plasmid.

Next, to create anti-PD1 shRNA-free constructs (p2A-GFP and pCARsf-2A-GFP)
to test the potency of CAR alone, we digested the p1s-2A-GFP vector with BamHI and
BglII to excise the U6-shRNA fragment and thereby yield p2A-GFP. However, we could
not do the same with p1s-CARsf-2A-GFP to get pCARsf-2A-GFP because the CARsf
DNA has a BamHI site in it, and therefore, we attempted to insert CARsf into the p2AGFP instead. Briefly, the BamHI and BglII double digested p1s-2A-GFP fragment was
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excised from the gel and allowed to self-ligate to form p2A-GFP. The ligation sample was
used to transform XL-1 Blue, and the plasmid extracted from the strain was analyzed on 1
% agarose gel.
First of all, six bands in the p1s-2A-GFP double digested sample indicate that the
digestions are not complete or premature. These six bands correspond to 5,216 (HindIII to
SalI at 6,444), 4,261 (from SalI at 6,444 to SalI at 4,259), 3,415 (from SalI at 4,259 to
HindIII), 3,031 (from HindIII to SalI at 4,259), 2,185 (from SalI at 4,259 to SalI at 6,444),
and 1,230 (from SalI at 6,444 to HindIII) bps (Figure 2.19). These bands appear in Lanes
2 and 4 of Figure 2.29.
If the BamHI and BglII digestions are complete, the bands with length 4,261, 3,415,
and 1,230 bps should all be shortened by 544 bps (from BglII at 12 to BamHI at 556),
resulting in 3,717 (4,261-544), 2,871 (3,415-544), 686 (1,230-544) bps, respectively.
These three short bands are clearly shown in Lane 6 of Figure 2.29. Hence, p2A-GFP vector
construction is complete and confirmed. Sequencing is pending.
Similarly, if CARsf insertion into p1s-2A-GFP is complete, then the bands with
length 5,216, 4,261, and 3,031 bps should all have an increased length, resulting in 6,680
(5,216 + 1,464), 5,725 (4,261 + 1,464), and 4,495 (3,031 + 1,464) bps. All the three bands
are shown in Lane 8 of Figure 2.29. Hence, p1s-CARsf-2A-GFP vector construction is also
complete and confirmed. Sequencing is pending.
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Figure 2.30: Quality of p2A-GFP, p1s-2A-GFP, pCARsf-2A-GFP, and p1s-CARsf-2AGFP plasmids analyzed by HindIII and SalI double digestions in agarose gel
electrophoresis. Numbers in red indicate the molecular weight (in base pairs) of the DNA
ladder. Lane numbers are indicated in green. Lane 1: p2A-GFP (ampicillin grown, not from
a colony), Lane 2: double digest of Lane 1 plasmid, Lane 3: p1s-2A-GFP from colony #1,
Lane 4: double digest of Lane 3 plasmid, Lane 5: pCARsf-2A-GFP (ampicillin grown, not
from a colony), Lane 6: double digest of Lane 5 plasmid, Lane 7: p1s-CARsf-2A-GFP
from colony #1, and Lane 8: double digest of Lane 7 plasmid.

Finally, to construct pCARsf-2A-GFP, the HindIII-CARsf-SalI fragment was
ligated to HindIII and SalI double digested p2A-GFP using T4 DNA Ligase. The ligated
sample was immediately used to transform XL-1 Blue competent cells, and the pDNA
extracted from an overnight culture of ampicillin-containing LB media was analyzed on a
1 % agarose gel (Figure 2.30). The complete double digestions of all the plasmids that were
constructed until now were analyzed. We know that complete digestions of HindIII and

69

SalI on these plasmids would give only three fragments discussed before. The 2,185 band
(from SalI at 4,259 to SalI at 6,444) did not change in size in any of the constructed
plasmids (Lanes 2, 4, 6, 8 in Figure 2.30). The biggest band, i.e., 3,031 (from HindIII to
SalI at 4,259), is increased in size only in the CARsf containing plasmids (Lanes 6 and 8
in Figure 2.30). And the smallest band, i.e., 1,230 (from SalI at 6,444 to HindIII at 1,228),
is reduced in size only in the U6-shRNA construct-free plasmids (Lanes 2 and 6 in Figure
2.30). These results demonstrate that all the construction of plasmids, namely, p2A-GFP,
pCARsf-2A-GFP, and p1s-CARsf-2A-GFP, is complete and confirmed. Nevertheless,
sequencing of all three plasmids may still be necessary.
2.5.2.1.5.

Test of pDNA constructs on Jurkat

Figure 2.31: Transfection of Jurkat cells using the newly constructed plasmids using 10
mM calcium-assisted PEI polyplexes (a) in comparison to lipofectamine 3000-based
lipoplexes analyzed at 120 hpt using flow cytometer. The horizontal line serves as a
threshold value for easy comparisons. All comparisons (only the MFI not GFP+
percentage) are made with the “pUC18” group; Results are presented as mean ± standard
deviation (n=2 (a) and n=3 (b); two-way ANOVA with Dunnett’s multiple comparisons,
**** p < .0001, *** p = 0.0005 to 0.0009, and * p = 0.0152 to 0.0493).
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We tested the newly constructed plasmids on the transfection of Jurkat cells using
calcium-assisted PEI formulation compared to the Lipofectamine 3000 formulation. For
reasons discussed earlier in the chapter, we used pUC18 as a negative control. We found
that pCARsf-GFP (with the pGFP vector backbone) outperformed its positive control
pGFP in both versions of formulations (Figure 2.31). Similarly, pCAR-IRES-GFP has
outperformed its positive control pIRES-GFP, however ineffective (Figure 2.31). A
common factor in both these plasmids is the addition of CAR DNA. We suspected that the
Kozak sequence present in the CAR ORF is responsible for such enhanced GFP expression.
Interestingly, only p2A-GFP worked similarly to pGFP, but the other pcDNA3.1backbone plasmids did not show significant transfection efficiency. However, to properly
gauge the level of transfection efficiency these plasmids can offer, a suitable transfection
host such as the Human embryonic kidney 293 (HEK293) cells or Chinese hamster ovary
(CHO) cells is required.
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CHAPTER III

DESIGN, SYNTHESIS, AND PURIFICATION OF AN N-TERMINAL CYSTEINE
CONTAINING MOUSE INTERLEUKIN-2 FOR SITE-SPECIFIC
BIOCONJUGATIONS

3.1.

Background and Significance

3.1.1.

Interleukin-2: Secretion, Regulation, and Signaling
Interleukin-2 (IL-2) is a primary cytokine and a T cell growth factor due to its role

in providing proliferative signals to T cells by engaging with the IL-2 receptor (IL-2R). It
is predominantly secreted by the Th cells in the secondary lymphoid organs (such as lymph
nodes) and, to a lesser extent, by the Tc cells, NK cells, and NKT cells (Onur Boyman and
Sprent 2012). The IL-2 production is strongly induced in antigen-activated Th and Tc cells,
although synthesis by the latter is relatively weak. The silencing of the Il2 gene regulates
IL-2 production via a transcription factor called B lymphocyte-induced maturation protein
1 (BLIMP1 or PRDM1) (Onur Boyman and Sprent 2012). In a negative feedback
mechanism, high-level expression of BLIMP1 activated by the IL-2 signaling represses the
IL-2 production. However, unless there is prolonged exposure to an antigen, memory
differentiated effector T cells (particularly TCM cells) express low levels of BLIMP1 and
thereby retain the ability to produce IL-2. In the event of persistent TCR-mediated
stimulations and the IL-2 signals, T cells induce the expression of Fas and FasL and thereby
promote AICD (Onur Boyman and Sprent 2012).
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Figure 3.1: The formation of IL-2/IL-2R complex and signal transduction. Transpresentation of IL-2 is mediated by Dendritic cells (DC) in this example. (Onur Boyman
and Sprent 2012). Used with Permission.

IL-2 induces signaling by binding to the IL-2R, which comprises of 3 subunits,
namely CD25 (IL-2R), CD122 (IL-2R), and the CD132 (c) (G. A. Smith, Taunton, and
Weiss 2017; Jiang, Zhou, and Ren 2016; K. A. Smith 2006; Lamaze et al. 2001; Malek and
Castro 2010; Stauber et al. 2006). Monomeric CD25, also known as the low-affinity IL2R, is expressed on activated T cells and can associate with IL-2 by itself, but the affinity
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is relatively low (Malek and Castro 2010; Onur Boyman and Sprent 2012) (Kd ≈ 10 nM),
and this binding induces no signal transduction (Figure 3.1) (Onur Boyman and Sprent
2012). The heterodimeric IL-2R (Figure 3.1) composed of CD122 and CD132 has
intermediate-affinity (Kd ≈ 1 nM) (Jiang, Zhou, and Ren 2016; Onur Boyman and Sprent
2012) and is found on memory cytotoxic CD8+ T cells (Figure 3.2) (Jiang, Zhou, and Ren
2016) and natural killer (NK) cells (Jiang, Zhou, and Ren 2016; Vazquez-Lombardi et al.
2017). Finally, the high-affinity IL-2R is made of all three (hence known as the trimeric
receptor) subchains (Kd ≈ 10 pM) (Malek and Castro 2010; Stauber et al. 2006; Onur
Boyman and Sprent 2012; G. A. Smith, Taunton, and Weiss 2017) and is predominantly
expressed on the surface of effector T cells and CD4+ CD25+ FoxP3+ regulatory T (Treg)
cells (Stauber et al. 2006; Vazquez-Lombardi et al. 2017; O. Boyman 2006).
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Figure 3.2: The expression of the IL-2R on different immune and non-immune cells. “-”,
indicates the background expression level; “+”, low expression level; “++” high expression
level; “+++”, very high expression level. (Onur Boyman and Sprent 2012). Used with
Permission.

While all T cells constitutively express CD132 (Figure 3.2), naïve T cells do not
significantly express CD25 (G. A. Smith, Taunton, and Weiss 2017), except the Treg cells
(Onur Boyman and Sprent 2012). Nevertheless, immediately after activation, T cells
upregulate the expression of CD25 (G. A. Smith, Taunton, and Weiss 2017), which induces
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a remarkable increase in the uptake of IL-2. After endocytosing the quaternary complex
(IL-2-IL-2R), CD25 is recycled back to the cell surface while CD122 and CD132 along
with IL-2 are rapidly degraded (Duprez and Dautry-Varsat 1986; Hémar et al. 1995; G. A.
Smith, Taunton, and Weiss 2017; Yu et al. 2000; Stauber et al. 2006).
For effective signal transduction, the IL-2R has to form a hetero-trimeric (IL-2R,
IL-2R, and c) complex (Yu et al. 2000). The  subunit does not have a signaling domain
(Fan et al. 2018), and hence the internalization of the IL-2/IL-2R complex depends solely
on the  subunit and the c. The IL-2R chain binds to Janus family kinase 1 (JAK1) while
the c binds to JAK3 (Figure 1.4) (Ross and Cantrell 2018). The occupancy of the IL-2R
triggers the JAK1/JAK3 activation. Although with relatively low affinity, the intermediateaffinity receptor (IL-2R and c) can internalize IL-2 and provide signals in human
memory Tc cells and NK cells. Interestingly, however, due to the inability of IL-2 to bind
to the dimeric mouse IL-2R () architecture (Gesbert, Morau, and Thèze 2005; Kumaki
et al. 1993; Chastagner et al. 1996; Ross and Cantrell 2018), most biological functions of
IL-2 in mice are mediated by the trimeric-receptor (Ross and Cantrell 2018).
3.1.2. Production of IL-2 at laboratory scale
High-scale production of IL-2 is a laborious and time-consuming undertaking, and
therefore, most commercially available recombinant IL-2 are expensive for general use in
biological laboratories. Therefore, attempts were made to simplify the production process
and overproduce IL-2 more cheaply.
Production of protein of interest requires that a plasmid DNA (pDNA) encoding
the protein of interest be introduced into a host organism. In place of pDNA, transposon
systems can also be used that can integrate into the host genome. Selecting a suitable host
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for producing a protein of interest has simplified over decades of scientific research in
recombinant protein technology. Today, many researchers use Escherichia coli (E. coli)
for the production of many proteins due to its fast growth rate and high protein yield; Yeast
systems such as Saccharomyces cerevisiae and Pichia pastoris, to produce eukaryotic
proteins that often require post-translational modifications (PTMs) such as glycosylation,
phosphorylation, N-terminal methionine removal, and N-acetylation; Mammalian systems
such as Chinese Hamster Ovary (CHO) and Human Embryonic Kidney (HEK 293) cell
lines are used majorly for the approved recombinant therapeutic proteins (Khan 2013;
Tripathi and Shrivastava 2019).
Research shows that the eukaryotic protein IL-2 does not require glycosylation for
effective function (Robb et al. 1984; Weir and Sparks 1987). Therefore, we simply chose
the bacterial system for the production of IL-2 as PTMs are not required. Further, we chose
E. coli as it is a well-established cell factory and the most popular expression platform
(Rosano and Ceccarelli 2014). The main advantages of using E. coli include unparalleled
growth kinetics, a doubling time of just twenty minutes, inexpensive media components,
fast and easy transformation with exogenous DNA, and high cell density culture generation
with a theoretical density limit of around 200 g dry cell weight per liter (Rosano and
Ceccarelli 2014).
The E. coli strain BL21 DE3 combined with the T7 promoter-based expression
vector is a widely employed production strategy for expressing recombinant proteins
(Zhang et al. 2015). This strategy is efficient due to the constitutive expression of T7 RNA
polymerase (T7 RNAP) in BL21 DE3, a protein with an 8-fold faster transcription activity
relative to the E. coli RNAP (Zhang et al. 2015). The gene encoding T7 RNAP is under the
tight control of the lacUV5 promoter (PlacUV5), a strong variant of the wild-type lac
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promoter. Lactose, a disaccharide, is a positive regulator of the lac operon (Figure 3.3) in
bacteria. Lactose functions by inhibiting the lac repressor and promoting the structural
genes' transcription (Z, Y, and A in Figure 3.3) in the lac operon.

Figure 3.3: Regulation of the lac operon. The genes – I, Z, Y, and A encode the Lac
repressor, -galactosidase, Permease, and Transacetylase, respectively. The function of the
lac repressor is to bind to the operator region (O) and block the binding of the RNA
polymerase to the promoter region (P), thereby preventing the transcription of adjacent
structural genes (Z, Y, and A). Lactose present in bacteria prevents the binding of lac
repressor to the operator region, thereby inducing the expression of the structural genes.
(Griffiths et al. 1999). Used with Permission.

Similarly, the expression of T7 RNAP under the control of PlacUV5 can be induced
by using lactose or its structural analog, Isopropyl--D-1-thiogalactopyranoside (IPTG).
One great benefit of using IPTG over lactose is that the Lac Z product, -galactosidase,
cannot hydrolyze IPTG as it converts lactose into glucose and galactose. Therefore, lactose
but not IPTG will eventually be consumed and depleted by the bacteria. Often, the
concentration of IPTG dictates the expression level of the final product (a recombinant
protein) in BL21 DE3. The T7 RNAP, whose expression is induced by IPTG, can bind to
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any T7 promoter present in the host and, in this manner, lead to the expression of the
recombinant protein. Therefore, BL21 DE3 should first be transformed with T7 promoterbased expression vectors such as pET-3a, pET-3b, pET-3c, and pET-3d to express the
protein of interest.
Most of the IL-2 molecules, like many other eukaryotic proteins expressed in E.
coli, remain insoluble. Therefore, its production in E. coli leads to protein aggregations and
the formation of inclusion bodies (Halfmann et al. 1993). This phenomenon is particularly
true when high levels of eukaryotic proteins are produced. Inclusion bodies are formed due
to misfolding (inaccurate folding) or partial folding of proteins, absence or low-expression
of chaperones & post-translational machinery (in case of eukaryotic proteins), a reduced
environment in the cytosol, and overexpression of proteins that exceeds 2 % of the total
cellular protein (Singh et al. 2015).
Mild solubilizing agents can dissolve inclusion bodies to get inactive or denatured
formed of proteins. However, extraction, refolding, and purification can be done, although
these are often time-consuming and expensive. Nevertheless, due to the specificity of
protein aggregations, most proteins found in the inclusion bodies are often just the protein
of interest. Hence, if proper extraction methods are implemented to isolate protein from
inclusion bodies, one can reduce the dependence on extensive chromatography techniques.
Although the formation of inclusion bodies can be prevented by strictly regulating
the temperature and induction levels, one desirable and effective strategy to increase the
quantity of purified protein of interest is to elevate the expression level of native (bacterial)
chaperones or to transform the bacteria with different chaperone system to aid the protein
folding.
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Despite many efforts of the bacterial cells to properly fold the newly synthesized
protein, such as the fine regulation of protein levels and ribosomal protection of the nascent
polypeptide chains, the aggregation and misfolding of many of them cannot be entirely
avoided (Sabate, De Groot, and Ventura 2010). In response to such misfolding, a genetic
transcriptional response is triggered in bacterial cells. This response involves increasing
the expression levels of the heat-shock proteins (HSPs) and chaperones besides the changes
in the levels of ribosome-associated proteins (Sabate, De Groot, and Ventura 2010). In this
translational and post-translational regulation, a heat-shock sigma factor called 32
regulates the expression of chaperonin proteins such as ClpB, DnaK, DnaJ, GroES, GroEL,
GrpE, IbpA, and IpbB (Sabate, De Groot, and Ventura 2010). Three main chaperone
complexes aid the folding of newly synthesized polypeptides in bacteria: i) GroEL-GroES
(ELS), ii) DnaK-DnaJ-GrpE (KJE), and iii) Trigger factor (TF).
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Figure 3.4: Representation of the protein folding mechanism involving the three wellcharacterized chaperone systems – Trigger Factor, DnaK-DnaJ-GrpE, and GroES-GroEL.
(Sabate, De Groot, and Ventura 2010). Used with Permission.

The first chaperone to associate with a nascent polypeptide chain is the 48 kDa
protein, TF (Sabate, De Groot, and Ventura 2010). TF comprises an N-terminal ribosomebinding domain (RBD), a peptidyl-prolyl cis/trans isomerase activity domain (PPIase), and
a C-terminal domain whose function is unknown. All these domains interact with the
growing polypeptide chain at the ribosome and aids in protein folding. DnaK cooperates
with TF in aiding the folding of the growing polypeptide chain (Figure 3.4). While TF
works independently of Adenosine-triphosphate (ATP), the KJE and the ELS complexes
are dependent on ATP for their function.
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The KJE system involves four steps: i) The ATP-driven co-chaperone, DnaJ, binds
to the unfolded polypeptide chain, ii) DnaK, comprised of a 44 kDa N-terminal nucleotidebinding domain (NBD) and a 25 kDa substrate-binding domain (SBD), binds to the
polypeptide-DnaJ complex at the solvent-exposed hydrophobic regions of the unfolded
polypeptide chain and activates the DnaJ’s ATP hydrolytic activity, thereby stabilizing the
ADP bound state, which has more affinity to bind to a substrate, iii) The nucleotide-release
cofactor, GrpE, dissociates ADP from DnaK, and finally iv) DnaK binds to ATP stabilizing
the low-affinity state and triggers the release of the folded protein (Sabate, De Groot, and
Ventura 2010).
GroEL comprises 14 identical 57 kDa subunits forming two stacked heptameric
rings (Figure 3.4, green and red ring structures). At the same time, the GroES (Figure 3.4,
orange protein) is a disk-shaped heptameric protein comprised of seven identical 10 kDa
subunits (Sabate, De Groot, and Ventura 2010). The ELS systems function via two
principal actions: i) the binding of non-natively folded protein in an open ring of the GroEL
by making multivalent hydrophobic interactions between non-natively folded protein and
the apical domains of the GroEL; ii) protein folding in an encapsulated hydrophilic
chamber formed by ATP and GroES as a lid on top of the GroEL homotetradecameric
protein (Tyagi, Fenton, and Horwich 2009). In a mechanism directed by the ATP/GroES
lid, the GroEL apical domain makes rigid body movements that release the protein into the
GroES-domed hydrophilic chamber, where the protein folds and is subsequently released
(Tyagi, Fenton, and Horwich 2009).
Here, we have designed an N-terminal Cysteine containing mouse IL-2 (C-IL2) by
simply adding a Methionine and Cysteine to the N-terminus and six Histidine residues at
the C-terminus of a mouse IL-2 (Accession number #AAA39281, a 169 amino acid
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protein). The N-terminal Cysteine was designed for the site-specific bioconjugations to
therapeutic macromolecules. Such IL-2-functionalized payloads can be delivered to the IL2 receptor (IL-2R)-expressing T Lymphocytes. The 6-Histidines (Histag) at the C-terminus
were designed for affinity purification using Nickel-charged Nitrolotriacetic acid (NiNTA) crosslinked agarose resin. It is known in literature and practice that the Histag
containing recombinant protein can be purified when high concentrations of Imidazole an analog for the side-chain of Histidine - is used to strip off the recombinant protein bound
to the Ni-NTA agarose resin. To purify C-IL2 folded in its native form and to prevent the
formation of inclusion bodies to some extent, we employed chaperone proteins that aid in
the folding of C-IL2 synthesized in an E. coli strain BL21 DE3.
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3.2. Materials and Methods
3.2.1.

Materials
Tris (Fisher Bioreagents), Glycine (Fisher Bioreagents), 2-Mercaptoethanol

(−ME, Millipore Sigma), Isopropylthio--galactosidase (1 M IPTG solution, Teknova),
L-Arabinose (Acros Organics), Tetracycline (Fisher Bioreagents), Ampicillin (Alfa
Aesar), Chloramphenicol (Alfa Aesar), Lysozyme (Affymetrix), Sodium monobasic
phosphate (Sigma Aldrich), Sodium dibasic phosphate (Sigma Aldrich), Sodium Chloride
(Fisher Scientific), Magnesium Chloride (Millipore), Potassium Chloride (Sigma Aldrich),
Sodium Hydroxide (Acros), Acetic Acid (Acros), Sodium n-Dodecyl Sulfate (SDS,
Thermo Scientific), EthyleneDiamineTetraAcetic acid (EDTA, Acros Organics), Glycerol
(Alfa Aesar), Guanidium hydrochloride (Fisher Bioreagents), Urea (Fisher Chemical),
Imidazole (Sigma Aldrich), TCEP (Thermo Scientific), Calcium Chloride (Millipore
Calbiochem), Agarose (Alfa Aesar), RNase A (Thermo Scientific), Universal Nuclease for
Cell Lysis (PierceTM Thermo Scientific), Protamine Sulfate from Salmon Sperm (TCI),
Tryptone (Fisher Bioreagents), Yeast Extract (Fisher Chemical), Bacteriological Agar
(Sigma Aldrich), Nickel-charged NitroloTriacetic Acid (Ni-NTA) agarose resin
(ThermoFisher Scientific), 14 mL Culture tubes (Fisher Scientific), Adenosine-5’triphosphate disodium salt (ATP, Alfa Aesar), OmniPur(R) PMSF (Millipore), Leupeptin
(Affymetrix), 10-250 kDa PageRulerTM Prestained Protein Ladder (Thermo Scientific),
PE-conjugated anti-mouse CD25 antibody (clone PC61, BD Biosciences), FITC
conjugated anti-mouse CD122 antibody (clone TM-beta1, eBioscience), and APC
conjugated anti-mouse CD132 antibody (clone TUGm2, Biolegend) were used as
purchased from manufacturers.
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3.2.2.
3.2.2.1.

Preparation of Media, Buffers, and Solutions
Luria-Bertani (LB) Media
LB media was prepared using 10 g Tryptone, 5 g Yeast Extract, and 10 g Sodium

Chloride in 1 liter of pure water and heat-sterilized in Yamato SM510 autoclave.
Autoclaved LB media was stored in 4 0C until further use. LB agar media was prepared by
including 20 g bacteriological agar (or agar-agar, Sigma Aldrich) in the above composition.
Autoclaved LB agar was left to cool to nearly 45 0C before pouring on bacterial culture
plates.
3.2.2.2.

Lysozyme Stock Solution
A 50 mg/mL stock solution was prepared by mixing 500 mg of ultrapure Lysozyme

in 10 mL of ultrapure water and stored in -20 0C until further use.
3.2.2.3.

Stock Solution A (SSA) and B (SSB)
A 10X SSA buffer (200 mM Sodium Monobasic Phosphate and 5 M Sodium

Chloride) was prepared in 1-liter using 27.6 g NaH2PO4 and 292.9 g of NaCl. Similarly,
10X SSB buffer (200 mM Sodium Dibasic Phosphate and 5 M Sodium Chloride) was
prepared in 1-liter using 28.4 g Na2HPO4 and 292.9 g of NaCl. SSA and SSB were stored
at room temperature until further use.
3.2.2.4.

Denaturing Lysis Buffer (DLB)
DLB (30 % glycerol, 6 M Guanidium Hydrochloride, 20 mM Sodium Phosphate,

500 mM NaCl, pH 7.8) was prepared in 100 mL using 30 mL 100 % Glycerol, 57.3 g GnHCL, 0.58 mL 10X SSA, and 9.42 mL 10X SSB. DLB was stored at room temperature
until further use.
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3.2.2.5.

Denaturing Binding Buffer (DBB)
DBB (8 M Urea, 20 mM Sodium Phosphate, 500 mM NaCl, pH 7.8) was prepared

in 100 mL using 48.1 g Urea, 0.58 mL 10X SSA, and 9.42 mL 10X SSB. DBB was stored
at room temperature until further use.
3.2.2.6.

Denaturing Wash Buffer (DWB)
DWB (8 M Urea, 20 mM Sodium Phosphate, 500 mM NaCl, pH 6.0) was prepared

in 100 mL using 48.1 g Urea, 7.38 mL 10X SSA, and 2.62 mL 10X SSB. DWB was stored
at room temperature until further use.
3.2.2.7.

Imidazole Solution
A 3 M Imidazole stock solution (3 M Imidazole, 20 mM Sodium Phosphate, 500

mM Sodium Chloride, pH 6.0) was prepared in 100 mL using 20.6 g Imidazole, 8.77 mL
10X SSA, and 1.23 mL 10X SSB. Imidazole solution was stored at room temperature until
further use.
3.2.2.8.

PMSF Stock Solution
A 200 mg ultrapure powder was dissolved in 11.48 mL of Isopropanol to make a

final concentration of 0.1 M, aliquots of 500 L were made and stored in -20 0C until
further use.
3.2.2.9.

Leupeptin Stock Solution
A 5 mg ultrapure powder was dissolved in 4 mL of sterilized ultrapure water to

make a final concentration of 1.25 mg/mL and was stored in -20 0C until further use.
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3.2.2.10. Glycine Buffer (GB)
A 500 mL GB solution (100 mM Glycine, 10 mM Calcium Chloride, and 5 mM
Magnesium Chloride, pH 8.6) was made using 4.855 g of glycine sodium salt hydrate, 735
mg of CaCl2, and 2.5 mL of 1 M MgCl2 solution.
3.2.2.11. Sodium Chloride Solution
A 1 M NaCl solution was prepared using 2.64 g of sodium chloride in 45 mL water.
3.2.2.12. Native Purification Buffer (NPB)
A 5X NPB (250 mM Sodium Phosphate, 2.5 M Sodium Chloride, pH 8.0) was
prepared in 250 mL using 7 g NaH2PO4 and 29.2 g of NaCl. NPB was used to make native
binding, wash, and elution buffers. NPB was stored at room temperature until further use.
3.2.2.13. Native Binding Buffer (NBB)
A 1X NBB (50 mM Sodium Phosphate, 0.5 M Sodium Chloride, 10 mM Imidazole,
pH 8.0) was prepared in 30 mL using 6 mL 5X NPB and 107 L of 2.8 M Imidazole. NBB
was stored at room temperature until further use.
3.2.2.14. Native Wash Buffer (NWB)
A 1X NWB (50 mM Sodium Phosphate, 0.5 M Sodium Chloride, 20 mM
Imidazole, pH 8.0) was prepared in 50 mL using 10 mL 5X NPB and 357 L of 2.8 M
Imidazole. NWB was stored at room temperature until further use.
3.2.2.15. Native Elution Buffer (NEB)
A 1X NEB (50 mM Sodium Phosphate, 0.5 M Sodium Chloride, 300 mM
Imidazole, pH 8.0) was prepared in 25 mL using 5 mL 5X NPB and 2.7 mL of 2.8 M
Imidazole. NEB was stored at room temperature until further use.
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3.2.2.16. ATP Stock solution
A 180 mM ATP (551.15 Da) stock solution was prepared by dissolving 2 g of ATP
in 20 mL of pure water. ATP solution was stored at room temperature until further use.
3.2.2.17. ATP wash buffer (AWB)
A 1X AWB (20 mM HEPES, 10 mM Imidazole, 5 mM ATP, 10 mM MgCl2, 150
mM KCl, and 1 g/mL Leupeptin, pH ~ 7.0) was prepared in 40 mL using stock solutions
of 1 M HEPES, 2.8 M Imidazole, 180 mM ATP, 1 M MgCl2, 1 M KCl, and 100 g/mL
Leupeptin. AWB was stored at room temperature until further use.
3.2.2.18. PAGE Gel Fixing Solution
A 1-liter stock solution (40 % Ethyl Alcohol and 10 % Acetic Acid) was prepared
by mixing 100 g of acetic acid with 400 mL of alcohol and up to 600 mL of pure water.
The fixing solution was stored at room temperature until further use.
3.2.3.

Bacterial Transformation
Using the manufacturer's recommended protocol, E. coli BL21 DE3 competent

cells (Agilent Technologies) were first transformed with a chloramphenicol resistant
chaperone plasmid, pG-KJE8. Simultaneously, cells were transformed with pUC18 (an
ampicillin-resistant control plasmid) separately to compare the transformation efficiencies.
The solution with transformed cells was spread with a sterile L-shaped glass spreader on
Ampicillin-containing LB agar plates. Single colonies from ampicillin plates were selected
with a sterile inoculation loop and inoculated in 8 mL of ampicillin-containing LB media.
Bacteria were allowed to replicate overnight at 37 0C and 250 rpm in a incubator-cum
shaker. Later, aliquots of bacteria in 25% glycerol-containing LB media were prepared and
stored in -80 0C until further use.
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Next, the pG-KJE8 transformed BL21 DE3 cells were separately transformed
with pET-3a/C-IL2 and pET-3a/IL2-HPhA using the manufacturer’s recommended
protocol. Transformed cells were initially grown on plates with ampicillin and
chloramphenicol-containing LB-media. Single colonies were selected with a sterile
inoculation loop and inoculated in 8 mL of ampicillin and chloramphenicol-containing LB
media. Bacteria were allowed to replicate overnight at 37 0C and 250 rpm in a incubatorcum shaker. Later, aliquots of bacteria in 25% glycerol-containing LB media were prepared
and stored in -80 0C until further use. The transformed cells were therefore named BL21
DE3 pG-KJE8 pET-3a/C-IL2 and BL21 DE3 pG-KJE8 pET-3a/IL2-HPhA.
3.2.4.

Protein Production
BL21 DE3 pG-KJE8 pET-3a/C-IL2 were grown overnight in 8 mL of ampicillin

and chloramphenicol-containing LB media at 37 0C and 250 rpm in an incubator-cum
shaker. Later, 8 mL inoculum is transferred to 750 mL of fresh LB media and aliquoted
into 2*250 mL in 1-liter flasks and 4*62.5 mL 250-mL flasks. Next, culture was grown at
37 0C and 250 rpm until the optical density (OD) at 600 nm (OD600) reached nearly 0.15.
At this point, the expression of the G-KJE8 chaperone system was induced with 1 mg/ml
L-Arabinose and 2.5 ng/ml Tetracycline. After the culture reached an OD600 within 0.40.8, the expression of C-IL2 was induced with 200 M IPTG. Then, the culture was grown
overnight at room temperature (22-25 0C, unless otherwise indicated) and 250 rpm.
For the production of IL2-HPhA from BL21 DE3 pG-KJE8 pET-3a/IL2-HPhA,
the same conditions mentioned above were followed except that the chaperone induction
concentrations were reduced to 0.5 mg/ml of L-Arabinose and 1 ng/ml of Tetracycline
while increasing the IL2-HPhA induction concentration to 1 mM IPTG.
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3.2.5.

Purification Protocols

3.2.5.1.
3.2.5.1.1.

Native Conditions
Preparing the Lysate
The 750 mL culture was aliquoted into 15*50 mL in 50 mL Falcon tubes, and the

cells were harvested by centrifugation for 10 minutes at 5,000 rpm. The supernatants were
discarded, and each bacterial pellet was resuspended in NBB along with 1 mg/ml
Lysozyme, 25 units/ml of Nuclease, and 10 ug/ml of RNase A. The suspension was
incubated on ice for 30 minutes, after which the samples were treated with three cycles of
{10-second pulses at 40 % amplitude using Sonic Dismembrator (Ultrasonic Processor,
Fisher Scientific) and 10-second cooling on ice}. Next, the samples were centrifuged for
15 minutes at 3,000 g. The supernatants were carefully transferred and combined in fresh
50 mL tubes. The pellets containing the cellular debris were discarded.
3.2.5.1.2.

Preparing the Resin
2 mL of Ni-NTA agarose resin was pipetted into a 15-mL Falcon tube and washed

with 6 mL of ultra-pure water by centrifugation at 800 g for 1 minute. Next, the resin was
washed twice with 6 mL of NBB by centrifugation.
3.2.5.1.3. Protein Binding and Elution
The bacterial lysate was incubated with 2 mL of washed Ni-NTA agarose resin
in 50-mL tubes for 60 minutes at room temperature (22-25 0C) on a tube rotator. Later, the
resin and lysate-containing tubes were centrifuged at 800 g for 1 minute. The supernatant
was discarded without disturbing the resin. The resin solution was then loaded on a 10 mL
purification column (Qiagen) bed and allowed to settle by gravity. After the lysate had
passed through the column, the resin was washed twice with 4 mL NBB. Next, the resin
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was washed twice with 8 mL of native wash buffer. Finally, the protein was eluted using
5-10 mL of NEB in steps of 1 mL.
3.2.5.2. Hybrid Conditions
3.2.5.2.1. Preparing the Lysate
The 750 mL culture was aliquoted into 15*50 mL in 50-mL Falcon tubes, and the
cells were harvested by centrifugation for 10 minutes at 5,000 rpm. The supernatants were
discarded, and each bacterial pellet was resuspended by vigorous vortexing in DLB. After
incubation at room temperature (22-25 0C) for 10 minutes, the samples were treated with
three cycles of {10-second pulses at 40 % amplitude and 10-second cooling on ice}. Next,
the samples were centrifuged for 15 minutes at 3,000 g. The supernatants were carefully
transferred and combined in fresh 50-mL tubes. The pellets containing the cellular debris
were discarded.
In the case of IL2-HPhA, cells were harvested at 5,000 rpm for 10 minutes at 4
0

C. The supernatant was discarded, and the pellet was dissolved in 8 mL of GB solution.

After vigorous vortexing to dissolve the pellet, 1 mg/ml lysozyme was added, mixed, and
allowed to lyse the cells for 30 minutes at 37 0C in a water bath. Next, 19.22 g of Urea (8
M) was added to 40 mL of total lysate, vigorously vortexed to completely solubilize Urea,
and left on a tube rotator for 15 minutes at room temperature. Later, the solution was
centrifuged at 4,696 g for 15 minutes at 4 0C, and the pellet was discarded.
3.2.5.2.2.

Preparing the Resin
2 mL of Ni-NTA agarose resin was pipetted into a 15-mL Falcon tube and washed

with 6 mL of ultra-pure water by centrifugation at 800 g for 1 minute. Next, the resin was
washed twice with 6 mL of DBB by centrifugation.
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3.2.5.2.3.

Protein Binding and Elution
The bacterial lysate was incubated with 2 mL of washed Ni-NTA agarose resin

in 50-mL tubes for 60 minutes at room temperature (22-25 0C) on a tube rotator. Later, the
resin and lysate-containing tubes were centrifuged at 800 g for 1 minute. The supernatant
was discarded without disturbing the resin. The resin solution was then loaded on a 10 mL
purification column bed and settled by gravity. After the lysate had passed through the
column, the resin was washed twice with 4 mL DBB and then washed twice with 4 mL
DWB. Next, the resin was washed twice with 8 mL of NWB, 10 mL NWB containing 5 %
2-ME, twice with 8 mL NWB, 10 mL NWB containing 50 mM Imidazole, 10 mL NWB
containing 75 mM Imidazole, 10 mL NWB containing 100 mM Imidazole, and 10 mL
NWB containing 150 mM Imidazole. Finally, the protein was eluted using 5-10 mL of
NEB in steps of 1 mL.
In the case of IL2-HPhA, a 1 ml Ni-NTA agarose resin was added to the
supernatant and allowed to bind for 2 hours at room temperature on a tube rotator. Next,
the resin was loaded onto a 10 mL purification column and washed twice with DBB, once
with 1 M NaCl solution, twice with 8 mL of NWB, 10 mL NWB containing 100 mM
Imidazole, 10 mL NWB containing 150 mM Imidazole, and 10 mL NWB containing 200
mM Imidazole. Finally, the protein was eluted using 5-10 mL of NEB in steps of 1 mL.
3.2.6.

PolyAcrylamide Gel Electrophoresis (PAGE)
The protein samples from lysate, washes, and elutions were analyzed in a

denaturing PAGE. First, protein samples with or without 100 mM 2-ME were treated with
70 0C for 20 minutes in a water bath. Samples were then loaded in a 12-well (20 l sample
capacity) 4-20 % pre-cast protein gel (Bio-Rad) and run for 30 minutes at 200 V in 1X
SDS tank buffer (25 mM Tris, 192 mM Glycine, 0.1 % SDS, pH 8.6) in Mini-PROTEANTM
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Tetra System (Bio-Rad) powered by PowerPac HC (Bio-Rad). For non-denaturing
conditions, 1X Native tank buffer (25 mM Tris, 192 mM Glycine, pH 8.6) was used.
After the run is complete, the gel is washed thrice each for 5 minutes in 100 mL
of ultrapure water to remove excess SDS, then fixed for 15 minutes at room temperature
using a fixing solution. Finally, the gel was incubated overnight in 50 mL of QC Colloidal
Coomassie Stain (Bio-Rad).
3.2.7.

Mammalian Cell Culture
For regular maintenance, an IL-2 dependent Cytotoxic T-Lymphocyte Line (CTLL-

2, ATCC #TIB-214) was cultured with 50 units (1 unit ~ 0.5 ng) per mL of C-IL2 in RPMI
complete media (RPMI 1640 with L-glutamine, 1 mM Sodium Pyruvate, 10 % Fetal
Bovine Serum, 2-ME) at 37 0C and 5 % CO2 in a Heracell VIOS 160i CO2 Incubator.
3.2.8.

Functional Assay, Antibody Staining, and Flow Cytometer measurements
25,000 CTLL-2 cells were plated in a 96-well plate with 50 units / mL of C-IL2

in RPMI complete media and incubated at 37 0C and 5 % CO2. At 4, 24, and 48 hours postplating, all cells were retrieved and washed separately in 3 mL of FACS buffer (1X PBS,
2 mM EDTA, 0.5 % BSA) by centrifugation at 400 g for 5 minutes.
To check the surface expression of the IL-2 receptor (IL-2R), 50,000 CTLL-2
cells with 100 ng of indicated antibody were incubated in FACS buffer for 30 minutes at 4
0

C. Later, cells were washed in 3 mL of FACS buffer by centrifugation at 400 g for 5

minutes.
After carefully discarding the supernatant, tubes were blotted on Kimwipes, 300
L of FACS buffer was added to each cell pellet, resuspended, and 200 l of each sample
was measured for the total number of cells in an Attune NxT Flow Cytometer (Invitrogen).
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3.2.9.

Graphical Representation and Statistical Analysis
Scatter plots and histograms were plotted using v10.0 FlowJo software. All

statistical analyses were performed, bar and line graphs were plotted using v8.0 Prism
software (GraphPad). We employed a 1-way or 2-way ANOVA analysis with Dunnett’s
multiple comparisons to validate the statistical significance.
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3.3. Results and Discussion
3.3.1.

Design of N-terminal Cysteine containing mouse IL-2 encoding Plasmid
A mouse IL-2 precursor’s coding sequence (CDS) with accession number

#AAA39281 was obtained from the NCBI protein databank. The 20 amino acid signal
peptide (MYSMQLASCV TLTLVLLVNS) on the N-terminus was removed from the
CDS. Next, a Cysteine (C) on the N-terminus and 6 Histidine residues (HHHHHH) on the
C-terminus were added to the mouse IL-2 sequence (APTSSSTSSS TAEAQQQQQQ
QQQQQQHLEQ LLMDLQELLS RMENYRNLKL PRMLTFKFYL PKQATELKDL
QCLEDELGPL RHVLDLTQSK SFQLEDAENF ISNIRVTVVK LKGSDNTFEC
QFDDESATVV DFLRRWIAFC QSIISTSPQ). Using an online bioinformatics tool, the
protein sequence was converted to a DNA sequence with the most likely codons for E. coli.
A stop codon (TAA) was added to the 3’-end of the DNA sequence. Next, a start codon
containing NdeI restriction site sequence (CAT ATG) was added on the termini of the DNA
sequence to aid in the NdeI digestion of the synthesized gene construct and insert into the
NdeI-digested pET-3a plasmid. This 483 base (containing 157 amino acids protein) DNA
sequence was translated to a protein sequence (Figure 3.5) using the Expasy tool to test
whether all bases in the DNA sequence are intact and code for the correct amino acids.

Figure 3.5: Predicted protein sequence from the supplied 483 base DNA sequence in the
Expasy webtool. “HM” at the termini indicates the amino acid residues encoded by the
NdeI sequence, while a “-” indicates the stop codon. Therefore, the translated protein (CIL2) is shown in light red background.
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Figure 3.6: pET-3a/C-IL2 vector constructed and viewed in v5.3 SnapGene Viewer. The
C-IL2 encoding DNA sequence immediately after the NdeI site is displayed in red. The 6Histag is highlighted in dark green.

As intended in the design, the protein had an N-terminal Methionine and Cysteine
along with six Histidine residues on the C-terminus; hereafter called “C-IL2”. The C-IL2’s
DNA sequence inserted at the NdeI site of the pET-3a plasmid (an ampicillin-resistant
expression vector) was custom synthesized by General Biosystems, Inc (now Gene
Universal, Inc). A stop codon was used in the C-IL2’s DNA sequence to prevent the fusion
of the C-IL2 protein sequence and T7-Tag (ATGGCTAGCA TGACTGGTGG
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ACAGCAAATG GGT) native to pET-3a. The manufacturer verified the plasmid
containing the C-IL2 encoding gene (hereafter “pET-3a/C-IL2”, Figure 3.6) by Sanger
sequencing and Agarose Gel Electrophoresis before supplying it to us.

Figure 3.7: Quality and confirmation of C-IL2 encoding gene insertion into pET-3a vector
analyzed by agarose gel electrophoresis. Numbers in red indicate the molecular weight (in
base pairs) of the DNA ladder. Lane numbers are indicated in green. Lane1: pET-3a/C-IL2
vector, Lane 2: BamHI and SalI double digested pET-3a/C-IL2, and Lane 3: DNA Ladder.
Figure supplied by Gene Universal, Inc.

From the agarose gel (Figure 3.7), a band near (below) the 1,000 bp (483 + 418)
marker in the double digested plasmid demonstrated that the pET-3a plasmid contains the
insert of size 483 bps within the otherwise BamHI (position 510) and SalI (928 in original
plasmid but 1,405 in Figure 3.7) fragment of size 418 bps (928-510). The second band
between 3,000 and 5,000 bp markers indicates the insert-free fragment of the pET-3a with
a size of 4,216 bps (5117-(483+418)). Without digestions, the plasmid (Lane 1 in Figure
3.7) appears to have the characteristic uncut plasmid bands in agarose gel – the top one
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indicating the open circular conformation and the bottom one indicating the supercoiled
conformation.
3.3.2.

Initial attempts to synthesize and purify C-IL2
We transformed BL21 DE3 with pET-3a/C-IL2 and selected the clone from an

ampicillin-containing LB agar plate. Initially, we attempted to purify the protein using
native conditions (keeping the native folding of protein), denaturing conditions (denatures
the protein), and hybrid conditions (denature initially and then allow for native folding)
during purification, but failed to either express or purify it (data not shown). As the
literature suggested, we thought that the C-IL2 was forming inclusion bodies. Although
inclusion bodies can be treated with harsh techniques involving ultracentrifugation,
solubilizing agents, denaturation followed by protein renaturation, we decided to attempt
to aid the C-IL2’s in vivo folding using the chaperone systems and thereby allow for easy
extraction of C-IL2. Instead of elevating the expression levels of native (bacterial)
chaperones, we decided to transform the bacteria with chaperone-expressing plasmids,
giving us tighter control over chaperone expression.
3.3.3.

Synthesis and purification of C-IL2 using chaperone-transformed bacteria
We have transformed the bacteria with chaperone expressing plasmids (Figure

3.8) and pET-3a/C-IL2 resulting in five different strains (Figure 3.8) of C-IL2 expressing
bacteria, namely, BL21 DE3 pG-KJE8 pET-3a/C-IL2, BL21 DE3 pGro7 pET-3a/C-IL2,
BL21 DE3 pG-KJE7 pET-3a/C-IL2, BL21 DE3 pG-Tf2 pET-3a/C-IL2, and BL21 DE3
pTf16 pET-3a/C-IL2.
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Figure 3.8: Five different chaperone expression plasmids. pG-KJE8 expresses the ELS and
the KJE system chaperones, pGro7 only the ELS system, pKJE7 only the KJE system, pGTf2 expresses ELS and TF, and pTf16 only the TF. Source: Takara product (#3340)
manual.

Figure 3.9: Ampicillin- and Chloramphenicol-containing LB agar plates showing five
different strains of BL21 DE3, each expressing a different chaperone protein combination
and C-IL2 encoded by A130 gene (random gene name given by General Biosystems, Inc).
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During the initial efforts to check which chaperone system is aiding the effective
folding of C-IL2 and purifying the protein via native protocol, we found that the ELS and
KJE system together were optimal as we saw significant bands of C-IL2 from BL21 DE3
pG-KJE8 pET-3a/C-IL2 samples compared to others (data not shown). We have used the
pG-KJE8 system for our future production processes.

Figure 3.10: Comparison between the lysates (native protocol) of naked (non-transformed)
BL21 DE3 (Lane 1) versus transformed BL21 DE3 pG-KJE8 pET-3a/C-IL2 (Lane 2)
analyzed in a reducing SDS-PAGE gel. Numbers in red indicate the molecular weight (in
kDa) of the prestained protein ladder. Lane numbers are indicated in green. Lane 3 and
Lane 4 indicate the flowthrough (post-resin binding) sample and elution samples from the
BL21 DE3 pG-KJE8 pET-3a/C-IL2, respectively. The orange arrow on the right indicates
the position and presence of C-IL2 in Lane 2 & 4 but is absent in Lane 1 & 3.
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Comparing the lysates of naked (non-transformed) BL21 DE3 and BL21 DE3 pGKJE8 pET-3a/C-IL2 demonstrates the differences between the protein expressions (Figure
3.10). Due to the induction of chaperone and C-IL2 expression using LArabinose/Tetracycline and IPTG, respectively, some distinct bands (GroEL ~ 60 kDa,
GroES ~ 10 kDa, DnaK ~ 70 kDa, DnaJ ~ 40 kDa, GrpE ~ 22 kDa, and C-IL2 ~ 18.2 kDa)
appear in the transformed bacterial lysate but not in the naked bacterial lysate (Figure 3.10).
Furthermore, the bands between 15 & 25 kDa and 40 & 55 kDa markers are disappearing
post-resin binding in flowthrough (Lane 3), whose reappearance in the elutions samples
(Lane 4) demonstrates the specificity of these proteins to the Ni-NTA resin (Figure 3.10).
Although the C-IL2 bands appear at the predicted marker position, the impurities
in the elutions pose a significant concern (Lane 4, Figure 3.10). In addition, we found that
the lysozyme-mediated bacterial cell lysis assisted by sonication was ineffective. A
significant amount of bacterial cells in the pellets remained unlysed. Besides, genomic
DNA contamination was a major problem in the lysate. Therefore, we switched our
purification protocol from native conditions to hybrid conditions. In hybrid protocol,
bacterial cells are initially lysed by guanidium hydrochloride (GnHCL)-based lysis buffer
(DLB), protein is made to bind to the resin equilibrated with Urea-containing binding
buffer (DBB), the resin is washed using Urea-containing wash buffer (DWB), and then
washed twice with native wash buffer (NWB) before finally eluting using native elution
buffer (NEB).
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Figure 3.11: Comparison between the migration patterns of commercially available
recombinant mouse IL-2 (mIL2) versus the affinity chromatography purified N-terminal
Cysteine containing mouse IL-2 (C-IL2) in a reducing SDS-PAGE gel. Numbers in red
indicate the molecular weight (in kDa) of the prestained protein ladder. C-IL2 is from a
longtime stored -20 0C aliquot of production batch #36.
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Figure 3.12: Analysis of production batch #41 (B41) of C-IL2 in a reducing SDS-PAGE
gel. Numbers in red indicate the molecular weight (in kDa) of the prestained protein ladder.
Lane numbers are indicated in green. Lane 1: 5 % 2-ME-containing 25 mM Imidazole
wash, Lane 2: 25 mM Imidazole wash #3, Lane 3: 25 mM Imidazole wash #4, Lane 4: 50
mM Imidazole wash, Lane 5: 100 mM Imidazole wash, Lane 6: 150 mM Imidazole wash,
Lane 7: Elution 1, Lane 8: Elution 2, and Lane 9: Elution 3.

After many efforts to purify C-IL2 using the hybrid protocol, we were able to elute
the protein. A representative reducing SDS-PAGE gel comparing the bands of C-IL2 (18.2
kDa) with the commercially available recombinant mouse IL-2 (mIL2, 17.2 kDa,
Peprotech) is shown in Figure 3.11. The gel demonstrates that the C-IL2 has a higher
molecular weight than the mIL2. However, we had many impurities eluted along with CIL2 in the hybrid protocol as well. Therefore, we developed a series of imidazole gradient
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washing steps before elutions to eliminate the impurity as much as possible. It is
demonstrated that the main impurity (band at 25 kDa marker) eluting along with C-IL2 is
a non-histag protein (Figure 3.12). However, due to its robust non-specific interaction with
the resin, it is eluted along with C-IL2. It is also possible that this impurity is a 22 kDa
GrpE protein from the KJE chaperone system, and its interaction with C-IL2 could have
led to resin-binding. It is known that GrpE migrates at the 29 kDa marker in SDS-PAGE
gel (Takara product manual).
3.3.4.

Attempts to eliminate the believed-to-be chaperone contamination from
eluted protein
We observed that the eluted protein sample contained many non-specific proteins

that are not supposed to have the histag. Therefore, we attempted to eliminate these
impurities. We initially hypothesized that the eluted protein must have the histag and
therefore speculated that these non-specific proteins bind to the resin in a fused or bound
state to C-IL2. Hence, we speculated these to be the chaperone proteins that were aiding in
the folding of C-IL2. It is reported that the treatment of resin-bound proteins with MgATP
(Magnesium assisted Adenosine-triphosphate) would dissociate the chaperone proteins,
especially the DnaK, from the resin-bound histag protein and hence aid in eluting the purest
form of protein sample (Rial and Ceccarelli 2002; Joseph and Andreotti 2008).
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Figure 3.13: Effect of ATP-treatment as a wash incubation step before eluting C-IL2
analyzed in an SDS-PAGE gel. Numbers in red indicate the molecular weight (in kDa) of
the prestained protein ladder. Lane numbers are indicated in green. Lane 1: ATP-nontreated
eluted protein without 2-ME, Lane 2: ATP-nontreated eluted protein with 2-ME, Lane 3:
ATP-treated eluted protein without 2-ME, Lane 4: ATP-treated eluted protein with 2-ME.

Encouraged by these reports, we attempted to purify the eluted protein further.
After binding the lysate proteins to the resin and wash steps involved in the hybrid protocol,
we incubated the resin-containing column with ATP-containing buffer (AWB) for 2 hours
at 4 0C on a tube rotator. We eluted the protein post-incubation and found that ATP
treatment did not affect the purity of the eluted sample when analyzed in an SDS-PAGE
gel (Figure 3.13). Fascinatingly, a smear in the 2-ME non-treated samples disappeared in
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the 2-ME treated samples, indicating that these smears are formed due to disulfide bridges
between different sulfhydryl-containing proteins (Figure 3.13). Nonetheless, a comparison
of 2-ME treated versus nontreated samples in the gel demonstrated that the eluted sample
has a Cysteine-containing protein corresponding to the bands of C-IL2 (between 15 and 25
kDa markers in Figure 3.13). It must be noted that this batch of purification did not involve
the use of a purification column but a 15-ml falcon tube. Due to the crude way of
purification, many impurities in the elution samples are not surprising.

Figure 3.14: Test for the existence of disulfide bonds between IL-2 molecules analyzed in
an SDS-PAGE gel. Numbers in red indicate the molecular weight (in kDa) of the prestained
protein ladder. Lane numbers are indicated in green. Recombinant mouse IL-2 (mIL-2)
without (Lane 1) and with (Lane 2) 2-ME, and B35 C-IL2 without (Lane 3) and with (Lane
4) 2-ME.
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Figure 3.15: Top view (a) and Side view (b) of mIL-2 showing Cys-72 (in alpha-helix) and
Cys-128 (in the loop) in red (forms intramolecular disulfide bridge) and Cys-140 (in alphahelix) in blue (has no Cysteine partner) analyzed in v2.4 Pymol Educational using PDB ID
4YQX.

Finally, we tested whether mouse IL-2 (mIL-2) exists in dimer form just like C-IL2
does. We tested both proteins in SDS-PAGE gel in the presence and absence of a reducing
agent, 2-ME (Figure 3.14). The gel demonstrates that only the C-IL2 exists in dimer forms.
Furthermore, the side chain of Cys-140 (blue residue in Figure 3.15) in mIL-2, known to
be uninvolved in disulfide bonds, is orienting towards the molecule's center. Hence, it
cannot form intermolecular disulfide bonds. These results demonstrate that the Cysteine in
C-IL2 is at the N-terminus, perhaps followed by Methionine.
It is known that the N-terminal methionine is excised in E. coli by an enzyme known
as methionine aminopeptidase (MAP) (Ph.-Herve et al. 1989; Gentle, De Souza, and Baca
2004; Frottin et al. 2006; Rosen and Francis 2017). Furthermore, the presence of second
amino acid with a side chain length of more than 3 Å leads to inefficient excision of
methionine (Ph.-Herve et al. 1989). The methionine excision of proteins with the second
amino acid being Glycine, Alanine, Proline, Serine, Threonine, Valine, or Cysteine was
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reported to be approximately within 97–71 % in the decreasing order of efficiency
corresponding to the increasing length of the side chain (Ph.-Herve et al. 1989). The
methionine excision efficiency of proteins with Cysteine as the second amino acid was
71.0 ± 4.7 % in E. coli (Ph.-Herve et al. 1989; Gentle, De Souza, and Baca 2004). More
importantly, if N-terminal methionine excisions of proteins such as C-IL2 are efficient, it
is likely that the N-terminal Cysteines form ring structures called thiazolidines caused due
to the condensation of ketones or aldehydes with the 1,2-amino thiol group of N-terminal
Cysteine (Gentle, De Souza, and Baca 2004; Rosen and Francis 2017). As a preventive
measure, the use of high concentrations of free Cysteine molecules was suggested to be
added before and after inducing such recombinant proteins with IPTG to skip the formation
of disulfide bonds with other Cysteine-containing bacterial proteins (Gentle, De Souza, and
Baca 2004). In addition, an overnight reaction with 0.4 M methoxylamine in a buffer-free
or acid buffered environment was suggested to reverse the ring formation and free the side
chain of N-terminal Cysteines after harvesting the recombinant protein (Gentle, De Souza,
and Baca 2004; Rosen and Francis 2017). However, since we did not use glucosecontaining LB media, pyruvate concentration would remain at normal levels native to E.
coli BL21 DE3. And also, because we observed the disulfide bridge forming ability of CIL2, we can reasonably conclude that forming thiazolidines in the case of overly expressed
C-IL2 is less likely.
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3.3.5.

Functional assay

Figure 3.16: The surface expression of the IL-2 receptor (IL-2R) subunits (CD25, CD122,
and CD132) in Day 6 (from initial culture) CTLL-2 cells analyzed by flow cytometer. Red
peaks indicate the unstained control, and the blue peaks indicate the stained samples.

To test the proliferative ability of C-IL2 on an IL-2 dependent mouse Cytotoxic T
cell Line (CTLL-2), we first verified the expression of the IL-2 receptor (IL-2R) subunits
on CTLL-2 (Figure 3.16). The expression levels of CD25 are very high, while that of
CD122 is significant. Surprisingly, the expression level of CD132 is not significant or
undetectable. Since the CD122 and CD132 are not recycled back to the cell surface, we
suspected that the expression of CD132 is shallow and that such low expression is not
detectable by the flow cytometer due to the fast uptake of IL-2.
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Figure 3.17: Effect of IL-2 starvation on the surface expression of the IL-2 receptor (IL2R) subunits (CD25, CD122, and CD132) in Day 8 (from initial culture) CTLL-2 cells
analyzed by flow cytometer. (a) Non-starved samples and (b) 4-hour starved samples. Red
peaks indicate the unstained control, and the blue peaks indicate the stained samples.

To confirm whether CD132 is expressed, we starved the CTLL-2 cells of IL-2 for
4 hours and then verified the IL-2R subunit expression. Clearly, the cells were expressing
CD132, and its expression was not detectable due to the fast internalization of IL-2 (Figure
3.17). IL-2 starvation (Figure 3.17b) impacted the levels of CD122 as well, although not
very significant. These expression kinetics also confirms that the CTLL-2 has a very low
expression of CD132 during the initial stages, i.e., up to Day 8 of culture.
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Figure 3.18: The surface expression of the IL-2 receptor (IL-2R) subunits (CD25, CD122,
and CD132) in Day 9 (a) versus Day 14 (b) CTLL-2 cells analyzed by flow cytometer. Red
peaks indicate the unstained control, and the blue peaks indicate the stained samples.

111

Cell Count (x104)

6.0

4.0

2.0

0
4

24

48

Time (hours)
Figure 3.19: Proliferation of an IL-2 dependent CTLL-2 cell line (Day 9 of initial culture)
in the presence of C-IL2 analyzed by flow cytometer. Results are presented as mean ±
standard deviation (n=3).

Next, we verified the expression of IL-2R subunits on Day 9 and Day 14 and found
that CD132 expression is detectable even without IL-2 starvation (Figure 3.18). Hence, we
concluded that the expression of CD132 increases after Day 8 of initial culture and remains
steadily significant and detectable from Day 9 of initial culture. Finally, we tested whether
the C-IL2 can proliferate the CTLL-2 cell line in 2-day culture (Figure 3.19). We confirmed
that C-IL2 could rapidly proliferate the CTLL-2 cell line.
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3.4. Conclusion
Interleukin-2 (IL-2), a crucial cytokine required for the proliferation and
modulation

of T Lymphocytes,

has

many therapeutic benefits. Particularly,

bioconjugations strategies such as N-terminal amine targeting reactions or biotinstreptavidin interactions involving IL-2 have been previously shown to be effective in
delivering nanocapsules (Frick et al. 2016) and superparamagnetic iron-oxide
nanoparticles (SPIONs) (Ayyadevara, Ahmadi, and Roh 2021) to activated T cells (ATCs).
Therefore, the design, synthesis, and purification of IL-2, a molecule used for site-specific
bioconjugations, is a highly profitable endeavor.
Nonetheless, it is known that IL-2, like many other recombinant proteins, forms
inclusion bodies in bacterial hosts during production (Weir and Sparks 1987). Besides,
mouse IL-2 (mIL-2) in general is classified as an unstable protein (as characterized by
Expasy’s Protparam webtool). Here, we designed an N-terminal Cysteine containing mIL2 (C-IL2) by simply adding a Methionine-Cysteine pair and 6 Histidine residues at the Nterminus and C-terminus of the original coding sequence of mIL-2 (Alanine-1 to Glutamic
acid-149), respectively. Our initial efforts to purify the protein from E. coli BL21 DE3 have
failed, perhaps due to the formation of inclusion bodies and instability. However, by the
exogenous introduction and tightly regulated expression of five chaperonin proteins,
namely, the DnaK, DnaJ, & GrpE from the KJE system and GroES & GroEL from the ELS
system, we were able to purify the protein using a hybrid purification protocol in which the
protein is first denatured during cell lysis and allowed to renature during purification. Even
after subjecting to solubilizing agents such as Guanidium Hydrochloride and Urea, the
eluted protein was potent enough to rapidly proliferate the IL-2 dependent mouse Cytotoxic
T cell Line (CTLL-2), indicating that the protein has renatured. Our PAGE-based analysis
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suggested that the C-IL2 has a Cysteine residue that is capable of forming disulfide bridges.
Altogether, with functionally potent C-IL2 and currently available bioconjugations
strategies, we can potentially aim to deliver complex nanoparticles such as nucleic acid
and polycationic polymer complexes, called polyplexes, to the otherwise known hard-totransfect ATCs.
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3.5. Future Directions
3.5.1.

Bioconjugation of C-IL2 and Polyethyleneimine
To test whether site-specific bioconjugations using the thiol in the side chain of N-

terminal Cysteine is possible, we attempted to conjugate C-IL2 to 25 kDa branched
polyethyleneimine (PEI) via Sulfo-LC-SPDP (Figure 3.20). Briefly, PEI was reacted with
two molar excess of Sulfo-LC-SPDP in 1X PBS (with 1 mM EDTA and 0.02 % NaN3, pH
7.4) for 30 minutes at room temperature on a tube rotator. Then the purified (desalted to
remove unreacted crosslinker) pyridyldithiol-activated PEI was allowed overnight to react
with equimolar C-IL2 in the presence or absence of a reducing agent, Dithiothreitol (DTT,
disulfide breaker).

Figure 3.20: Bioconjugation Scheme for C-IL2 and 25 kDa branched PEI using SPDP. (a)
Activation of PEI with pyridyldithiol, (b) Reaction between C-IL2 and pyridyldithiolactivated PEI, and (c) Structures of different SPDP reagents. Reconstructed figure from
source (Thermo Scientific SPDP Crosslinkers Manual).
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Figure 3.21: Bioconjugation of C-IL2 and 25 kDa branched PEI analyzed in an SDS-PAGE
gel. Numbers in red indicate the molecular weight (in kDa) of the prestained protein ladder.
Lane numbers are indicated in green. Lane 1: C-IL2 alone, Lane 2: Sample of
pyridyldithiol-activated PEI and C-IL2 without DTT during the reaction, and Lane 3:
Sample of pyridyldithiol-activated PEI and C-IL2 with DTT during the reaction.

It is demonstrated that all the bands in the DTT-free bioconjugation sample
disappear, indicating that the bioconjugation could have been successful. The presence of
the protein bands in the DTT-containing bioconjugation sample confirms that the
bioconjugation was not successful due to the break in the disulfide bond present in SulfoLC-SPDP besides confirming that PEI is not non-specifically (electrostatically) interacting
with the proteins in the C-IL2 sample. The complete absence of any protein band in the
DTT-free bioconjugation sample (Lane 2 in Figure 3.21) confirms that these proteins
interact with PEI via a sulfhydryl group present in them.
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3.5.2.

Design, Synthesis, and Purification of a mouse IL-2 fusion protein containing
HPhA
As an alternative to polycationic polymers such as PEI, which yield high

cytotoxicity, a DNA binding fusion protein of IL-2 was designed. The homodimeric form
of the Hyperthermophilic archaeal histone (HPhA) from the hyperthermophilic archaeon,
Pyrococcus horikoshii, is known for its DNA binding ability (Li et al. 2003; Deng et al.
2015). HPhA displays hyperthermostability which results from the organism’s ability to
grow at 95 0C (Li et al. 2003). HPhA was reportedly used for in vitro transfection of cell
lines such as NIH 3T3, HL-7702, HepG2, HEK 293, and Cos 7 (Weng et al. 2004). Later,
a scientific group reported using HPhA in transfecting the CHO cells with pDNA via the
LDL/2-macroglobulin receptor-mediated endocytosis (Deng et al. 2015).

Figure 3.22: IL2-HPhA protein sequence design. The initiation codon or start codon is
indicated in blue, mouse IL-2 from the original CDS in grey, GGGGS linker in dark grey,
thrombin recognition sequence in turquoise, H5WYG endosomal escape sequence in
green, Nuclear localization signal (NLS) in yellow, GGGGS linker in dark grey, HPhA
sequence in teal, 6-Histag in pink, and a stop codon indicated as an asterisk (*) in red.
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Figure 3.23: Side view (a) and Top view (b) of HPhA protein in homodimeric form. One
subunit is indicated in red and the other in green only to show how the dimer is formed and
shaped. (a) The N-terminal residues of both subunits are indicated in blue. Source:
Constructed in Pymol Educational using PDB file with ID 1KU5.
Taking advantage of this hyperthermostable protein, we designed a fusion protein
containing HPhA at the C-terminus of mouse IL-2 (Figure 3.22). To aid in the native
folding of both proteins independently, we inserted a GGGGS linker at the C-terminus of
IL-2 and the N-terminus of HPhA (Figure 3.23). Within the flank sequence of GGGGS,
we inserted a thrombin recognition sequence (PRS) that helps thrombin cleave the fusion
protein (Nelson and Guyer 2011; X. Chen, Zaro, and Shen 2013), resulting in a disulfide
bridge between IL-2 and HPhA, an H5WYG sequence that helps in the endosomal escape
of DNA complexes (Midoux et al. 1998), and an SV40 large tumor antigen derived nuclear
localization signal (NLS) that aids in the nuclear import of DNA complexes (Zanta,
Belguise-Valladier, and Behr 1999). Finally, we inserted a 6-Histag sequence at the Cterminus of the HPhA for affinity purification purposes. Since the N-terminal residues of
HPhA face opposite directions, we assumed that the IL-2 might not hinder the dimerization
by steric hindrance. Besides, we also assumed that the GGGGS linker would further
prevent such steric hindrance.
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Figure 3.24: pET-3a/IL2-HPhA vector constructed and viewed in v5.3 SnapGene Viewer.
The IL2-HPhA encoding DNA sequence within the NdeI site is displayed in red.
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Figure 3.25: Quality and confirmation of IL2-HPhA encoding gene insertion into pET-3a
vector analyzed by agarose gel electrophoresis. Numbers in red indicate the molecular
weight (in base pairs) of the DNA ladder. Lane numbers are indicated in green. Lane1:
EcoRI and XbaI double digested pET-3a/IL2-HPhA vector; arrow in green indicates the
faint band whose DNA fragment contains the IL2-HPhA ORF, and Lane 2: pET-3a/IL2HPhA. Figure supplied by Gene Universal, Inc.

The designed fusion protein was translated into a DNA sequence and was inserted
at the NdeI site of the pET-3a vector. The resulting plasmid, pET-3a/IL2-HPhA (Figure
3.24), was custom synthesized and supplied by Gene Universal, Inc. The plasmid was
confirmed to have the IL2-HPhA construct analyzed by double digestion-based agarose gel
electrophoresis (Figure 3.25). Next, the plasmid was used to separately transform the
competent cells of BL21 DE3 and BL21 DE3 pG-KJE8.
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Figure 3.26: Elutions of IL2-HPhA analyzed in an SDS-PAGE gel. Numbers in red indicate
the molecular weight (in kDa) of the prestained protein ladder. Lane numbers are indicated
in green. Lane 1: 2-ME treated IL2-HPhA, and Lane 2: nontreated IL2-HPhA.

BL21 DE3 pG-KJE8 pET-3a/IL2-HPhA was used to express and purify IL2-HphA
(~ 31.753 kDa, pI 7.75). In gradient imidazole washing steps, we found that the fusion
protein has eluted at 100 mM imidazole concentration. After concentrating 100 mM wash
sample, we analyzed the protein on SDS-PAGE gel (Figure 3.26) and could confirm that
the protein is within the 25 and 35 kDa markers. Most importantly, the elution had only
one protein confirming that Ni-NTA resin would not non-specifically bind to BL21 DE3
pG-KJE8 lysate proteins in imidazole-containing buffers.
2-ME treatment did not affect the fusion protein, indicating the absence of free
Cysteines whose side chains are exposed for intramolecular disulfide bridges. This result
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is valid because a 2-ME wash was not performed during the purification of the fusion
protein, and hence we can eliminate the possibility that the fusion protein requires more
time to make intramolecular disulfide bridges. These results support that C-IL2 had an Nterminal Cysteine and was eluted from the Ni-NTA column with other thiol-containing
bacterial lysate proteins.
The SDS-PAGE gel (Figure 3.26) demonstrates that the HPhA subunit of the fusion
protein is not free to form a dimer indicating a potential barrier for its DNA binding ability.
The fusion protein was tested for its pDNA binding ability in an agarose gel electrophoretic
assay. We found that the fusion protein does not retard the migration of pDNA,
reconfirming that the fusion protein in non-dimer form cannot bind to nucleic acids.
The fusion protein was also tested for its ability to proliferate activated primary
mouse T cells. However, the cells did not grow over time, while those in the recombinant
mouse IL-2 (mIL-2) samples had grown rapidly. This result indicates that the IL-2 in the
fusion protein is either not accessible for interaction with IL-2R or has rapidly degraded in
cell culture media. Nonetheless, more experiments must be performed to determine
whether the fusion protein can proliferate T cells in vitro and bind and deliver nucleic acids.
It appears that the fusion protein cannot form a dimer, perhaps because of the
sterical hindrance caused by IL-2. Hence, I propose that a monomer form of HPhA must
be biosynthesized, or the thrombin cleavage reaction must be optimized to separate IL-2
and HPhA. Either way, the fusion protein can be mixed with monomeric HPhA and allow
to form a dimer. This would be an attractive strategy to enhance the DNA binding
capability. Besides, only a fraction of the dimerized fusion protein can be used to bind to a
nucleic acid for the IL-2R-mediated endocytosis, while the rest of the nucleic acid can be
complexed with the dimers of monomeric HPhA.
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CHAPTER IV

EXPLOITING THE INTERLEUKIN-2 RECEPTOR-MEDIATED ENDOCYTIC
PATHWAY FOR THE TARGETED ASSOCIATION AND INTRACELLULAR
DELIVERY OF NANOPARTICLES INTO PRIMARY MOUSE T
LYMPHOCYTES
Contents of this chapter (until conclusion) are derived from the publication
DOI: 10.1021/acs.bioconjchem.1c00212 (Authors: V. S. S. Abhinav Ayyadevara, Armin Ahmadi, KyungHo Roh)

4.1.

Background and Significance
Delivery of different cargoes into non-phagocytic cells is challenging in general.

Among many somatic cell types, primary T Lymphocytes are well understood for their
intrinsic resistance to internalize foreign materials. Thus, most current efforts to genetically
engineer T cells mainly rely on viral vectors for intracellular delivery of transgenes, despite
the high manufacturing costs (Magnani et al. 2020) and safety concerns (Thomas, Ehrhardt,
and Kay 2003). Due to the remarkable success stories in T cell-based immunotherapies,
the interest and need for developing a novel non-viral modality that facilitates targeted
delivery of foreign materials into T cells are more significant than ever.
For quite some time now, receptor-mediated endocytosis has been exploited to
deliver various cargoes into non-phagocytic cells. In the case of T cells, plasmid DNA
(pDNA) encoding an anti-CD19 chimeric antigen receptor (CAR) gene was successfully
delivered to transfect murine T cells via the CD3 (receptor)-mediated endocytosis (T. T.
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Smith et al. 2017a). Also, siRNA delivery into activated T cells was demonstrated in a
murine asthma model utilizing the transferrin receptor (Yuran Xie et al. 2016).
Here, we explored the potential of leveraging the IL-2 receptor (IL-2R)-mediated
endocytosis for T cell-specific intracellular delivery of various cargoes. The recombinant
human IL-2 (hIL-2) protein has been used as a potent antitumor agent for metastatic renal
cancer and metastatic melanoma (Rosenberg 2014; Schrama, Reisfeld, and Becker 2006).
The chimeric fusion proteins of IL-2 and diphtheria toxin (Kaminetzky and Hymes 2014)
or pseudomonas endotoxin (Fishman et al. 1994) have been developed as IL-2R-targeting
therapeutics. More recently, a fusion protein of hIL-2 and mouse antibody fragment
crystallizable region (Fc) has been shown to increase the antitumor activity at the tumor
microenvironment by selectively depleting the Treg cells (Vazquez-Lombardi et al. 2017).
Besides, recombinant IL-2 molecules have been successfully conjugated to the surface of
liposomes (Zheng et al. 2013; Konigsberg et al. 1998) or hydroxyethyl starch nanocapsules
(Frick et al. 2016) either for induction of robust proliferation of adoptively transferred T
cells (Zheng et al. 2013) or for targeted delivery of therapeutic agents to IL-2R-expressing
T cells (Konigsberg et al. 1998; Frick et al. 2016). Altogether, these examples demonstrate
the feasibility of conjugating IL-2 with various cargoes as a general strategy to target and
deliver these cargoes into the IL-2R-expressing cell populations, particularly the activated
T cells.
Different receptors may follow distinct endocytic pathways (Rejman et al. 2004).
Depending on the involved endocytosis pathways, different maximum sizes of deliverable
cargoes have been previously identified, for example, 150-200 nm in clathrin-mediated
endocytosis (Klauber et al. 2016; Rejman et al. 2004; Kumari, MG, and Mayor 2010) and
around 120 nm in the caveolae-mediated pathway (Kumari, MG, and Mayor 2010).
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Interestingly, particles of ~500 nm were also reported to enter the host cells predominantly
via the caveolae-mediated pathway (Rejman et al. 2004), which indicates that such cargo
size limits may be affected by other factors in addition to the nature of involved endocytic
pathways. It has been reported that IL-2R-mediated endocytosis occurs in a clathrinindependent pathway (Lamaze et al. 2001). In other studies, it was reported that the
internalization of CD122 is mediated neither by clathrin nor caveolae (Grassart et al. 2008;
P. Chen, Yao, and Huang 2017; Kumari, MG, and Mayor 2010), but by the formation of
small and uniformly sized (50 – 100 nm) invaginations at the plasma membrane surface
(Kumari, MG, and Mayor 2010), which is dependent on Dynamin for vesicle formation
and other GTPases - RhoA and Rac1 for stimulation of Pak1 and Pak2 (Kumari, MG, and
Mayor 2010; Grassart et al. 2008). To our knowledge, no previous report systematically
studied the targeted association and intracellular delivery of cargoes of different sizes using
IL-2R-mediated endocytosis.
Here, we employed a series of superparamagnetic iron oxide nanoparticles
(SPIONs) of different core diameters, 50, 100, and 200 nm, as model cargo materials and
tested the efficiencies of IL-2R-mediated association and endocytosis by activated primary
mouse T lymphocytes. We found that the C-terminal conjugation of IL-2 can enable 50 nm
SPIONs to effectively get delivered into activated T cells on most days of pan T cell
culture. 100 nm SPIONs can significantly be delivered into activated T cells on Day 3 of
culture when the expression of high-affinity IL-2R was found to be optimal. The
endocytosis of 200 nm SPIONs was relatively minimal. We can incur a practical size limit
in cargo between 100 and 200 nm for effective intracellular delivery using IL-2R-mediated
endocytosis. These results provide a substantial foundation for further development of
formulations and various payloads (nucleic acids, drugs, imaging agents, toxins,
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polypeptides, or nanoparticles) that can be delivered to activated T cells using IL-2Rmediated endocytosis for the engineering of T lymphocytes in the rapidly growing field of
cellular immunotherapies.
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4.2.

Materials and Methods

4.2.1. Materials
Tris (Thermo Scientific), NaCl (Fisher Chemical), EDTA (Acros Organics),
sodium azide (Fisher Chemical), bovine serum albumin (BSA, Fisher BioReagents), 10 X
phosphate-buffered saline (PBS) powder (Fisher Scientific), ACK lysing buffer (Gibco),
RPMI 1640 with L-glutamine (Gibco), fetal bovine serum (FBS, characterized grade,
HyClone), Penicillin-Streptomycin (P/S, Gibco), 2-mercaptoethanol (2-ME, Gibco),
disposable vacuum filter/storage system (Corning), 0.2 m PTFE membrane syringe filter
(GE Whatman), cell strainers (Corning Falcon), MS columns (Miltenyi Biotec), 96-well
white plates (Corning Costar), 96-well clear plates (Corning Costar), 96-well culture plates
(Corning Costar), and 24-well culture plates (Corning Falcon) were used as received from
the manufacturers. Recombinant mouse IL-2 (mIL-2) and human IL-2 (hIL-2) were
purchased from Peprotech. Biotinylated human IL-2 (hIL-2-avitag) was purchased from
Acro Biosystems. PE-Cyanine7 conjugated anti-mouse CD4 antibody (clone RM4-5,
eBioscience), APC conjugated anti-mouse CD8a antibody (clone 53-6.7, BD Biosciences),
unconjugated anti-mouse CD25 antibody (clone 7D4, Bio X Cell), PE-conjugated antimouse CD25 antibody (clone PC61, BD Biosciences), FITC conjugated anti-mouse CD122
antibody (clone TM-beta1, eBioscience), and APC conjugated anti-mouse CD132 antibody
(clone TUGm2, Biolegend) were purchased from corresponding manufacturers.
Streptavidin-conjugated superparamagnetic iron oxide nanoparticles (SPIONs) of
diametrical sizes 50, 100, and 200 nm were purchased from Ocean Nanotech. Electron
microscopy grade 50% glutaraldehyde solution, 16% paraformaldehyde, and 0.2M sodium
cacodylate buffer were purchased from Electron Microscopy Sciences (Hatfield, PA).
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4.2.2. T cell isolation and culture
All primary T cells were obtained from the spleen of C57BL/6J mice (Jackson
Laboratory) maintained under a pathogen-free environment via MACS using the mouse
pan T cell Isolation II kit (Miltenyi Biotec). All procedures involving mice followed the
protocols approved by the IACUC of the University of Alabama in Huntsville. Immediately
after isolation, T cells were activated using Dynabeads Mouse T-activator CD3/CD28
(Gibco) at cell: bead ratio of 1:1 in RPMI complete media (RPMI 1640, 10% FBS, P/S, 2ME) containing mIL-2 (30 U/ml). T cells were cultured at an initial density of 1 x 106
cells/ml in a 24-well plate and incubated at 37 oC and 5 % CO2 in a Heracell VIOS 160i
CO2 incubator. As regular maintenance, cells were monitored every day and were split (3x)
when the live-cell density reached 3 x 106 cells/ml. Fresh mIL-2 was provided after
splitting the cells. After Day 6, cells were collected, washed by centrifugation at 250 g for
5 minutes, suspended in fresh media containing mIL-2, and reactivated using Dynabeads
at a cell: bead ratio of 1:1 plated at a density of 1 x 106 cells/ml.
4.2.3. Protein quantitation
Before and after biotinylation and purification, all proteins were measured for their
concentrations using the BCA protein assay kit (Thermo Scientific Pierce) using NanoDrop
OneC (Thermo Scientific) spectrophotometer. All samples, including the BSA standards,
were incubated at 60 oC for 30 minutes in a water bath before taking measurements.
4.2.4. Biotinylation and quantitation
hIL-2 was reacted with 5, 10, or 20 molar excess of NHS-PEG4-Biotin (Thermo
Scientific, NPB) in 0.1M sodium bicarbonate buffer (pH 8.3) for 30 minutes at room
temperature on a tube rotator. Lysozyme (Sigma Aldrich) was reacted with two molar
excess of NPB under the same reaction conditions. After each reaction, the biotinylated
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proteins were purified using 0.5 mL 7 kDa MWCO Zeba spin desalting columns (Thermo
Scientific). Post-purification, the number of biotins per protein molecule was immediately
confirmed by HABA assay (Pierce) following the manufacturer’s recommended protocol.
4.2.5. Fluorescent dye labeling
Biotinylated lysozyme, streptavidin (New England BioLabs), and anti-mouse
CD25 antibody (clone 7D4) were separately labeled with Alexa Fluor 488 NHS Ester
(Molecular Probes) at a molar ratio of 1:14, 1:20, and 1:50, respectively, in 0.1M sodium
bicarbonate buffer (pH 8.3) for 30 minutes at room temperature (22-25 0C) on a tube rotator
in a dark condition. After the reaction, labeled proteins were purified using 0.5 mL or 5
mL 7 kDa MWCO Zeba desalting columns and stored at 4 oC. Streptavidin-coated SPIONs
of 50, 100, and 200 nm in diameter were labeled with AF488 NHS-ester at particle: dye
molar ratio of 1:69,277, 1:319,444, and 1:1,801,204, respectively, in 0.1M sodium
bicarbonate buffer (pH 8.3) for 30 minutes at room temperature on a tube rotator in a dark
condition. After the reaction, the beads were centrifuged at 21,100 g for 10 minutes, and
the supernatant was discarded. Beads were rewashed in PBS and stored in BSA buffer at 4
o

C.

4.2.6. Loading of IL2 onto SPIONs and determination of surface densities
To determine the correlation between the loading conditions and surface densities,
we incubated different amounts of AF488-labelled and biotinylated lysozyme (50, 100, or
250 ng) with varying quantities (10, 15, or 20 g) of SPIONs in 100 l of BSA buffer for
60 minutes at 4 oC on a tube rotator. After incubation, the SPIONs were centrifuged at
21,100 g for 10 minutes, and the supernatant was carefully aspirated. The quantification of
lysozyme was performed by measuring the fluorescent intensities of each supernatant using
the Synergy HTX spectrophotometer (with 485/20 excitation filter and 528/20 emission
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filter). The concentration of each lysozyme supernatant was calculated from the measured
fluorescent intensity value using a 4-parameter logistic calibration curve obtained from
serially diluted lysozyme standards. The amount of lysozyme loaded onto the surface of
SPIONs was determined by comparing the lysozyme quantities in the supernatant before
and after each incubation. The surface density was calculated by dividing the molar
quantities of loaded lysozymes by the total surface area of SPIONs employed, assuming
the SPIONs are perfect spheres with the corresponding diameter of 50, 100, or 200 nm. For
loading of hIL-2-avitag, the same protocol was followed by matching the molar quantity
of biotinylated protein.
4.2.7. DLS measurements
hIL-2-loaded SPIONs were washed with PBS, centrifuged down at 21,100 g for
10 minutes, and then resuspended in 1,300 l of water just before measurements. The zaverage size and zeta potential were measured using Zetasizer Nano (Malvern) for 3-5
cycles per measurement.
4.2.8. Plating for IL-2-mediated association and endocytosis
To test streptavidin as a model protein cargo, we incubated biotinylated IL-2 with
two molar excess of AF488-labeled streptavidin in PBS for 30 min at room temperature on
a tube rotator in a dark condition. The resulting formulation was supplied directly to 25,000
cells per well (96-well plate). The dosage of each formulation was normalized by the
quantity of IL-2 at 348.48 fmol per well (10 X or 300 U/ml) for all formulations. To test
the delivery of SPIONs, IL-2-loaded AF488-labeled SPIONs were resuspended in RPMI
complete media, and 166 ng of each SPIONs were supplied to 25,000 T cells per well. 1x
mIL-2 was provided to each well that was not supplied with IL-2-loaded SPIONs. Culture
plates containing SPIONs were centrifuged at 1,900 g for 30 minutes at 4 oC before
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transferring them to the incubator. No more fresh culture media or IL-2 were supplemented
until the cells were analyzed at indicated time points.
4.2.9. Flow Cytometry
At each indicated time point, all cells from experimental plates were carefully
retrieved. About 50,000 cells/sample were washed and incubated with 100 ng of each
antibody in 100 l of PBS for 30 minutes at 4 oC. Cells were washed in FACS buffer (PBS,
0.5 % BSA, 2 mM EDTA) by centrifugation at 400 g for 5 minutes at 4 oC, resuspended in
300 l of FACS buffer to be measured by Attune NxT Flow Cytometer (Invitrogen). To
differentiate signals coming from the total association from internalization, 0.4 % trypan
blue (Gibco) was added to each sample to quench extracellular green fluorescent dyes. All
data were analyzed and plotted using FlowJo software (v10.0).
4.2.10. Confocal Laser Scanning Microscopy
Before retrieval, cells were stained with 75 nM Lysotracker Deep Red (Invitrogen)
and with 2x CellMask Orange Plasma Membrane Stain (Invitrogen) by incubating for 2
hours and 10 min, respectively, at 37 oC in the 5% CO2 incubator. The stained cells were
washed twice in PBS and then fixed with 2 % paraformaldehyde (ThermoFisher Scientific)
for 30 minutes at room temperature. Cells pellets are prepared by centrifugation at 400 g
for 5 minutes at 4 oC, re-suspended in a mixture of 1X PBS & Prolong Diamond antifade
with DAPI (Molecular Probes), mounted on a glass slide, and covered by a coverslip. Slides
were left in the dark at room temperature until they were examined under a Zeiss LSM 700
confocal microscope (with 405, 488, 555, and 639 nm excitation lasers). All images were
analyzed and processed in Zeiss Zen Blue software (v3.2).
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4.2.11. Transmission Electron Microscope
At indicated time points, T cells incubated with SPIONs were retrieved and fixed
using Karnovsky’s fixative (2% PFA, 2% glutaraldehyde, 0.1M sodium cacodylate, pH
7.4) for 30 minutes at room temperature. Fixed cells were washed twice in 0.1M sodium
cacodylate buffer and stored at 4 oC for 16 hours. Further mounting, staining, sectioning,
and TEM imaging were performed by the High-Resolution Imaging Facility (HRIF) at the
University of Alabama at Birmingham (UAB).
Briefly, the specimens were rinsed several times with 0.1 M sodium cacodylate
buffer (pH 7.4) and incubated with 1 % osmium tetroxide in cacodylate buffer for one hour
in the dark. After four rounds of rinsing for 15 minutes each with cacodylate buffer, the
specimens were dehydrated through a series of graded treatments with ethyl alcohols from
50 to 100%. After dehydration, the specimens were immersed in 2 changes of 100%
propylene oxide (PO) for 10 minutes each, and in a 50: 50 mixture of PO and the
embedding resin (Embed 812, Electron Microscopy Sciences, Hatfield, PA) for 12 18
hours. Each specimen was finally transferred to fresh 100 % embedding media, which were
then polymerized overnight in a 60 0C embedding oven. The specimen blocks were thin
sectioned using a diamond knife (Diatome, Electron Microscopy Sciences, Hatfield, PA)
at 70 – 90 nm (silver to pale gold using color interference), and sections were placed on
copper grids. The sections were further stained with heavy metals, uranyl acetate, and lead
citrate for contrast. After drying, the grids were then viewed on a Tecnai Spirit 120 kV
TEM (FEI, Hillsboro, OR). Digital images were taken at 2,100 – 4,400 X magnifications
using an AMT BioSprint 29 CCD camera.
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4.2.12. Statistical Analysis
All statistical analyses were performed using v9.0 Prism software (GraphPad).
One-way or two-way ANOVA analysis with Dunnett’s or Sidak’s multiple comparisons
was employed to validate the statistical significance for multiple group comparisons.
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4.3.

Results

4.3.1. IL-2R expression profiles in pan T cell culture
To study the IL-2R-mediated association and endocytosis, we first examined the
IL-2R subunits' surface-expression dynamics during the 12-Day culture of mouse primary
pan T cells. In our regular culture, we employed Dynabeads coated with anti-CD3 and antiCD28 for activation of T cells on Day 0 and 6 and supplemented with mIL-2 (30 U per 106
cells) when the cells were split typically on Day 2, 3, 4, 8, 9, and 10.
As expected, most pan T cells isolated from the mouse spleen were negative in
CD25 and CD122 before activation on Day 0, indicating that most were naïve T cells
(Figure 4.1a, b). In agreement with the previous finding that T cells express CD132 at all
states (G. A. Smith, Taunton, and Weiss 2017), the majority of cells were positive for
CD132 on Day 0 (Figure 2.1a). The expression level of CD25 dramatically increased upon
activation (~ 25 fold increase in MFI by Day 1). In comparison, the expression levels of
CD122 and CD132 fluctuated without significant changes throughout the 12-day culture
(Figure 4.1a,c). Accordingly, most T cells were CD25+ on Day 2 and afterward, while the
sizes of CD122+ or CD132+ populations showed some fluctuations (Figure 4.1a,b). It was
also notable that the expression of CD25 was even more significantly upregulated after
reactivation (on Day 6) and reached its maximum level on Day 8 (Figure 4.1c). However,
both CD122 and CD132 were quite minimally expressed on the surface in the same period.
Ironically, this could be due to the increased uptake of IL-2 and trimeric IL-2R followed
by degradation of CD122 and CD132. Indeed, the percentage of T cells displaying CD122
or CD132 was significantly higher when the T cells were left without IL-2 for 165 minutes
(mIL-2 starvation) compared to the T cells maintained in the presence of IL-2 (Figure 4.2).
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Figure 4.1: Surface expression dynamics of IL-2R subchains on primary mouse T cells
during 12-day culture. Black arrows indicate the time point when the T cells were
(re)activated by using the Dynabeads coated with anti-CD3 and anti-CD28 antibodies. (a)
Histograms of CD25, CD122, and CD132 measured by flow cytometry (shade in blue)
overlaid with their respective unstained control (shade in red). (b) Expression of IL-2R
subunits by percent positive cells. (c) MFI fold difference between the stained and
unstained samples. (d) The dynamics of CD4+ (black) and CD8+ (red) T cells were
indicated by percent positive cells of the indicated population. (e) The dynamics of CD25+
cells among CD4+ (black) or CD8+ T cell populations. (f) The dynamics of CD122+ cells
among CD4+ (black) or CD8+ T cell populations. (b, d-f) Results in the figure are
represented as mean ± standard deviation (n = 3).

In addition to IL-2R subchains, we examined the compositions of CD4+ and CD8+
T cells in our culture. We observed that the percentage of CD4+ T cells was steadily
decreasing while that of CD8+ T cells increased throughout the 12-Day culture (Figure
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4.1d). Indeed, it is known that activated CD8+ T cells have much higher proliferative
responsiveness to IL-2 than CD4+ T cells in vitro (Foulds et al. 2002; Au-Yeung et al. 2017;
G. A. Smith, Taunton, and Weiss 2017). The increased proliferative response of CD8+ T
cells can be partially explained by the higher expression level of CD122 on CD8+ T cells
compared to CD4+ cells on Day 4 and later (Figure 4.1f) (G. A. Smith, Taunton, and Weiss
2017). The CD4+ T cell population became almost zero after reactivation at the end of Day
6 (Figure 4.1d).

Figure 4.2: Effect of IL-2 starvation on the surface expression level of IL-2R subunits on
Day-2 T cells. Expression levels of indicated subunits were measured by flow cytometry
with or without the IL-2 starvation for 165 minutes. (a) Percentage positive for displayed
IL-2R subunits; Results are represented as mean ± standard deviation (n=3, two-way
ANOVA with Sidak’s multiple comparisons, ** p < 0.01 and **** p <0.0001). (b)
Representative raw histograms of “not starved” (top) and “starved” (bottom) conditions;
red and blue colors indicate the unstained controls and the stained samples, respectively.

Altogether, we could identify T cells on Day 3 ideal for IL-2R-mediated association
and intracellular delivery, as the highest percentages of both CD4+ T cells and CD8+ T cells
would be equipped with high-affinity trimeric receptors on their surfaces.
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4.3.2. IL-2 conjugation strategy and delivery of streptavidin
As the most straightforward strategy to employ IL-2R-mediated association and
endocytosis to deliver various cargoes into the T cells, we decided to conjugate
recombinant IL-2 with multiple payloads. Among different bioconjugation methods, we
selected the biotin-streptavidin binding, one of the most robust non-covalent interactions
with a dissociation constant (Kd) in the order of 4 x 10-14 M (Fairhead and Howarth 2015).
Taking benefit from the significant homology between the mouse (mIL-2) and human IL2 (hIL-2) (62 % identity, Figure 4.3a,b) and their comparable efficacies on murine T cells
(Figure 2.4), we employed the recombinant hIL-2 in the current study. For the first step of
bioconjugation, we studied two different ways of biotinylation, one being the chemical
(NHS-PEG4-Biotin) reaction using the activated ester targeting the primary amine side
groups of random lysine residues or enzymatic biotinylation reaction targeting Avi-tag
residue at the C-terminus of hIL-2.
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Figure 4.3: The mouse IL-2 (mIL-2) and human IL-2 (hIL-2) structure and properties. (a)
Protein BLAST alignment of mIL-2 (P04351) and hIL-2 (P60568); Residues in yellow
within the hIL-2 sequence are known to interact with the human IL2R; Lysines are
underlined; Cysteine 125 in the original CDS of hIL-2 is substituted with Alanine (green)
in recombinant hIL-2. (b) Properties of recombinant mIL-2 and hIL-2; “Gravy” refers to
Grand Average of Hydropathicity obtained from ProtParam tool in www.expasy.org. (c)
The crystal structure of hIL-2 (red) complexed with IL-2R (PDB ID: 2ERJ) depicted using
Pymol; CD25 (green), CD122 (blue), and CD132 (magenta); Lysine residues are
represented as yellow spheres with their respective amino acid numbers. T3 and T133 of
hIL-2 are labeled in purple and cyan, respectively, to aid localization of the termini of hIL2 in the crystal structure.
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Figure 4.4. The potency of murine and human IL-2 on mouse T cells. The potencies of
different doses of mIL-2, hIL-2, and hIL-2-Avitag were compared by measuring the
number of cells after 24- and 48-hour incubation on Day-9 cells of a mouse T cell culture.
Each value of hIL-2 and hIL-2-avitag was compared to the respective mIL-2 control and
denoted with the corresponding statistical significance marks. Results in the figure are
represented as mean ± standard deviation (n = 3, one-way ANOVA with Dunnett’s multiple
comparisons, **** p < 0.0001, * p < 0.05).
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Figure 4.5: Quenching efficiencies of varying percentages of trypan blue for extracellular
green fluorescence. For fixation, murine primary pan T cells (on culture Day 2) were
incubated within 2% paraformaldehyde for 30 minutes at room temperature. The fixed T
cells were stained by Alexa Fluor 488-labeled anti-mouse CD25 antibody (clone 7D4)
before being analyzed by flow cytometry in the presence of indicated percentage of Trypan
Blue. (a) A collection of representative histograms. (b) The mean fluorescent intensity
(MFI). Results in the figure are represented as mean ± standard deviation (n=3).

By employing three different NHS-PEG4-Biotin to hIL-2 ratios of 5, 10, and 20,
we acquired hIL-2 with varying biotinylation ratios (biotin per IL-2) of 1.5, 3.3, and 5.6,
respectively. As the efficiency of enzymatic biotinylation reaction for Avi-tag was
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approximately 60 %, the biotinylation ratio of hIL-2-avitag is considered to be 0.6. We first
examined how these varying degrees of biotinylation on random lysine residues or Cterminus affect the efficacies of the recombinant hIL-2. Interestingly, none of these
biotinylated hIL-2 demonstrated a significant reduction in efficacies compared to
unmodified hIL-2 control (Figure 4.6a).
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Figure 4.6: Comparisons of differently biotinylated hIL-2. (a) Potencies of differently
biotinylated hIL-2 were examined by the proliferation of Day-3 T cells after 24- and 48hours post-plating; Two-way ANOVA with Dunnett’s multiple comparisons, **** p
<0.0001. (b-e) Effects of differently biotinylated hIL-2 on Alexa Fluor 488-labeled
streptavidin (SV) delivery to Day-3 T cells. Total association (measured in the absence of
trypan blue) (b, c) and uptake (measured in the presence of 0.4% trypan blue) (d, e) of
streptavidin are plotted for the percent positive cells (b, d) and MFI (c, e). Results in the
figure are represented as mean ± standard deviation (n=3).
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Encouraged by this result, we first proceeded to test how efficiently these
biotinylated hIL-2 of different biotinylation ratios can deliver a simple and relatively small
model protein cargo, streptavidin. To differentiate the quantities of internalized IL2conjugated streptavidin from the total amount of associated (internalized cargoes plus the
cargoes attached to the cell-surface) IL-2-streptavidin conjugates, we measured the T cells
with or without the trypan blue during flow cytometry. As trypan blue cannot penetrate
through the live cell membranes, only the extracellular fluorescent dyes will be quenched
in the presence of trypan blue (Rejman et al. 2004; Illien et al. 2016; Ho et al. 2017). Our
validation experiment using the fixed T cells labeled with Alexa Fluor 488-conjugated antimouse CD25 antibody (clone 7D4) confirmed that 98.63 ± 1.40 % of extracellular dyes'
fluorescence signals are effectively quenched in the presence of 0.4% trypan blue (Figure
4.5). Activated T cells on Day 3 were incubated for 4, 8, and 24 hours with the indicated
hIL-2 formulation with dye-labeled streptavidin. Among the chemically biotinylated
groups, the total association and uptake increased proportionally to the biotinylation ratio
(Figure 4.6b-e). However, the hIL-2-avitag with the lowest biotinylation ratio significantly
outperformed all the chemically biotinylated groups (Figure 4.6b-e). In 24 hours of
incubation, the streptavidin cargo was intracellularly delivered to 90 ± 1.85 % of T cells
by hIL-2-avitag compared to only 58 ± 0.21 % by hIL-2-B5.6 (Figure 4.6d). The superior
performance of hIL-2-avitag over chemically biotinylated hIL-2 formulations is more
pronounced in the MFI values (Figure 4.6c,e). Altogether, we concluded that biotinylated
hIL-2 could effectively deliver model cargo, streptavidin, into the T cells using IL-2Rmediated endocytosis and the C-terminal enzymatic biotinylation was selected as the best
conjugation strategy. We decided to employ only hIL-2-avitag (hereafter just IL-2 unless
mentioned otherwise) for further studies.
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4.3.3. Characterization of IL-2-loaded SPIONs
To study IL-2R-mediated delivery of bigger cargoes, we decided to employ
streptavidin-coated superparamagnetic iron-oxide nanoparticles (SPIONs) of defined
diametrical sizes of 50, 100, and 200 nm. We first standardized the loading of biotinylated
proteins onto these SPIONs using AF488-labelled and biotinylated lysozyme (biotin:
lysozyme ratio of 1.2, 14.3 kDa) as a model protein. By varying the quantities of lysozyme
(50, 100, 250 ng) and SPIONs (10, 15, or 20 g) in a fixed volume of loading buffer (100
l), we could systematically control the surface densities of lysozyme on SPIONs (Figure
4.7). Employing the same loading conditions, we prepared SPIONs of varying IL-2 surface
densities as summarized in Table 4.1.

Figure 4.7: Loading conditions for biotinylated lysozyme (model protein) onto the surface
of SPIONs. Correlations between the quantity of biotinylated lysozyme and the resulting
surface density were made for (a) SPION50 (b) SPION100 and (c) SPION200; Varying
amounts, 10, 15, and 20 g of SPIONs were employed in each incubation reaction, which
was indicated in red, green and blue color, respectively.
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Bead
name

IL-2/bead

IL-2/100
nm2

Z-avg size (d.
nm)

PDI

Zeta Pot. (mV)

50

-

-

121.9 ± 1.36

0.148 ± 0.01

-1.407 ± 0.31

50_1

86

1.09

137.2 ± 1.40

0.230 ± 0.01

-1.602 ± 0.41

50_2

194

2.47

184.8 ± 8.32

0.525 ± 0.00

-2.540 ± 0.75

50_7

529

6.74

188.2 ± 6.02

0.456 ± 0.07

-1.676 ± 66

50_10

810

10.31

213.2 ± 28.22

0.519 ± 0.07

-3.814 ± 0.38

100

-

-

254.4 ± 4.87

0.237 ± 0.01

0.712 ± 0.24

100_2

872

2.77

340.7 ± 10.09

0.373 ± 0.02

0.656 ± 0.74

100_7

2398

7.63

539.8 ± 40.07

0.676 ± 0.10

-0.456 ± 1.08

100_10

3100

9.87

638.7 ± 28.94

0.560 ± 0.04

-0.332 ± 1.81

100_20

6008

19.12

834.1 ± 100.56

0.708 ± 0.06

-2.454 ± 1.58

200

-

-

353.5 ± 7.05

0.232 ± 0.01

-1.852 ± 0.17

200_1

1675

1.33

519.5 ± 19.71

0.380 ± 0.01

-2.022 ± 0.30

200_2

3474

2.75

801.9 ± 20.56

0.556 ± 0.11

-2.664 ± 0.51

200_7

8316

6.60

803.2 ± 135.99

0.618 ± 0.04

-2.954 ± 0.83

200_10

13854

10.99

737.9 ± 74.88

0.598 ± 0.03

-3.268 ± 0.82

Table 4.1: Physicochemical characteristics of naked and IL-2-loaded SPIONs. Bead names
are represented as X_Y, where X indicates the diameter of SPION core in nm and Y
indicates the estimated IL-2 surface density (number of IL-2 per 100 nm2). PDI:
Polydispersity index.
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Figure 4.8: Physicochemical characterization of SPIONs. (a-c) Size and polydispersity
index (PDI) of unmodified and IL-2-loaded SPION50 (a), SPION100 (b), and SPION200
(c). (d-f) Zeta potential of unmodified and IL-2-loaded SPION50 (d), SPION100 (e), and
SPION200 (f). On graphs, unmodified SPIONs are indicated with their respective core size
in nm, i.e., 50, 100, or 200. The IL-2-loaded SPIONs are represented as X_Y, where X
indicates the diameter of SPION core in nm and Y indicates the estimated IL-2 surface
density (number of IL-2 per 100 nm2). All statistical comparisons are made for the zaverage size of each IL-2-loaded SPION group with respect to their unmodified SPION
control. Results in the figure are represented as mean ± standard deviation (n = 3 for size
and PDI, n = 5 for zeta potential measurements); (a-c) two-way ANOVA, (d-f) one-way
ANOVA with Dunnett’s multiple comparisons, **** p < 0.0001, * p < 0.05, ** p < 0.01.

Next, we evaluated the hydrodynamic size, the size distribution, and the net surface
charge (zeta potential) of each IL-2-loaded SPIONs using DLS (Figure 4.8, Table 4.1). As
expected, the unmodified SPIONs showed quite monodisperse (PDI < 0.25) size
distributions. The Z-average hydrodynamic diameters were much bigger than the ironoxide core sizes, namely, 121.9 ± 1.36, 254.4 ± 4.87, and 353.5 ± 7.05 nm, for SPION 50,
100, and 200, respectively. As the surface densities of IL-2 increased, the Z-average
diameters of SPIONs also increased (Figure 4.8a-c, Table 4.1), which mainly originated
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from increasing PDI due to aggregations. For the SPIONs of all sizes, the zeta potential
values linearly decreased as the surface densities increased (Figure 4.8d-f, Table 4.1),
which strongly supports that the loading of IL-2 was systematically varied in a controlled
manner.
4.3.4. Delivery of IL-2-loaded SPIONs of varying sizes into the primary pan T cells
We tested the efficiency of IL-2-mediated association and endocytosis of SPION
cargoes on the activated primary T cells on Day 3 of culture (Figure 4.1). First, we tested
the effect of free IL-2 on the association and uptake of IL-2-conjugated SPIONs for
incubation time up to 24 hours. As we found that the presence of free IL-2 in the culture
media indeed slightly lowered the association and uptake of IL-2-conjugated cargoes,
potentially due to the competition in binding (Figure 4.9), we incubated the T cells with
IL-2-conjugated SPIONs without any free IL-2 in the culture media for 24 hours before
further analyses. As expected, associations of all IL-2-loaded SPION groups were
significantly superior to those of unloaded (naked) SPION groups (Figure 4.10a-c), which
indicates that IL-2 can successfully promote the selective association of cargoes onto the
IL-2R-expressing T cells without an apparent restriction in the size of cargo up to several
hundred nanometers. However, it was interesting that the association was optimal at
different surface densities of IL-2 for SPION50 vs. SPION100 or SPION 200. While 7 IL2 per 100 nm2 was optimal for SPION50 (50_7), 2 IL-2 per 100 nm2 was optimal for
SPION100 (100_2) or SPION200 (200_2) (Figure 4.10a-c).
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Figure 4.9: Effects of the presence of free IL-2 during incubation on the delivery of
SPION50 to Day-3 T cells. Alexa Fluor 488-labeled SPION50s were loaded with 345 molar
excess of hIL-2-Avitag. “50” in green color indicates the SPION50s without loaded hIL-2.
The association (a) and uptake (b) of hIL-2-loaded SPION50s after indicated hours of
incubation with or without the free IL-2 were measured by flow cytometry, indicated as
“50-IL-2 Unwashed” in blue and “50-IL-2 Washed” in red, respectively. Results in the
figure are represented as mean ± standard deviation (n = 3).
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Figure 4.10. Delivery of SPIONs of varying sizes and varying IL-2-densities to Day-3 T
cells. Total association (without trypan blue, a-c) and uptake (in the presence of 0.4%
trypan blue, d-f) of naked and IL-2-loaded SPION50 (a, d), SPION100 (b, e), and
SPION200 (c, f) of varying surface densities were measured at 24-hours post-plating. On
graphs, “CO” indicates the cell only control group. Unmodified (naked) SPIONs are
indicated with their respective core size in nm, i.e., 50, 100, or 200. The IL2-loaded
SPIONs are represented as X_Y, where X indicates the diameter of SPION core in nm and
Y indicates the estimated IL-2 surface density (number of IL-2 per 100 nm2). All statistical
comparisons are made for the SPION+(%) of each IL-2-loaded SPION group with respect
to their unmodified SPION control. Results in the figure are represented as mean ± standard
deviation (n = 3; one-way ANOVA with Dunnett’s multiple comparisons, **** p < 0.0001,
** p = 0.01, * p < 0.05, *** p < 0.0005).

To properly examine the extent of SPIONs internalized by IL-2R-mediated
endocytosis, we again employed trypan blue to selectively quench the fluorescence signals
originating from extracellular SPIONs (Rejman et al. 2004; Illien et al. 2016; Ho et al.
2017). First, we performed another experiment to directly validate the trypan blue’s ability
to selectively quench the fluorescent signals originating from the extracellularly associated
SPIONs. We incubated either live (non-fixed) or fixed T cells on Day 3 with SPIONs as a
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positive or a negative control group for endocytosis, respectively (Figure 4.11). Both nonfixed and fixed cells showed significantly enhanced associations with the IL-2-loaded
SPION50_7 compared to the naked SPION50. However, in the presence of 0.4% trypan
blue, a statistically significant enhancement in fluorescent signals of SPION50_7 relative
to SPION50 was achieved only in live (non-fixed) cells, but not in fixed cells (Figure 4.11),
which indicates that the signals in the presence of 0.4% trypan blue originate from
intracellular SPIONs.

Figure 4.11: Validation for exclusive and complete quenching of extracellular green
fluorescence from the SPION50 labeled with Alexa Fluor 488 using 0.4% Trypan Blue.
Fixed and non-fixed murine pan T cells (on culture Day 3) were incubated with indicated
SPIONs for 24-hours before analysis by flow cytometry. “TB-” and “TB+” indicate the
absence and presence of trypan blue during the flow cytometry measurements,
respectively. “50” and “50_7” indicate the unmodified SPION50 and the SPION50 loaded
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with IL-2 at a surface density of 7 IL-2 per 100 nm2, respectively. “CO” indicates a cellonly control group. (a) A collection of representative overlays of histograms for non-fixed
vs. fixed cells, with or without trypan blue. (b) Percent of AF488-positive cells and (c)
mean fluorescence intensity (MFI) of AF488. (b, c) Results in the figure are represented as
mean ± standard deviation (n = 3, two-way ANOVA with Dunnett’s multiple comparisons,
*** p = 0.0002, **** p < 0.0001).

Indeed, significantly higher percentages of T cells endocytosed the IL-2-loaded
SPIONs than the naked (“50” or “100” or “200”) control SPIONs (Figure 4.10d-f) in all
size groups. In comparison to the association behavior, the percentages of T cells that
contain the internalized SPIONs became smaller as the sizes of cargoes increased from
SPION50 to 100 to 200 (Figure 4.10d-f), which indicates that the efficiency of endocytosis
is significantly affected by the size of payloads (Rejman et al. 2004). Meanwhile, the
SPIONs having IL-2 densities that showed the maximum association also demonstrated the
optimal uptake (50_7, 100_2, and 200_2). While 13.1 ± 0.3 % of T cells were positive in
the uptake of 50_7, it reduced to 10.7 ± 2.3 % for 100_2, and it further reduced down to
a mere 4.5 ± 0.6 % for 200_2.
4.3.5. Intracellular uptake confirmed by CLSM and TEM
We employed confocal laser scanning microscopy (CLSM) to investigate further
the whereabouts of these SPIONs (Figure 4.12a-b). First, we confirmed that many T cells
are associated with the SPIONs regardless of the size of SPIONs. By using z-stack imaging
and co-staining endolysosomes (red), nucleus (blue), lipid membrane (orange), together
with SPIONs (green), we could differentiate the externally associated SPIONs from the
internalized SPIONs. We found most internalized SPIONs (indicated by “i” in Figure
4.12a) within or in the close vicinity of endolysosomes. To overcome the resolution limit
of the optical microscopy, we employed transmission electron microscopy (TEM) as well.
We could confirm that these IL-2-loaded nanocargoes are internalized by the T cells, and
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they were found either inside of endolysosomes or within the cytoplasm (Figure 4.12c,
Figure 4.13).

Figure 4.12. Confocal laser scanning microscope (CLSM) and transmission electron
microscope (TEM) images of Day-3 T cells treated with IL-2-loaded SPIONs. (a, b) CLSM
images of T cells incubated with indicated SPION samples in Split (a) or Ortho (b) view.
SPIONs (S) labeled with AF488, lysosomes (L) stained by Lysotracker Deep Red, nucleus
(N) stained with DAPI, and cell membrane (CM) stained by Cell Mask Orange were
represented in green, red, blue, and orange color, respectively; “MIP” refers to maximum
intensity projection view; “i” indicates the SPIONs inside the cells co-localized with
endolysosome. Scale bar is 2 m for SPION50_7 and 5 m for SPION100_2 and
SPION200_2. (c) Representative TEM image of T cells incubated with SPION50_7; Scale
bar is 2 m; The area marked by a black square was zoomed in as an inset; Arrows in red
indicate individual SPIONs co-localized within a single endolysosome.

152

Figure 4.13. Transmission electron microscope (TEM) image of Day-3 T cells incubated
with SPION50_7. Red arrows are added to indicate the SPION50s.

4.3.6. Association and uptake profiles throughout different days of the T cell culture
Using 50_7, 100_2, and 200_2 SPIONs, we examined the fluctuations of the
association and uptake of IL-2-loaded SPION cargoes over the 12-Day T cell culture. As
we expected based on the expression profiles of IL-2R subchains (Figure 4.1), the
association patterns showed maximum around Day 3, when the trimeric IL-2R would be
expressed by the largest T cell population (Figure 4.14a-c). It was intriguing to observe
that the associations of none of these cargoes showed significant increases after
reactivation of T cells, even if the CD25 expression level was orders of magnitude higher
on those days compared to Day 3. This result indicates that the association of these SPION
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cargoes by IL-2 is mainly driven by high-affinity IL-2R (trimer) instead of the abundance
of the low-affinity receptor (monomeric CD25).

Figure 4.14. Delivery of SPIONs to the T cells on different days of culture. “0” refers to
unactivated cells, and the rest of the numbers indicate the day of culture post activation.
Association (a-c) and uptake (d-f) of naked and IL-2-loaded SPION50_7 (a, d),
SPION100_2 (b, e), and SPION200_2 (c, f) were measured at 24-hours post-plating on
each day. All IL-2-loaded SPIONs (red) are compared with their respective unmodified
(naked) SPION controls (green). Results in the figure are represented as mean ± standard
deviation (n = 3; two-way ANOVA with Dunnett’s multiple comparisons, *** p < 0.0001,
** p < 0.005, * p < 0.05, **** p < 0.0001).
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Figure 4.15. Mean fluorescence intensity (MFI) analysis for the delivery of IL-2-loaded
SPION50_7, SPION100_2, and SPION200_2 on the T cells throughout the 12-Day culture.
On each indicated day on the x-axis, the SPIONs were incubated for 24 hours with the T
cells before being analyzed by flow cytometry. “0” refers to the unactivated cells.
Association (a-c) and uptake (d-f) of SPION50_7 (a, d), SPION100_2 (b, e), and
SPION200_2 (c, f) was measured by MFI values and represented as mean ± standard
deviation (n = 3; two-way ANOVA with Dunnett’s multiple comparisons, * p < 0.05, ** p
= 0.0038, *** p = 0.0003, **** p < 0.0001).

It is worth mentioning that neither a significant association nor uptake was observed
for any of these SPION cargoes on Day 0 cells, i.e., unactivated T cells, reconfirming that
the delivery of IL-2-conjugated cargo is entirely dependent on the availability of IL-2R on
the T cell surface. Similar sizes of the activated T cell populations internalized 50_7 on all
tested days (Figure 4.14d). Meanwhile, the same T cells could significantly internalize
100_2 only on Day 3 (Figure 4.14e). In this particular setup, 200_2 particles were not
uptaken by the T cells on any of the tested days (Figure 4.14f). These association and
internalization trends were well supported by the MFI values of flow cytometry data
(Figure 4.15).
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4.4.

Discussion
Receptor-mediated endocytosis is a complex biological process in which the

surface expression of the transmembrane receptor is the prerequisite for binding to its
ligand. Upon successful binding, the conformational change(s) on the signaling receptor’s
subunit(s) induces the otherwise untriggered downstream processes at the receptor's
cytoplasmic domain. In the case of the IL-2R, IL-2-induced conformational changes in the
receptor subunits CD122 and CD132 were previously demonstrated by Förster resonance
energy transfer (FRET) in confocal microscopy (Pillet et al. 2010). To maintain
homeostasis, the ligand & subunit(s) of some signaling receptors (e.g., IL-2R) are
endocytosed and sorted into the recycling or degradation compartments.
IL-2R with three subchain components is one of the few receptors almost
exclusively expressed by the activated T cells and Treg cells (Onur Boyman and Sprent
2012; O. Boyman 2006). There have been previous efforts to chemically conjugate IL-2
molecules onto the surface of liposomes and nanocapsules for their targeted delivery to IL2R-expressing T cell populations (Zheng et al. 2013; Konigsberg et al. 1998; Frick et al.
2016). Here, we systematically investigated the effects of the sizes of nanocargoes on the
total association and internalization of IL-2-conjugated nanocargoes into the activated T
cells via IL-2R-mediated endocytosis.
For a direct implication of in-vitro engineering of primary T lymphocytes, we used
murine primary pan T cells activated by using the Dynabeads coated with anti-CD3 and
anti-CD28 antibodies, the most commonly used and clinically relevant synthetic tool for T
cell expansion in adoptive T cell therapies, and checked the variations of the expression
level of all IL-2R subchains over the 12-Day culture (Figure 4.1). It is noteworthy that
initially dominating CD4+ population decreases over time, and almost the entire T cell
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population upon the second activation on Day 6 became CD8+. So the data acquired postreactivation roughly represents the IL-2R expression profile of CD8+ T cells alone. At this
point, it is unclear whether CD4+ and CD8+ T cells are intrinsically different in IL-2Rmediated endocytosis. However, a comparison between Day 3 and Day 11 in the
internalization of SPIONs provides an exciting insight. The expression level of IL-2R was
comparable on Day 3 and Day 11 (Figure 4.1b). While SPION50_7 was effectively
internalized on both Day 3 and Day 11, SPION100_2 was only internalized on Day 3 but
not on Day 11 (Figure 4.14d, e). This stark difference could originate from the endocytic
behaviors between CD4+ and CD8+ T cells or those with different activation histories. Such
potential difference in endocytosis capabilities among different T cell subsets and
differentiation states becomes an intriguing topic to investigate more carefully in the future.
To conjugate IL-2 onto the cargo most efficiently, we carefully studied the effect
of biotinylation on the efficacies of IL-2 and the efficiency of the delivery of small cargo,
streptavidin (Figure 4.6). It turns out that the biotinylation randomly targeting the side
group of lysine residues itself was not detrimental to the efficacy of IL-2. Moreover, a
higher number of biotin per IL-2 molecule up to 5.6 was beneficial for the delivery of
streptavidin. However, these IL-2 molecules with multiple biotin moieties were all inferior
to C-terminally biotinylated IL-2 (the average biotin to IL-2 ratio of 0.61) in terms of cargo
delivery. These puzzling results can be interpreted by studying the locations of lysine
residues in relevance to the 3D crystal structure of IL-2 and IL-2R. The recombinant hIL2 possesses a total of 11 lysine residues (Figure 4.3a). Meanwhile, the 24 residues, L12,
E15, H16, L18, L19, D20, K35, R38, F42, K43, F44, Y45, E61, E62, P65, E68, L72, D84,
N88, V91, E95, T123, Q126, and I129, within the central core of hIL-2 engage in the
interaction with the hetero-trimeric human IL-2R (Stauber et al. 2006) (Figure 4.3c). While
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the modification with small biotin moiety may not interfere with the IL-2-IL-2R
interactions, the conjugation of cargoes of significant sizes such as streptavidin onto any
centrally positioned lysine residues might cause a significant steric hindrance. Thus, K8
and K9 are potentially the only lysine residues that can be used for successful conjugation
and delivery of cargo (Figure 4.3c). It seems that the higher random biotinylation up to the
tested ratio of 5.6 was beneficial due to the enhanced chance of biotinylating on K8 or K9
residues. However, this haphazard biotinylation approach was not as efficient as enzymatic
C-terminal conjugation, for C-terminal conjugation guarantees to avoid sterical hindrance
while keeping the central core untouched for effective engagement with IL-2R. Based on
the crystal structure of IL2-IL-2R, we presume the conjugation to the other terminus (Nterminus) of IL-2 might be as efficient (Penichet et al. 2001; Penichet and Morrison 2001;
Dela Cruz, Morrison, and Penichet 2005; Ongaro et al. 2020; Gillies et al. 1992), which
needs to be confirmed by further investigation.
There are various cargoes of different sizes, such as polymeric nanoparticles, drug
carriers, biological molecules, polyplexes, and imaging probes, that can potentially induce
a paradigm shift in current T cell therapeutics and their manufacturing if they can
effectively be delivered into the T cells. We selected the SPIONs of well-defined sizes as
our model cargoes. We prepared and characterized the SPIONs of three different sizes
loaded with four different IL-2 surface densities per size group. Interestingly, the maximum
association and uptake were obtained at different densities of IL-2 for SPION50 (7 IL-2
per 100 nm2) vs. SPION100 or SPION200 (2 IL-2 per 100 nm2). The variation in the surface
curvature between the SPIONs of different diameters and the resulting IL-2 spatial
arrangement may have been the origin of the difference in optimal engagement with T
cells. However, it is also possible that simply the difference in aggregation behaviors of
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each SPION group (PDIs in Figure 4.8a-c) may have contributed more significantly to the
difference in association behavior onto the T cell surface and the distribution of SPIONs.
It is worth noting that the z-average sizes of SPIONs 100 and 200 significantly increased
proportional to the IL-2 densities, mainly due to the increased aggregations (higher PDIs)
(Figure 4.8b,c). This makes it difficult to precisely correlate the core sizes of SPION
cargoes with their respective uptake efficiencies. The superior association and uptake of
SPION100 with a minimal IL-2 density (i.e., SPION100_2) (Figure 4.11b, e) could be due
to its minimal aggregation compared to the others with higher densities (Figure 4.8b).
Similar experiments with other nanocargo platforms with less of an intrinsic tendency of
aggregation would benefit further investigations.
More conclusive results were obtained in terms of the size difference. Overall,
SPIONs of all tested sizes could associate with the T cells expressing high-affinity
(trimeric) IL-2R at relatively high efficiencies up to 40 – 50 % of total T cell populations,
depending on the days of culture and the dosages. However, the uptake by receptormediated endocytosis was inversely proportional to the sizes of the cargoes. Moreover, this
trend applies to SPIONs of varying sizes and to streptavidin (a much smaller cargo), which
was endocytosed by about 90% of the T cells (Figure 4.6d).
It must be noted that a previous study (Frick et al. 2016) reported a significant
delivery of IL-2-functionalized hydroxyethyl starch (HES) nanocapsules with a
hydrodynamic size around 215 nm up to 80 % of primary human activated T cells via the
IL-2R. However, the study did not distinguish the endocytosed particles from associated
(membrane-bound and internalized) particles. The study claimed that all dye-positive T
cells have uptaken IL-2-functionalized dye-labeled HES nanocapsules based on the notion
that all IL-2R associated particles would be internalized and without which the T cells
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would not be stimulated. Contrastingly, in our study, we clearly distinguished the
internalized particles from the associated AF488-labeled SPIONs. Besides we have
reported here that the association of these particles with activated T cells is quite high (up
to 55 %) while the uptake is limited (up to 15 %). Therefore, the findings of this study are
novel and outstanding.
The concept of maximum limit in the size of cargoes that each receptor-mediated
endocytosis can internalize has been well documented (Kumari, MG, and Mayor 2010).
For IL-2R, the endocytosis of IL-2R containing CD122 was previously shown to occur
within a vesicular size of 50-100 nm (Kumari, MG, and Mayor 2010). Hence, we can
expect that there could be a maximum cargo size of around 100 nm. Based on our flow
cytometry studies, it was clear that the endocytosis of SPION200 was very much limited
compared to those of SPION50 and SPION100. Furthermore, due to the scarcity, we could
not find any TEM images clearly showing the T cells with internalized SPION200.
However, using CLSM, we could identify some SPION200 co-localized with intracellular
lysosomes (Figure 4.12a-b). Nevertheless, the current study results provide precious
guidelines that nanoscale cargo should be designed within a diametrical size around 100 200 nm for effective intracellular delivery using IL-2R-mediated endocytosis.
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4.5.

Conclusion
Here, we investigated the bioconjugation of IL-2 as a potential strategy to

intracellularly deliver nanocargoes of varying sizes to activated primary murine T cells
(ATCs) via the IL-2R-mediated endocytosis. Indeed, IL-2- conjugated nanocargoes of
varying sizes were successfully delivered to IL-2R-expressing ATCs. It was shown that the
bioconjugation should be made using the C-terminal amino acids instead of random Lysine
residues of IL-2 for better cargo delivery. The efficiencies of endocytosis (internalization
or uptake) were inversely proportional to cargo size. Our results imply a practical cargo
core-size limit around 100−200 nm in the IL-2R-mediated endocytic pathway. In other
words, IL-2-functionalized payloads with a hydrodynamic diametrical size of ≤ 340.7 ±
10.09 nm can be delivered to IL-2R-expressing ATCs.
Meanwhile, the associations of IL-2-loaded cargoes onto the IL-2R-expressing
ATCs were not significantly affected by size. These definitive conclusions imply that the
size of nanocargo should be appropriately designed according to the purpose of T cell
engineering. Even if the SPIONs were employed as model cargoes in the current study, the
efficient associations of SPIONs with ATCs would provide new prospects to develop novel
imaging modalities for ATCs. To deliver transgenes (e.g., CAR gene) into T cells, the
nucleic acid payloads should be designed to be smaller than the proposed maximum size
limit for effective endocytosis via the IL-2R. Altogether, the bioconjugation and delivery
strategy described in this report will be broadly applicable to the engineering and
manufacturing of T cell immunotherapies.
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4.6.

Future Directions
The findings of this study can serve as a general guide for the design of novel drug

delivery applications specific to Tregs and activated T cells in vivo and in vitro.
Furthermore, the current formulation i.e. the IL-2-functionalized SPIONs itself can directly
be used in the medical field to coat the T cell membrane and/or to deliver them to T cells
to track the migration patterns and activity sites of activated T Lymphocytes in vivo using
magnetic resonance imaging (MRI). For this, some animal model studies must be
conducted to access the efficiency of delivery, specificity, toxicity, and change in
behavioral patterns.
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CHAPTER V

PRELIMINARY TRANSFECTIONS OF THE PRIMARY MOUSE ACTIVATED
T LYMPHOCYTES VIA THE IL-2R USING IL-2-FUNCTIONALIZED
POLYPLEXES

5.1. Background and Significance
The introduction of transgenes into T cells is a highly sought-after endeavor. T cellspecific transfections are extremely difficult to achieve due to their inherent resistance to
uptake foreign materials. However, previous reports showed that IL-2-functionalized
nanocapsules with a hydrodynamic size (Dz ± relative SD) of 215 ± 28 nm were
successfully delivered to primary human activated T cells in vitro and mouse CD25+ T
cells in vivo (Frick et al. 2016). As reported in the previous chapter regarding the size
restrictions of the IL-2R, transfection of T cells via the IL-2R-mediated endocytosis is
possible when the polyplexes (nucleic acids and polymer complexes) are less than ~ 341
nm in diameter. We attempted to optimize the polyplex formulation to transfect the T cells
via the IL-2R using the same bioconjugation strategy indicated in the previous chapter. In
this chapter, we attempted to transfect the primary mouse activated T cells with IL2functionalized polyplexes. Here, we hypothesized that IL2-functionalized polyplexes that
fall within a hydrodynamic diametric size of 341 nm would be able to transfect the IL-2Rexpressing mouse T cells.
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5.2. Materials and Methods
5.2.1. Materials
Tris (Thermo Scientific), NaCl (Fisher Chemical), non-glycosylated Streptavidin
(52.8 kDa, New England BioLabs), EDTA (Acros Organics), sodium azide (Fisher
Chemical), bovine serum albumin (BSA, Fisher BioReagents), 10 X phosphate-buffered
saline (PBS) powder (Fisher Scientific), ACK lysing buffer (Gibco), RPMI 1640 with Lglutamine (Gibco), fetal bovine serum (FBS, characterized grade, HyClone), PenicillinStreptomycin (P/S, Gibco), 2-mercaptoethanol (2-ME, Gibco), disposable vacuum
filter/storage system (Corning), 0.2 m PTFE membrane syringe filter (GE Whatman), cell
strainers (Corning Falcon), MS columns (Miltenyi Biotec), 96-well white plates (Corning
Costar), 96-well clear plates (Corning Costar), 96-well culture plates (Corning Costar), and
24-well culture plates (Corning Falcon) were used as received from the manufacturers.
Recombinant mouse IL-2 (mIL-2) and human IL-2 (hIL-2) were purchased from
Peprotech. Biotinylated human IL-2 (hIL-2-avitag) was purchased from Acro Biosystems.
5.2.2. T cell isolation and culture
All primary T cells were obtained from the spleen of C57BL/6J mice (Jackson
Laboratory) maintained under a pathogen-free environment via MACS using the mouse
pan T cell Isolation II kit (Miltenyi Biotec). All procedures involving mice followed the
protocols approved by the IACUC of the University of Alabama in Huntsville. Immediately
after isolation, T cells were activated using Dynabeads Mouse T-activator CD3/CD28
(Gibco) at cell: bead ratio of 1:1 in RPMI complete media (RPMI 1640, 10% FBS, P/S, 2ME) containing mIL-2 (30 U/ml). T cells were cultured at an initial density of 1 x 106
cells/ml in a 24-well plate and incubated at 37 oC and 5 % CO2 in a Heracell VIOS 160i
CO2 incubator. As regular maintenance, cells were monitored every day and were split (3x)
164

when the live-cell density reached 3 x 106 cells/ml. Fresh mIL-2 was provided after
splitting the cells. After Day 6, cells were collected, washed by centrifugation at 250 g for
5 minutes, suspended in fresh media containing mIL-2, and reactivated using Dynabeads
at a cell: bead ratio of 1:1 plated at a density of 1 x 106 cells/ml.
5.2.3. Protein quantitation
All proteins were measured for their concentrations using the BCA protein assay
kit

(Thermo

Scientific

Pierce)

using

NanoDrop

OneC

(Thermo

Scientific)

spectrophotometer. All samples, including the BSA standards, were incubated at 60 oC for
30 minutes in a water bath before taking measurements.
5.2.4. Polyplex preparations
First, 25 kDa branched Polyethyleneimine (PEI) is modified with a 10 molar excess
of NHS-PEG4-Biotin (NPB) in 1X PBS pH 7.4 for 30 minutes at room temperature on a
tube rotator. Next, the solution is desalted using ZebaTM 7 kDa MWCO spin column
equilibrated in pure water. The extent of biotinylation is verified immediately using the
HABA assay (Pierce Biotin Quantitation Kit) by following the manufacturer’s
recommended protocol. The biotin to PEI ratio was found to be 3.
To prepare polyplexes, briefly, 5 g of pGFP or 3 g of GFP mRNA is complexed
with modified PEI at the indicated weight (polymer to nucleic acids) ratios or N/P
(nitrogens in polymer to phosphates in nucleic acids) ratios for 15 to 20 minutes at room
temperature.
Condense and Attach Strategy (ConA): Biotinylated polyplexes prepared in pure
water at indicated weight ratios or N/P ratios were treated with the indicated molar ratio of
streptavidin (SV) in pure water for 60 minutes at 4 0C on a tube rotator. Later, the indicated
165

molar ratio of hIL-2-avitag was added and allowed to react with SV-coated polyplexes for
an additional 60 minutes at 4 0C on a tube rotator.
Attach and Condense Strategy (ACon): Biotinylated PEI was treated with the
indicated molar ratio of SV in pure water for 60 minutes at 4 0C on a tube rotator. Next,
SV-coated PEI was used to condense nucleic acids in pure water at indicated weight ratios
or N/P ratios. Later, the indicated molar ratio of hIL-2-avitag was mixed and allowed to
coat SV-coated polyplexes for an additional 60 minutes at 4 0C on a tube rotator.
Strategy 3 (S3): First, SV and hIL2-avitag conjugates were prepared in pure water
at indicated equimolar ratios for 60 minutes at 4 0C on a tube rotator. Biotinylated
polyplexes were prepared in pure water at indicated weight ratios or N/P ratios. Next,
biotinylated polyplexes and SV-hIL-2-avitag conjugates were incubated in pure water at
indicated molar ratios for an additional 60 minutes at 4 0C on a tube rotator.
5.2.5. DLS measurements
In the case of polyplexes, samples with initial reaction volumes within 100-200 l
were made up to 1,300 l just before measurements. The z-average size and zeta potential
were measured using Zetasizer Nano (Malvern) for 3-5 cycles per measurement.
5.2.6. Transfection
Polyplexes prepared in pure water were diluted with a total of 1,300 l of RPMI
complete media that contained approximately 25,000 primary mouse T cells along with 1
X mIL-2. Twelve wells (three replicates each for four-time points) of 105 l were aliquoted
for each control group in a 96-well plate. Plates with cells were then placed in the CO2
incubator until measurements were obtained.
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5.2.7. Flow Cytometry
At each indicated time point, all cells from experimental plates were carefully
retrieved. Cells were washed in FACS buffer (PBS, 0.5 % BSA, 2 mM EDTA) by
centrifugation at 400 g for 5 minutes at 4 oC, resuspended in 300 l of FACS buffer to be
measured by Attune NxT Flow Cytometer (Invitrogen). All data were analyzed and plotted
using FlowJo software (v10.0).
5.2.8. Statistical Analysis
All statistical analyses were performed using v9.0 Prism software (GraphPad).
One-way or two-way ANOVA analysis with Dunnett’s or Sidak’s multiple comparisons
was employed to validate the statistical significance for multiple group comparisons.
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5.3. Results and Discussion
First, to functionalize the polyplexes with biotinylated IL-2 (hIL-2-avitag or just
IL-2 hereafter), streptavidin must be coated on the 25 kDa branched polyethyleneimine
(PEI)-based polyplexes or conjugated to the PEI. This bioconjugation can be achieved in
three different strategies: i) ConA: Condense the nucleic acids with biotinylated PEI and
then attach Streptavidin (SV) onto the biotin-containing polyplexes, ii) ACon: attach SV
to biotinylated-PEI and then condense nucleic acids, and iii) Strategy 3 (S3): conjugate SV
and IL-2 at equimolar concentrations and then coat the SV-IL-2 conjugate onto the biotincontaining polyplexes. In strategies one and two, IL-2 is loaded on the streptavidinattached polyplexes, using the same protocol the SPIONs were loaded with IL-2 described
in this chapter.

Figure 5.1: The hydrodynamic size versus polydispersity index (PDI) (a) and net-surface
charge (b) of pGFP-polyplexes prepared using ConA and ACon strategies and analyzed by
Dynamic Light Scattering (DLS). “P25” refers to the polyplexes prepared using 25 kDa
PEI, “P25-bio” indicates the polyplexes prepared using biotinylated PEI, and “P25-SV”
indicates the polyplexes prepared using the PEI and SV conjugates following the strategies
“ConA” and “ACon”. Numbers in the brackets on the x-axis indicate the molar ratio of PEI
to Streptavidin (SV) used in the bioconjugation reaction. Results in the figure are
represented as mean ± standard deviation (n = 3 for size and PDI, n = 5 for zeta potential
measurements).
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First, we biotinylated PEI using NHS-PEG4-Biotin (NPB) and confirmed the
Biotin-to-PEI ratio to be 3 using HABA assay (Biotin Quantitation Assay, Pierce). Next,
we verified the physicochemical properties of polyplexes prepared using strategies one
(ConA) and two (ACon). The polyplexes prepared using biotinylated PEI alone (153.77 ±
3.48 nm) were bigger than those prepared using unmodified PEI (135.46 ± 2.31 nm)
(Figure 5.1a). The size data demonstrates that the ACon strategy is better than the ConA
strategy (Figure 5.1a) as the sizes of the polyplexes using the latter have increased with the
increase in the amount of SV used in the bioconjugation reaction. Supporting the possibility
that the SV had coated the polyplexes or have conjugated to the PEI, the net surface charge
of the polyplexes has increased with the amount of SV used in the bioconjugation reaction
(Figure 5.1b). This phenomenon is perhaps due to polyplexes' aggregation (PDI in Figure
5.1a) because SV (near neutral pI) is a neutrally charged protein in pure water and should
not alter the polyplexes’ net surface charge.

Figure 5.2: The hydrodynamic size versus polydispersity index (PDI) (a) and net-surface
charge (b) of IL-2-functionalized pGFP-polyplexes prepared using ConA and Acon
strategies and analyzed by Dynamic Light Scattering (DLS). Numbers in the brackets on
the x-axis indicate the molar ratio of PEI to SV to IL-2 used in the bioconjugation reaction.
Results in the figure are represented as mean ± standard deviation (n = 3 for size and PDI,
n = 5 for zeta potential measurements).
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Next, we functionalized these polyplexes with IL-2 and verified their
physicochemical properties. There was no enhancement in the mean size of the polyplexes
with an increase in the amount of IL-2 used in the bioconjugation reaction (Figure 5.2a).
However, the PDI (Figure 5.2a) of ConA samples is more significant than the ACon
samples, reflected in the polyplexes' net surface charge (Figure 5.2b). Overall,
functionalizing polyplexes with IL-2 did not have significant changes in the size and charge
of the polyplexes.

Figure 5.3: The hydrodynamic size versus polydispersity index (PDI) (a) and net-surface
charge (b) of IL-2-functionalized pGFP-polyplexes prepared using strategy 3 and analyzed
by Dynamic Light Scattering (DLS). Numbers in the brackets on the x-axis indicate the
molar ratio of PEI to SV to IL-2 used in the bioconjugation reaction. Results in the figure
are represented as mean ± standard deviation (n = 3 for size and PDI, n = 5 for zeta potential
measurements).

We have also verified the physicochemical properties of polyplexes prepared
using strategy 3 (S3). We found that the size and PDI of the polyplexes did not significantly
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change with an increase in the amount of SV-IL-2 conjugate used in bioconjugation
reaction (Figure 5.3a) up to a certain limit. Most fascinatingly, the net surface charge of
the polyplexes decreased gradually with an increase in the amount of SV-IL-2 conjugate
(Figure 5.3b). These results demonstrate that the polyplexes are likely functionalized with
IL-2, and such functionalization has no impact on the size of the polyplexes. The decreased
charge of the polyplexes is highly advantageous for receptor-mediated endocytic (RME)
transfections due to the prevention (to some extent) of charge-charge interactions the PEIbased polyplexes would usually display in non-RME-mediated transfections. Altogether,
we decided to test the transfection of pGFP-polyplexes prepared using S3.
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Figure 5.4: Cell counts of different pGFP formulations tested in the transfection of Day 3
Pan T cells analyzed using flow cytometer. Numbers on the x-axis indicate the hours posttransfection (hpt). “CO” refers to a cell-only control, and the rest of the samples are pGFPpolyplex formulations. Numbers within the brackets in the legend indicate the molar ratio
of PEI to SV to IL-2. “CO” and “P25-bio” controls but not others were supplemented with
1X mIL-2 at 0 hpt. Results in the figure are represented as mean ± standard deviation (n =
3).
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Figure 5.5: Overlaid histogram of different pGFP formulations tested in the transfection of
Day 3 Pan T cells analyzed at 48- (top), 72- (middle), and 96-hpt (bottom) using flow
cytometer. “CO” in the legend refers to a cell-only control, and the rest of the samples are
pGFP-polyplex formulations; Numbers in the sample names within the legend indicate the
molar ratio of PEI to SV to IL-2; Cell counts are also indicated in the legend as “Count”.
“CO” and “P25-bio” controls but not others were supplemented with 1X mIL-2 at 0 hpt.
Results in the figure are represented as mean ± standard deviation (n = 3).
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Cell counts and GFP-expression measurements for all indicated samples were taken at
48-, 72-, and 96- hours post-transfection (hpt). Unfortunately, none of the formulations was
able to transfect T cells (Figure 5.5). The cell counts of cell-only control and the nonfunctionalized polyplex controls (Figure 5.4, black and red) have initially grown to 72 hpt
but reduced at 96 hpt, probably because the samples were not supplied with additional
supplies mIL-2 after plating and the initial dose would have been exhausted. Interestingly,
the cell counts of the samples that contained lower amounts of SV-IL-2 conjugate have
gradually decreased (Figure 5.4, orange and green), indicating the possibility that the free
or unmodified IL-2 is absent or exhausted before 48 hpt. These samples contained 2.5
ng/well (orange) and 5 ng/well (green) of the total IL-2, of which at least 975 pg/well and
1.95 ng/well respectively must have been the unmodified protein, significantly higher than
600 pg/well mIL-2 in the cell-only and non-functionalized polyplex controls. Although we
currently do not understand why the unmodified IL-2 did not contribute to cell growth in
these samples, we can interpret that the modified IL-2 (on polyplexes) cannot enter the cell.
If IL-2 or its conjugates had entered the cell via IL-2R-mediated endocytosis, cell growth
must be observed.
Nonetheless, the cells had rapidly proliferated in the samples containing higher
amounts of SV-IL-2 conjugate (Figure 5.4, violet and purple). Therefore, if the nucleic
acids were delivered within 48 hours, cells could have expressed some GFP within the
tested time points as the cell divisions could have allowed the translocation of pGFP into
the nucleus. It is also possible that pGFP could not have dissociated enough from the
polymer to show any GFP expression, even if it had translocated into the nucleus.
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Figure 5.6: The hydrodynamic size vs. PDI (a) and net-surface charge (b) of mRNApolyplexes prepared at different N/P ratios in pure water (100 l) analyzed by Dynamic
Light Scattering (DLS, measured by Ms. Eva Barck). Results in the figure are represented
as mean ± standard deviation (n = 3 for size and PDI, n = 5 for zeta potential
measurements).

We have also tested whether a pool of GFP-encoding mRNA (GFP mRNA) instead of
pGFP can show some GFP expression upon successful intracellular delivery. For this, we
first optimized the mRNA-PEI complexes. We tested different N/P (nitrogens in PEI and
phosphates in nucleic acids) ratios to prepare polyplexes. Although N/P of 50 gave the
smallest polyplexes, the difference between the sizes from N/P of 20 and 50 is not
significant (Figure 5.6a), and hence we prepared polyplexes with N/P 20 for further
investigation. Besides, as the N/P ratio increased, the PDI also increased in general. Most
importantly, higher N/P ratios lead to greater cytotoxicity and, therefore, must be avoided
in general.
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Figure 5.7: The hydrodynamic size vs. PDI (a) and net-surface charge (b) of mRNApolyplexes prepared at different mRNA concentrations (reaction volumes) in pure water
(200, 100, 25, and 20 l respectively with concentrations on the x-axis) analyzed by
Dynamic Light Scattering (DLS, measured by Ms. Eva Barck). Results in the figure are
represented as mean ± standard deviation (n = 3 for size and PDI, n = 5 for zeta potential
measurements).

Figure 5.8: The hydrodynamic size vs. PDI (a) and net-surface charge (b) of pGFPpolyplexes prepared at w/w (PEI:pGFP) of 2.0 and different pGFP concentrations (reaction
volumes) in pure water analyzed by Dynamic Light Scattering (DLS, measured by Ms. Eva
Barck). Results in the figure are represented as mean ± standard deviation (n = 3 for size
and PDI, n = 5 for zeta potential measurements).
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Next, we tested whether the concentration of mRNA (technically speaking, the reaction
volume) during the reaction would alter the physicochemical properties of the resulting
polyplexes. The DLS data demonstrated that the smallest polyplexes (Figure 5.7a) with the
lowest net-surface charge (Figure 5.7b) could be achieved with the lowest mRNA
concentrations (or highest reaction volumes). However, the PDI (Figure 5.7a) appears to
be lower in the samples with the highest mRNA concentrations (or lowest reaction
volumes). Interestingly, however, the sizes and the PDI of the pGFP-polyplexes appear to
be slightly reduced with an increase in the pGFP concentration during the reaction (Figure
5.8a). In the case of the net surface charge, a similar trend in the mRNA-polyplexes (Figure
5.8b) is observed in pGFP-polyplexes (Figure 5.8b).

Figure 5.9: The hydrodynamic size vs. PDI (a) and net-surface charge (b) of IL-2functionalized mRNA-polyplexes prepared at N/P of 20 and 60 ng/L of mRNA during
reaction in pure water and then diluted in pure water (total volume 1,300 l) analyzed by
Dynamic Light Scattering (DLS, measured by Ms. Eva Barck). Numbers on the x-axis
indicate the molar ratios of PEI to SV to IL-2. Results in the figure are represented as mean
± standard deviation (n = 3 for size and PDI, n = 5 for zeta potential measurements).
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As a final step before transfection, we functionalized the mRNA-polyplexes with IL-2
and verified their physicochemical properties. Interestingly, the coating of mRNApolyplexes with the SV-IL-2 conjugates did not significantly change the size (Figure 5.9a).
However, the increase in the amount of SV-IL-2 conjugates in the bioconjugation reaction
had increased the PDI (Figure 5.9a) and reduced the net surface charge (Figure 5.9b) of the
polyplexes.
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Figure 5.10: Cell counts of different mRNA formulations tested in the transfection of Day
3 Pan T cells analyzed using flow cytometer. Numbers on the x-axis indicate the hours
post-transfection (hpt). “CO” refers to a cell-only control, and the rest of the samples are
mRNA-polyplex formulations. Numbers within the brackets in the legend indicate the
molar ratio of PEI to SV to IL-2. “CO” and “P25-bio” controls but not others were
supplemented with 1X mIL-2 at 0 hpt. 1X mIL-2 was supplied to cells in all groups at 24hpt. Results in the figure are represented as mean ± standard deviation (n = 3).
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Figure 5.11: Overlaid histogram of different GFP-mRNA formulations tested in the
transfection of Day 3 Pan T cells analyzed at 48- (top), 72- (middle), and 96-hpt (bottom)
using flow cytometer. “CO” in the legend refers to a cell-only control, and the rest of the
samples are GFP-mRNA-polyplex formulations; Numbers in the sample names within the
legend indicate the molar ratio of PEI to SV to IL-2; Cell counts are also indicated in the
legend as “Count”. “CO” and “P25-bio” controls but not others were supplemented with
1X mIL-2 at 0 hpt. 1X mIL-2 was supplied to cells in all groups at 24-hpt. Results in the
figure are represented as mean ± standard deviation (n = 3).
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Following the characterization of the mRNA polyplexes, we attempted to transfect the
Day 3 pan T cells using all the formulations. No significant GFP expression was measured
in any mRNA formulation group within 24 to 72-hpt (Figure 5.11). Nevertheless, there is
a very small secondary population within the 103 and 104 range on the GFP channel of all
polyplex controls (Figure 5.11) indicating that there could a small fraction (~6.5 % with
~3 % as a gating strategy) of cells expressing the GFP up to 48-hpt. This tiny fraction of
the supposedly GFP-expressing cells must be confirmed for expression with an additional
control such as having an mRNA that does not express GFP as we have previously shown
(Chapter II) that even a GFP non-coding expression vector could enhance the background
green fluorescence by simply associating with the cells. In addition, testing the effect of
increasing the GFP-mRNA on the GFP expression must be studied. In this experimental
setup, we added 1X mIL-2 to all the wells at 24-hpt to eliminate the suspicion that the cells
hadn’t proliferated enough. However, mRNA does not require translocation to the nucleus
for GFP expression, and hence the addition of free mIL-2 would only enhance the growth
of cells. Because the cells in the formulation-free (CO in Figure 5.10) group have
proliferated relatively rapidly within the first 48 hours, IL-2 must have been quickly
depleted. Therefore, many cells in the CO group had died within 48-72 hpt. The slow
growth of cells was observed in the unmodified polyplex group (P25-bio in Figure 5.10),
perhaps due to the toxicity of positively charged complexes. However, cells in the test
groups have continued to proliferate rapidly (however slowly within 48-hpt) after 48-hpt
likely due to the presence of free hIL-2-avitag within their formulations (Figure 5.10).
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Figure 5.12: The hydrodynamic size in terms of the major peak size (a) and net-surface
charge (b) of pGFP-polyplexes prepared in pure water (100 l) analyzed by Dynamic Light
Scattering (DLS, measured by Ms. Eva Barck). Results in the figure are represented as
mean ± standard deviation (n = 3 for size and PDI, n = 5 for zeta potential measurements).
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Figure 5.13: The hydrodynamic size pGFP-polyplexes prepared in pure water and diluted
in pure water (a), BSA buffer (PBS containing 0.1 % BSA, b), and RPMI complete media
(c) analyzed by Dynamic Light Scattering (DLS, measured by Ms. Eva Barck). Results in
the figure are represented as mean ± standard deviation (n = 3).

Although it is exciting and necessary to confirm the intracellular delivery of nucleic
acids and their translocation into the nucleus, the current formulations are inefficient. These
IL-2-functionalized polyplexes ranging from 156.1 ± 1.71 (mean ± SD) to 178.7 ± 0.36 nm
made in pure water are still within the hydrodynamic size limits (< 341 nm) of IL-2R-
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mediated endocytosis. However, adding these formulations to the cell culture media could
have significantly changed the size and charge. This hypothesis is well supported by the
data in Figure 5.12. Although the major peak size of the polyplexes diluted in RPMI
complete media is only slightly larger than those diluted in pure water, a second peak
(Figure 5.13b) ranging from 2,000 to 7,000 nm poses a significant concern as it is beyond
the size limits of IL-2R-mediated endocytosis. It must be noted that the smaller peaks
(around 10 nm) do not correspond to polyplexes but BSA or serum proteins (Figure
5.13b,c). Nevertheless, it is necessary to verify the size of IL-2-functionalized polyplexes
prepared in pure water and diluted in RPMI complete media.
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5.4. Conclusion
T cell-specific transfections are hard-to-achieve and studies have shown promising
methods with yet low transfection efficiencies. The reasons for low transfection
efficiencies could be many. However, mainly the amount of delivered nucleic acid
complexes and the number of nucleic acids that escaped the endosomes appear to be the
predominant factors that can decide the fate of transgene expression. In this study, we
carefully prepared and characterized the IL-2-functionalized polyplexes and yet couldn’t
show any considerable transgene expression in primary mouse activated T cells. Since the
particles in pure water seem to be within the cargo-size limits of the IL-2R-mediated
endocytosis, it is safe to consider that at least some of these complexes could have been
internalized (up to 10 %) by the T cells via the IL-2R, which, however, needs to be
confirmed. If this is proven to be true, then the failure in transgene expression could
indicate a potential failure of the transgene - to dissociate from PEI, endosomal escape,
remain undegraded in the endolysosome. Additionally, the IL-2-functionalized polyplexes
could have an increased size when suspended in serum-containing culture media, which
also needs to be further investigated. Overall, these parameters that can critically affect the
ability of IL-2-functionalized polyplexes to transfect T cells via the IL-2R-mediated
endocytosis must be further investigated to fully comprehend the true potential of the
current non-viral vector design.
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5.5. Future Directions
While investigating the means to lower the size of the IL-2-functionalized
polyplexes or unmodified polyplexes, in general, is fascinating and required, it is crucial
to discover the cargo-size restrictions of other ligand-receptor pairs unique to T
Lymphocytes. I propose here that the CD28 receptor system must be explored for potential
transfection attempts in T cells. CD28 is a co-stimulatory molecule expressed on T cells
(discussed in more detail in previous chapters). It is reported that 25 to 35 % of CD28 is
internalized (endocytosed) upon antibody binding (Céfaï et al. 1998). Also, 50 % of the
endocytosed receptors are segregated into the degradative system and the other 50 % into
the recycling pathway (Céfaï et al. 1998). Interestingly, CD28 is endocytosed via clathrincoated pits (Brzostek, Gascoigne, and Rybakin 2016). Clathrin-mediated endocytosis is
known to occur with an observed vesicular size within 150-200 nm (Kumari, MG, and
Mayor 2010). The CD28-mediated endocytosis could prove advantageous mainly because
its vesicular size is more than the IL-2R’s 50-100 nm (Kumari, MG, and Mayor 2010).
Although the ligands of CD28, namely, B7-1 (CD80) and B7-2 (CD86), can be used as
bioconjugation resources, anti-CD28 antibodies could prove particularly amenable for in
vivo applications, as the said ligands also interact with the immune checkpoint protein,
CTLA-4. Since CTLA-4 is a negative regulator of T cells, common ligands of CD28 and
CTLA-4 must be avoided in general. However, B7-1 and B7-2 can be used for initial testing
and in vitro applications, including adoptive T cell therapies.

184

CHAPTER VI

GENERATION OF ACELLULAR ARTIFICIAL ANTIGEN-PRESENTING
CELLS FOR OPTIMIZATION OF THE ACTIVATION LEVELS AND
POTENCY EVALUATION OF HER-2-SPECIFIC CAR-T CELLS

6.1.

Background and Significance

6.1.1. HER2 and Disease
The human epidermal growth factor receptor 2 (HER2) is an Epidermal Growth
Factor Receptor (EGFR)-related gene that was found to have tyrosine kinase activity
similar to EFGR (Moasser 2007). HER2 is also known as the erbB2 protein due to its
homologous nature to the avian erythroblastosis viral oncogene v-erbB (Moasser 2007).
The HER family proteins, HER1 (EGFR, erbB1), HER2 (erbB2, Her2/neu), HER3
(erbB3), and HER4 (erbB4), are type I transmembrane growth factor receptors (Perrier et
al. 2018; Moasser 2007). The basic structure of the HER family proteins consists of an
extracellular domain (ECD) which binds to a ligand, a transmembrane domain, and an
intracellular domain that has a tyrosine kinase activity (Figure 6.1). The interaction
between the ligand and the ECD leads to the dimerization and transphosphorylation at the
intracellular domains of HER2 (Moasser 2007). The phosphorylated tyrosine amino acid
residues then engage several signaling molecules leading to the activation of abundant
downstream second messenger pathways and crosstalk with other transmembrane
signaling pathways leading to different biological effects (Moasser 2007). The ligand-
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binding induces a change in the conformation of the ECD, leading to an active
conformation (Moasser 2007). Unlike other HER family proteins, HER2 does not bind to
any growth factors and has no known ligand (Moasser 2007; Perrier et al. 2018). Therefore,
its signaling function is activated by homo- or hetero-dimerization with another HERfamily protein (Moasser 2007; Perrier et al. 2018).

Figure 6.1: The structure of HER2 protein. LD1 and LD2 are the ligand-binding domains,
CR1 and CR2 are the cysteine-rich regions, TM is a transmembrane region, TK is the
catalytic tyrosine kinase domain, CT is a carboxy-terminal tail. (Lv et al. 2016). Used with
Permission.

The HER2 is a well-established therapeutic target protein due to its overexpression
in various solid tumors such as the breast, colon, gastric, ovary, head and neck, lung,
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bladder, uterine cervix, and esophageal cancers (X. Liu, Zhang, and Shi 2017). Out of all
these cancer types, breast cancer is the most frequent malignant condition in women
(Antoine and Maher 2020), in which approximately 20-25 % of breast cancers overexpress
HER2 (Priceman et al. 2018). In addition to the standard treatment options such as surgery,
radiotherapy, hormonal blockade, and chemotherapy, novel targeted therapies were
developed that exploit our current understanding of tumor biology (Antoine and Maher
2020). Nevertheless, these interventions cannot benefit all patients. Some subtypes, such
as triple-negative disease (HER2-, Estrogen Receptor- or ER-, Progesterone Receptor- or
PR-), remain particularly difficult to treat (Antoine and Maher 2020).
The role of HER2 in the signaling network leads to the development of anti-HER2
monoclonal antibodies (mAbs) that includes pertuzumab and trastuzumab for cancer
therapy (X. Liu, Zhang, and Shi 2017). Consequently, the median overall survival of
metastatic HER2+ breast cancer patients has improved (Priceman et al. 2018). Nonetheless,
in up to 50% of HER2+ breast cancer patients, management of metastatic disease in the
brain and the central nervous system (CNS) continues to be a clinical challenge primarily
due to the inability of mAbs to cross the blood-brain barrier (BBB) sufficiently (Priceman
et al. 2018). Therefore, cellular immunotherapies are actively investigated to treat solid
tumors in HER2+ cancers (Priceman et al. 2018).
6.1.2. Acellular Artificial Antigen Presenting Cells (aaAPCs)
A heterogeneous group of immune cells such as the B Lymphocytes, Dendritic cells
(DCs), Macrophages, and Langerhans cells forms the classical or professional Antigenpresenting cells (APCs) that mediate the cell-mediated immune responses by processing
and presenting antigens for the recognition by specific Lymphocytes such as T cells. The
professional APCs provide all the necessary signals (antigen presentation via the MHC
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molecules,

expression

of

co-stimulatory

surface-molecules,

and

secretion

of

cytokine/chemokine) for the T cells to activate, followed by recognition and destruction of
the antigen-expressing cells (Eiz-Vesper and Schmetzer 2020). DCs, in particular, present
tumor-specific antigens to T cells; therefore, cancer patients are often vaccinated with
APCs for in vivo T cell induction (Eggermont et al. 2014). Although several studies report
beneficial clinical outcomes with minor adverse side effects of natural APCs, several
serious limitations were also uncovered (Eggermont et al. 2014). These limitations include
the lack of knowledge of the optimal antigen-loaded DCs, time-consuming and expensive
isolation and ex vivo stimulation of autologous DCs, and finally, the variable quality of ex
vivo generated DCs (Eggermont et al. 2014). Besides, the antitumor responses mediated by
patient-derived DCs are not always consistent amongst donors, and that the production of
effector memory T cells has reduced function (Neal et al. 2017). The most concerning
limitation is that the DCs in cancer patients are often dysfunctional (Neal et al. 2017).
Therefore, to overcome the difficulties and limitations of using autologous APCs, artificial
APCs (aAPCs) are being developed (Eggermont et al. 2014; Eiz-Vesper and Schmetzer
2020).
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Figure 6.2: Comparison between in vivo DCs and in vitro DynabeadsTM in the activation
of resting T cells. Source: Thermofisher Product (DynabeadsTM Mouse T-Activator
CD3/CD28 for T-Cell Expansion and Activation, Gibco) webpage.

Although cell-based aAPCs (caAPCs) can be generated, they pose some
limitations, such as the variable efficiency of transgene transfections, exhaustion after
multiple rounds of growth, and expensive reagents. Therefore, acellular aAPCs (aaAPCs)
are being developed, which are cheaper, need minimal maintenance, and offer consistent
T cell activations. One most common aaAPC used for culturing T cells in vitro is the antiCD3 and anti-CD28 antibodies-coated superparamagnetic microparticles of diametrical
size 4.5 M (DynabeadsTM, Figure 6.2). The dynabeads function by mimicking the APCs
such as DCs in the activation of T cells (Figure 6.2).
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6.1.3. Significance
CAR-T cells against human HER2+ cancers have been previously generated by
many groups for clinical investigations including our collaboration partner, Refuge
Biotechnologies, Inc. These HER2 CAR-T cells can be activated by simply using soluble
HER2 molecules or HER2-coated aAPCs. Since soluble HER2 molecules do not generally
offer robust activation profiles, HER2-presentation using aAPCs was thought to be more
effective by noting the remarkable activation levels achieved by Dynabeads in T-cell
activations. Although caAPCs can be used to modulate HER2 CAR-T cells functionally,
we intend to use aaAPCs for the benefits discussed previously.
Apart from the antigen-presentation mechanisms, the use of checkpoint inhibitors
has been of particular interest in the field of CAR-T cell therapy. An immune checkpoint
protein known as the programmed death-ligand 1 (PD-L1 or B7-H1 or CD274) is
expressed on immune regulatory cells and some cancer cells. PD-L1 binds to its partner
programmed cell death protein 1 (PD1 or PDCD1 or CD279) expressed on the surface of
T cell. The interaction between PD1 and PD-L1 counters the positive signals provided by
the TCR and CD28 (Sharpe and Pauken 2018), rendering the T cells inactive. Since this
interaction is detrimental in CAR-T cell therapy, anti-PD1 antibodies (Pembrolizumab)
and anti-PD-L1 antibodies (Atezolizumab) were suggested to rescue the CAR-T cell
functions. To test whether HER2 CAR-T cells can be rescued by using the above
antibodies, a PD-L1-presenting model cell or an acellular particle is essential.
Here, we aimed to report the generation, standardization, and testing of HER2- and
PD-L1-coated aaAPCs for the functional modification of HER2 CAR-T cells. Our strategy
to generate aaAPCs includes using biotinylated HER2 and PD-L1, streptavidin-coated
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superparamagnetic iron-oxide microparticles of diametrical size 2.8 M (hereafter M280),
and the biotin & streptavidin bioconjugation technique.
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6.2.

Materials and Methods

6.2.1. Materials
EDTA (Acros Organics), Sodium Azide (NaN3, Fisher Chemicals), BSA (Fisher
BioReagents) were used as received from manufacturers.
6.2.2. Protein Quantitation
Before and after biotinylation and purification, all proteins were measured for their
concentrations using the BCA protein assay kit (Thermo Scientific Pierce) in NanoDrop
OneC (Thermo Scientific). All samples, including the BSA standards, were incubated at
600C for 30 minutes in a water bath before taking measurements.
6.2.3. Protein Labelling
Recombinant human HER2 (ErbB2) ectodomain was purchased from Acro
Biosystems, Inc. (DE, USA) (Cat. No. HE2-H5225). Initially reconstituted with ultrapure
water, the proteins were further diluted in 80 mM sodium bicarbonate buffer (pH 8.3). To
50 g of HER2 proteins, ~ 21.4 nmol of freshly prepared fluorescent dye with succinimidyl
ester (either Alexa Fluor 488 (AF488) or Alexa Fluor 647 (AF647), Invitrogen) was added,
and the reactions were allowed to occur overnight at 4 oC on a microtube rotator. The
reaction mixtures were buffer exchanged on desalting column (7 kDa MWCO) using 1X
PBS + 0.02 % (w/v) NaN3 (pH 7.4), and the resulting solutions were stored at 4 oC. The
final concentrations of HER2-AF488 and HER2-AF647 were 60 g/mL and 61g/mL,
respectively.
6.2.4. Determination of modification molar ratio of dye to HER2
For the final solution of HER2-AF488, the quantities of HER2 and AF488 were
measured separately. To quantify HER2, a combination of A280 and A205 measurements
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was employed using a Nanodrop One spectrophotometer (ThermoFisher).

For

quantification of AF488, fluorescence signals were measured using a multi-mode
microplate reader (Synergy HTX, Biotek, equipped with 485/20 nm excitation filter and
516/20 nm emission filter). The calibration curve was generated using a serially diluted
series of AF488 solutions (Figure 6.3). It was determined that approximately a 1:1 dye to
HER2 molar ratio was achieved.

Figure 6.3: The standard Curve was generated with five serial dilutions of AF488 starting
from 6.336 pmol/L.
6.2.5. Protein Biotinylation and Quantitation
For regular use, HER2 (70.2 kDa, Acro Biosystems, Cat. #HE2-H5225) was
reacted with a 20 molar excess of NHS-PEG4-Biotin (Thermo Scientific, NPB) in 0.1 M
Sodium Bicarbonate (Electron Microscopy Sciences) buffer pH 8.3 for 2 hours at 40C on a
tube rotator. After the reaction, the biotinylated protein was purified using 0.5 mL 7 kDa
MWCO Zeba Spin Desalting Columns (Thermo Scientific). Post-purification, the number
of biotins per protein molecule was immediately confirmed by HABA (Thermo Scientific
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Pierce Biotin Quantitation Kit) assay in a 96-well transparent microplate. By following the
manufacturer’s recommended protocol, we demonstrated that the mol ratio of biotin-toHER2 is within 7-8. Similarly, other ratios of HER2 and NPB have also been tested, and
the biotin-to-HER2 ratios were confirmed and indicated in Figure X. The biotin-to-protein
ratio of PD-L1-avitag (27.8 kDa, Acro Biosystems, Cat. #PD1-H82E5) is within 0.5-1.0 as
provided by the manufacturer.
6.2.6. Electrophoresis
The protein samples from lysate, washes, and elutions were analyzed in a
denaturing polyacrylamide gel electrophoresis (PAGE). First, protein samples with or
without 100 mM 2-ME were treated with 70 0C for 20 minutes in a water bath. Samples
were then loaded in a 12-well (20 l sample capacity) 4-20 % pre-cast protein gel (BioRad Laboratories) and run for 30 minutes at 200 V in 1X SDS tank buffer (25 mM Tris,
192 mM Glycine, 0.1 % SDS, pH 8.6). For non-denaturing conditions, 1X Native tank
buffer (25 mM Tris, 192 mM Glycine, pH 8.6) was used.
6.2.7. Microparticle Modifications
The main stock of Streptavidin-coated superparamagnetic 2.8-micron beads
(Dynabeads® M280 Streptavidin, hereafter just “M280”) were vigorously vortexed just
before use for disaggregation. M280 beads were washed twice in 1 X Phosphate Buffered
Saline pH 7.4 (PBS, Fisher Scientific cat. #BP665-1) on a magnetic separator (Invitrogen
DynaMagTM-2 Magnet). M280 beads were diluted to the appropriate volume using 1 X
PBS in a 1.5 ml microcentrifuge tube. An appropriate amount of biotinylated HER2 or PDL1-avitag was pipetted out onto the inside of the snap-cap of the beads-containing tube,
snap-closed the tube, and gently vortexed until the protein was adequately mixed with the
bead solution. The tubes were covered with parafilm, and the reaction was allowed
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overnight at 4 0C on a tube rotator in shake-and-rotate mode. Later, beads were briefly
centrifuged, resuspended, and the supernatant was discarded after magnetizing the beads
for 1 minute on the magnetic separator.
In loading both HER2 & PD-L1 onto microparticles, HER2 coating was followed
by PD-L1 at the aforementioned conditions. Beads were rewashed in 1X PBS, resuspended
in 1 X PBS up to appropriate volume, 2 % biotinylated BSA (w/w of M280 beads) was
added to the snap-cap of the tube, snap-closed the tube, and gently vortexed until
biotinylated BSA was adequately mixed with the bead solution. The tube was covered with
parafilm, and the reaction was allowed for 1 hour at 4 0C on a tube rotator in shake-androtate mode. Again, beads were briefly centrifuged, resuspended, and the supernatant was
discarded after magnetizing the beads for 1 minute on the magnetic separator. Beads were
washed twice in 1 X PBS, resuspended in 1 X PBS-Azide buffer (1 X PBS + 0.02% Sodium
Azide) at a concentration of 10 mg/ml, aliquoted into 50 ul volumes in 0.5 ml brown screwcap microcentrifuge tubes, and stored in 40C until taking measurements.
6.2.8. QIFI Assay and Flow Cytometry
Quantitative Analysis Kit - QIFIKIT® (cat. #K007811) was purchased from
Agilent. By following the manufacturer’s recommended protocol, we optimized the
voltages at 230 on Side-Scattering (SSC), 290 on Forward-Scattering (FSC), and 270 on
the BL1 channel (FITC) for the setup and calibration beads in Attune NxT Flow Cytometer
(Invitrogen). A standard curve was plotted with Mean Fluorescence Intensity (MFI) of
FITC-conjugated anti-mouse secondary antibody-stained calibration beads on X-axis and
Antigen Binding Capacity (ABC) values from the specific kit lot number on Y-axis.
1*105 HER2- or PD-L1- or HER2 & PD-L1- coated M280 beads were stained with
500 ng of mouse anti-human HER2 antibody clone #191924 (hereafter just “191924”) or
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mouse anti-human PD-L1 antibody (Atezolizumab biosimilar) in 50 ul of 1X BSA buffer
(1X PBS + 0.1 % BSA) for 1 hour at 40C on a tube rotator. Later, beads were resuspended
in a total of 1,050 ul of 1X FACS buffer (1X PBS, 0.5 % BSA, 2 mM EDTA). Beads were
centrifuged at 400 g for 5 minutes, and 1,000 ul of supernatant was discarded. 500 ng of
the above-mentioned secondary antibody was added, gently vortexed the solution, and the
reaction was allowed for 45 minutes at 4 0C on a tube rotator. Later, beads were washed
twice in FACS buffer by centrifugation. After discarding the supernatant, the tubes were
blotted on KimwipesTM to remove the residual fluid. To measure the ABC values and
percent modification of these microparticles, beads were resuspended in 300 l of FACS
buffer, and 200 l of each sample was analyzed at the same voltage settings as were used
in QIFI set up in the flow cytometer.
6.2.9. Graphical Representation & Statistical Analysis
Line and bar graphs were plotted, and all the statistical analyses were performed
using v9.0 Prism software (GraphPad). One-way or two-way ANOVA analysis with
Dunnett’s or Sidak’s multiple comparisons was employed to validate the statistical
significance in a multiple-group comparison. Scatter plots and histograms were plotted
using v10 FlowJo software.
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6.3.

Results and Discussion

6.3.1. Specific Detection of HER2-specific CAR-T cells
Detection of T cells is required in many immunological applications. It is
particularly advantageous to detect viable and functional T cells in co-culture assays using
fluorescence-activated cell sorting (FACS). Although T cells can be detected using antiCD3, anti-CD28, anti-CD4, and anti-CD8 antibodies in combinations or by themselves in
general, in some applications, it is necessary to distinguish and determine the percentage
of the transformed cells and non-transformed cells in a pool of both. One such application
is the transduction of T cells with chimeric antigen receptors (CARs), in which the
percentage of CAR-transduced T cells must be determined.
Anti-HER2 CAR-T cells expressing either CAR scFv's – FRP5 (mouse therapeutic
antibody specific for human HER2) or 4D5 were manufactured by our collaborators at the
Refuge Biotechnologies, Inc. We prepared Alexa-Fluor 647 (AF647)-labeled human
HER2 protein (HER2-AF647) for detection of CARs expressed on these CAR-T cells in
flow cytometry. To prevent the potential interference of the fluorescent dyes in CAR
binding to HER2 epitope, we kept the modification ratio of dye: HER2 minimal. In the
experiment performed by our collaborators, both CAR-T cells were successfully labeled
and detected in flow cytometry (data not shown).
The current labeling strategy mainly targets the primary amine of the Lysine side group
(i.e.,  amine), considering the position of the Lysine residues in the vicinity of CAR
epitopes. The extracellular domain of human HER2 protein contains 13 Lysine residues
(Figure 6.4a). From the crystal structure of the ectodomain of human HER2 complexed
with Herceptin Fab (PDB ID: 1N8Z), we know that only two lysine residues (K569 and
K593) are in the vicinity to 4D5 epitope (Figure 6.4), and especially K593 might directly
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get involved in its binding (Figure 5.4b). The modification in limited dye to HER2 ratio
(close to 1:1 ratio) must have allowed most of the HER2 epitopes to be detectable. In
theory, only about 1 out of 13 (7.7 %) of HER2 reagents would have been hindered from
being recognized by 4D5 CAR.

Figure 6.4: a 3-D sketch of the crystal structure of the extracellular domain of human HER2
(blue) complexed with Herceptin Fab heavy (cyan) and light (magentas) chains (PDB ID:
1N8Z). 13 Lysine residues within HER2 are marked in yellow color, and its side chains
are displayed as sticks.

6.3.2. Generation of aaAPCs for HER2-specific CAR-T cells
6.3.2.1.

HER2-loaded M280 beads as aAPCs

6.3.2.1.1. Confirming the bioconjugation strategy
After biotinylation, we quickly tested whether the biotinylated proteins would
effectively conjugate to streptavidin (SV). Therefore, a native polyacrylamide gel
electrophoresis (PAGE) was performed. The bands corresponding to the biotinylated
HER2, PD-L1, and BSA were displaced and smeared when the samples were treated with
SV before electrophoresis (Figure 6.5). Interestingly, BSA and SV conjugates appeared
near the top of the well, where proteins are usually loaded.
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Figure 6.5: Native PAGE Gel showing the extent of biotin-streptavidin interactions
between biotinylated proteins and streptavidin. “RBio” indicates the random biotinylation
of proteins using a chemical linker – NHS-PEG4-Biotin. Before running the gel, the
reaction between biotinylated proteins and Streptavidin (SV) was performed at pH 7 for 30
minutes at RT.

This result highlights the likelihood that the combined molecular weight of the
conjugate is enormous, and therefore the conjugate could not migrate into the PAGE gel.
Such huge conjugates could form due to the abundance of biotin on protein onto which
multiple streptavidin molecules could attach and inturn more biotinylated protein on the
conjugate.
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6.3.2.1.2. A strategy to determine the density of HER2 loaded on the beads
First, the QiFi kit was utilized to set up a window of analysis (Figure 6.6a) where
the fluorescence emitting particle populations will appear. The HER2 density (number per
bead) was estimated based on the standard curve (Figure 6.7) built using the measured
mean fluorescence intensity (MFI) values and manufacturer-supplied antigen-binding
capacity (ABC) of calibration beads (Figure 6.6b) from the kit.

Figure 6.6: Setup beads of QiFi kit showing the Window of Analysis (Left) and calibration
beads showing five bead populations (Right) – M1, M2, M3, M4, and M5. “BL1” refers to
the green emission channel or blue laser excitation 1 channel.
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Figure 6.7: A standard curve generated using the measured Mean Fluorescence Intensity
(MFI) values, and the manufacturer supplied antigen-binding capacity (ABC) values of the
calibration beads (M1, M2, M3, M4, and M5). MFI was measured using a flow cytometer.

6.3.2.1.3. Optimizing the buffer conditions for antibody staining

Figure 6.8: Effect of the loading quantity of HER2 on the ability to detect HER2+ beads
analyzed in the flow cytometer. Histogram overlays are shown in a half-offset view. 2 %
BSA-loaded M280 beads (in red) serve as a negative control.
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Loaded Sample

#HER2/Bead

2 % BSA

1,838

0.01 % HER2

3,548

0.05 % HER2

23,971

0.1 % HER2

40,243

0.25 % HER2

73,845

0.5 % HER2

86,579

Table 6.1: Density of HER2 at different loading quantities. ABC values were measured by
staining with primary and secondary antibodies in FACS buffer.

First, we prepared HER2-coated M280 beads by simply incubating the appropriate
amount of biotinylated HER2 with the appropriate quantity of M280 beads in an overnight
reaction at 4 0C. The next day, we measured the ABC values and percent positive HER2loaded beads. We found that with an increasing quantity of HER2 during loading, more
HER2 molecules coated the beads (Table 6.1), as indicated by the increase in MFI (shown
in a histogram view in Figure 6.8).
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Figure 6.9: Effects of using different buffer combinations in staining the HER2-loaded
beads using primary and secondary antibodies on the ability to detect the (a) antigenbinding capacity (ABC, number of HER2 per bead) and (b) HER2-positive beads by
percentage. The buffer combinations are represented as X_Y, where X is the buffer for the
primary antibody staining, and Y is the buffer for the secondary antibody staining. “BSA”
refers to PBS buffer containing 0.1 % BSA.

To standardize the antibody staining protocol for HER2-loaded microparticles, we
first verified the primary and secondary antibody binding ability in different buffer
combinations. The beads were stained with primary and secondary antibodies and
measured for the ABC values (HER2-density, i.e., #HER2 per bead) in the flow cytometer.
We tested PBS, BSA (PBS buffer containing 0.1 % BSA), and FACS (PBS buffer
containing 0.5 % BSA and 2 mM EDTA) buffers for primary antibody staining. However,
we only tested PBS or FACS buffers for secondary antibody staining. Unless otherwise
mentioned hereafter, we stained the beads with primary antibody for 60 minutes at 4 0C
and 45 minutes with secondary antibody at 4 0C. These reaction conditions were
recommended by Agilent Technologies, Inc to detect antigen on QiFi beads, and therefore,
we followed the same conditions for the detection of HER2 on M280 beads.
While BSA_FACS (BSA buffer for primary antibody staining and FACS buffer for
secondary antibody staining) and FACS_FACS combinations offered similar ABC values,
203

the PBS_PBS combination yielded lower ABC values (Figure 6.9a). The PBS_PBS
combination was not found to be optimal to detect the majority of HER2+ beads compared
to the BSA_FACS and FACS_FACS combinations (Figure 6.9b). These results suggest
that PBS buffer, in general, is not a suitable medium for antibody treatment used in
detecting the HER2+ beads. Compared to the BSA_FACS, the FACS_FACS combination
promoted HER2 detection even when lower HER2 loading weight percentages were used
(especially the 0.01 % HER2 in Figure 6.9b). This result indicates that FACS is the best
buffer for primary and secondary antibodies to detect their respective epitopes. Therefore,
we used only the FACS buffer for further investigation.
6.3.2.1.4. Optimizing the incubation time for primary antibody staining

Figure 6.10: Effects of using different incubation times for the primary antibody staining
of the HER2-loaded beads on the ability to detect the (a) antigen-binding capacity (ABC,
number of HER2 per bead) and (b) HER2-positive beads by percentage. The buffer
combinations are represented as X_Y, where X is the time period for the primary antibody
staining, and Y is the time period for the secondary antibody staining.

Next, we attempted to optimize the incubation time for the primary antibody.
Therefore, we fixed the secondary antibody staining time at 45 minutes because the QiFi
beads were stained for 45 minutes. However, the antigen recognition on QiFi beads and
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M280 beads could be different for various reasons, including the distance between two
antigens and the number of antigens per bead, in general. Therefore, optimizing the primary
antibody staining time is crucial for each antigen type in generating aaAPCs. The goal is
to minimize staining time as much as possible while not comprising with the ability to
detect a maximum number of antigens. Surprisingly, all the tested time periods – 30, 60,
and 120 minutes have offered similar detection capabilities for primary antibodies in terms
of ABC values and HER2-positive percentages (Figure 5.10). Therefore, 60 minutes of
primary antibody staining was used for future investigation to keep the protocol unchanged.
6.3.2.1.5. Selection of anti-HER2 antibody

Figure 6.11: Effects of using different clones of mouse anti-human HER2 antibodies –
191924 and H2M5B (4D5 biosimilar) on the ability to detect the (a) ABC values and (b)
HER2-positive beads by percentage.

Finally, we wanted to verify the differences between 2 different clones of antihuman HER2 antibodies in their ability to detect HER2 as they may detect different
epitopes of HER2. Since we aim to use HER2-loaded M280 beads for antigen presentation
to 4D5 CAR-T cells, it would be ideal for detecting the HER2 on M280 beads using a 4D5
antibody clone for its characterization instead of using 191924 clone as the detection
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capabilities could be different for each antibody clone. So we directly compared 191924
and 4D5 biosimilar antibody (H2M5B) in their ability to detect HER2 on M280 beads.
We found that 191924 detected more HER2 on M280 beads than H2M5B,
particularly when the loading weights of HER2 on M280 beads have increased (Figure
6.11a). Surprisingly enough, H2M5B was able to detect a majority of HER2+ beads at a
lower loading weight of HER2 on beads (Figure 6.11b). These results indicate that these
clones detect different epitopes and have an exclusive advantage over the other. Therefore,
we decided to use both antibody clones, 191924, for general ABC determination and
H2M5B to directly correlate the data from 4D5 CAR-T cells, such as the activation levels,
killing potency, and overall survival.
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6.3.2.1.6. Stability of HER2-loaded M280 beads

Figure 6.12: Effect of the quantity of biotinylated HER2 used to load M280 beads on the
(a) ability to detect bead by percentage and MFI (b) the density of HER2, and (c) the
stability of HER2 beads prepared in February 2020.

Activation levels of CAR-T cells depend on the number of antigens available to
them. Therefore, the number of HER2 molecules on M280 beads needs to be the same
when activation levels of HER2 CAR-T cells from two different time points are directly
compared to make any logical conclusion on the differences (if any) in the activation
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behavior. Hence, we decided to verify the stability of the beads in general by specifically
checking the variations in the ABC values of HER2-loaded M280 beads over time. For
this, we prepared M280 beads with three different loading weights of HER2 as they were
observed to yield different HER2 densities. First, we have shown here that the reaction
volume (in other words, the concentration of HER2 during the loading of M280 beads)
changes the HER2 density, although the quantity of HER2 during the reaction is the same
(Figure 6.12a,b). The diluted reaction had offered a different ABC value and different
HER2-positive percentage than the undiluted reaction. With three different ABC values,
we tested the changes in these ABC values over a period of nine months with three different
time points for measurements. The ABC values (# HER2/bead) of all the three differentdensity beads had reduced over time, with the most significant reduction occurring within
7 months of preparing the HER2-loaded M280 beads (Figure 6.12c). Therefore, we decided
to monitor the ABC values every month post-preparation and dispatch the HER2-loaded
M280 beads to our collaborator.
6.3.2.2.

HER2- and PD-L1-loaded M280 beads as aAPCs

Figure 6.13: Effect of the loading quantity of PD-L1 on the density of PD-L1 and
percentage detection of PD-L1+ beads. (a) ABC values on the left y-axis and PD-L1+ bead
percentage on the right y-axis, and (b) Histogram overlays in half-offset view.
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Loaded Sample

#PD-L1/Bead

2 % BSA

1,330

0.001 % PD-L1

3,512

0.005 % PD-L1

10,339

0.01 % PD-L1

18,836

0.025 % PD-L1

34,605

0.05 % PD-L1

42,334

0.075 % PD-L1

57,443

0.1 % PD-L1

61,281

0.2 % PD-L1

78,342

Table 6.2: Density of PD-L1 at different loading quantities. ABC values were measured by
staining with primary and secondary antibodies in FACS buffer.

To make the HER2- and PD-L1-loaded M280 beads, we first verified the effect of
loading quantity of biotinylated PD-L1 (hereafter just “PD-L1”) on the ABC values (#PDL1 per bead). We tested as low as 0.001 % to as high as 0.2 % of PD-L1 to load the beads.
First, it was clear that the ABC values increased with loading quantity (left y-axis in Figure
6.13, Table 6.2). Interestingly, we found that except 0.001, all other weight percentages
were able to offer the detection of a majority of PD-L1+ M280 beads (right y-axis in Figure
6.13a). Although the ABC value of 0.005 % loading condition is more than double the
0.001 % loading condition’s ABC value, the ability to detect PD-L1 on PD-L1-loaded
beads had tremendously increased with just a fivefold increase in the quantity of PD-L1
(right y-axis in Figure 6.13a).

209

Figure 6.14: Optimizing the loading of PD-L1 on 0.5 % HER2-loaded M280 beads by
weight percent analyzed in the flow cytometer. HER2 was detected using 191924
antibodies, and PD-L1 was detected by anti-hPDL1-mIgG1 (Atezolizumab biosimilar,
Invivogen). A FITC-conjugated anti-mouse antibody was used to detect both primary
mouse antibodies. Detection of (a) HER2 on 0.5 % HER2-coated M280 beads and PD-L1coated 0.5 % HER2-coated M280 beads. (b) PD-L1 on PD-L1-coated 0.5 % HER2-coated
M280 beads.
Next, we attempted to optimize PD-L1 coating density on 0.5 % HER2-loaded
M280 beads to generate an APC mimicking M280 beads with HER2 and PD-L1 on its
surface. Briefly, after coating the M280 beads with HER2, aliquots were made, and
variable quantities of PD-L1 were added and incubated to prepare HER2- and PD-L1coated beads. We estimated the HER2 and PD-L1 densities separately using their
respective antibodies 191924 and the atezolizumab biosimilar antibody (anti-hPDL1mIgG1, Invitrogen). We found that the ABC values on the HER2-/PD-L1-coated beads
fluctuated significantly compared to HER2-coated beads. In general, the ability to detect
HER2 on 1 % PD-L1 loading condition was lower compared to other conditions (Figure
6.14a). However, this trend was not observed in the detection of PD-L1. The density of
PD-L1 on HER2-/PD-L1-coated beads increased with PD-L1 loading quantity (Figure
6.14b). Although most PD-L1+ beads were detected at the lowest loading quantity of PD-
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L1, the density of PD-L1 in this condition was minimal. The 0.75 % PD-L1 loading
conditions seemed to have offered maximum PD-L1 coating on the beads (Figure 6.14b),
and therefore 1 % loading is not considered necessary for future investigations. Although
the 0.1 % loading condition gave the lowest PD-L1 density, it might be a significant
number of PD-L1 molecules to prevent the activation of CAR-T cells. Therefore, without
testing on CAR-T cells, the optimal density of PD-L1 cannot be confirmed. Nonetheless,
this approach of loading both antigens onto M280 beads appears to be a successful strategy
in generating aaAPC for CAR-T cells.
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6.4.

Conclusion
CAR-T cells are currently used in the T-cell-based immunotherapy of certain non-

Hodgkins lymphomas. The CAR-T technology has the potential to unlock treatment
options for many other cancers. However, modulating the CAR-T cell function is vital and
plays a significant role in the outcome of the treatment strategy. Using the patient’s
endogenous antigen-presenting cells (APCs) to activate CAR-T cells is complicated mainly
due to the maintenance issues and inconsistency in the activation levels. Therefore,
artificial APCs (aAPCs) have been suggested in which acellular aAPCs (aaAPCs) is
gaining much attention among the scientific community due to inexpensive reagents and
ease of manufacture & maintenance. In this study, we present a strategy to generate
aaAPCs in the form of HER2- and PD-L1 coated iron-oxide microparticles of size 2.8 M
(M280 beads). By simply regulating the amount of antigen during the antigen-loading of
the M280 beads, we can control the number of antigens present on the surface of the beads
and hence the activation level of anti-HER2 CAR-T cells. With a strategy to generate
different densities of antigens on M280-based aaAPCs, we can understand how the CART activations can be controlled. Most importantly, with these model particles mimicking
the cancer cells, we can standardize the dosage strategies of immune checkpoint inhibitors
to rescue the function of CAR-T cells in vitro and develop similar strategies to control the
in vivo functions in adoptive CAR-T therapy.
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SUMMARY
T cells are crucial immune cells. They can be subcategorized into T helper (Th) and
T cytotoxic (Tc) cells. While Th cells aid in the proliferation and recruitment of immune
cells, Tc cells mediates the death of infected or cancer cells. The activation of Th and Tc
cells is mediated by the T-cell receptor (TCR) recognition of the processed antigen
displayed on MHC class II and I respectively. Therefore, the effector functions of Th cells
depend on professional antigen-presenting cells (APCs) such as Dendritic cells (DCs), B
cells, and Macrophages, while those of the Tc cells depend on the antigen presentation by
all nucleated cells.
Infected or cancer cells often display their processed antigen on MHC-I. When Tc
cells recognize this antigenic peptide-MHC complex, they get activated and kill the target
cells. The ability of cancer cells to evade immunity by lowering the expression levels of
MHC-I and the ability of B cells to recognize an unprocessed antigen via the B-cell
receptors (BCRs), lead to the development of chimeric antigen receptors (CARs). CARs
comprise the antigen detection domains of a BCR and the signaling domains of a TCR. On
the other hand, sometimes the T cells cannot recognize the processed antigen even when
displayed on the MHC-I. In such cases, the TCR has to be endowed with the ability to
recognize a specific antigenic peptide. In adoptive T cell therapy, T cells from the patients
are isolated, tested for their ability to detect antigenic peptides, engineered if needed,
expanded in vitro, and finally infused into the patient. The expression of CAR or an
engineered TCR on T cells requires us to introduce the transgenes. Such gene delivery in
adoptive T cell therapy is currently being achieved by viral transductions. However, many
safety concerns arise from the use of viruses besides high manufacturing costs. Other
disadvantages include limitations in the size of the nucleic acids to package, high immune
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recognition, and immune clearance of the packaged viral particles. Therefore, the non-viral
vectors for transfections are currently being developed and used in research.
Although non-viral vectors such as polyethyleneimine (PEI) and poly(L-Lysine)
(PLL) are efficient carriers of nucleic acids, their transfection efficiencies are different for
different cell types. In some cell types, they are ineffective. In particular, T cells are known
for their intrinsic resistance to uptake foreign materials and thereby are classified as
difficult-to-transfect cells. Hence, developments in T cell transfections are much needed.
In this dissertation, we have reported the use of calcium chloride in the enhancement of
transfection efficiency of plasmid DNA (pDNA) in a model T cell line (Jurkat) using PEIpDNA complexes (polyplexes). In this study, the simple addition of calcium chloride to
the culture medium had enhanced the transgene expression to many folds. We showed that
calcium but not the chloride counter ions are increasing the associations of polyplexes and
Jurkat cells and thereby is enhancing the transfection efficiency. In this work, magnesium
a divalent cation similar to calcium did not enhance the transfection efficiency. However,
more divalent cations particularly the ones known to interact with the phosphates of DNA
must be tested to properly access whether the enhancing function is exclusive to calcium.
Developing an in vivo transfection reagent is difficult as multiple factors such as
off/on targetting, immune recognition and clearance, biocompatibility, cytotoxicity,
consistency are to be considered during the design. Importantly, to make the reagent
specific to T cells, the polyplexes need to be functionalized with a unique T cell ligand so
that a particular receptor can be targeted for transfections. We are interested in the
Interleukin-2 (IL-2) receptor (IL-2R)-mediated transfections as the expression of the IL2R is predominant in activated T cells and Tregs. As naïve T cells and other immune cells
have very low expression of the IL-2R, the in vivo formulations are supposed to have low
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off-targeting. To functionalize the polyplexes or any other foreign material in general, we
have designed an N-terminal Cysteine containing mouse IL-2 (C-IL2) for site-specific
bioconjugations in a sulfhydryl reaction. This is vital because site-specific bioconjugations
offer more consistent transfection efficiencies than does non-specific bioconjugation
techniques. In this dissertation, we report the production of C-IL2 from Escherichia coli
strain BL21 DE3 with the help of chaperone proteins. Our pymol and SDS-PAGE data
support the presence of an N-terminal Cysteine in C-IL2 readily accessible for site-specific
bioconjugations.
To fully comprehend the ability of the IL-2R to endocytose the transfection
formulation in T cells, we were determined to systematically study the cargo-size
limitations of the IL-2R for effective endocytosis in T cells. For this, we selected three
superparamagnetic iron-oxide nanoparticles (SPIONs) of sizes 50, 100, and 200 nm in
diameter. We utilized the C-terminal biotin containing IL-2 to coat the surface of the
streptavidin-conjugated SPIONs at varying densities of IL-2. In this dissertation, we report
that the IL-2R has an intrinsic core cargo size limit within 100 and 200 nm in diameter. In
other words, a cargo size with a hydrodynamic size of less than 341 nm can be effectively
(up to 15 %) endocytosed by activated T cells.
Using the same bioconjugation strategy, we attempted to functionalize the
polyplexes. After the characterization of the functionalized polyplexes using Dynamic
Light Scattering (DLS), we attempted to transfect the activated T cells. However, we could
not measure the significant expression of our model protein – Green fluorescent protein
(GFP). Our DLS data suggests that the polyplexes fall within the size limits of the IL-2R
and therefore we speculate that the reason for the failure in transfection is because of the
non-fruition of the processes downstream of the endocytosis such as the endosomal escape,
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disassembly of pDNA & PEI, and translocation to the nucleus. Besides, endolysosomal
degradation of pDNA is also possible. Hence, the future work could potentially and mainly
include the confirmation of polyplex internalization. If the endocytosis is proven
successful, attempts to understand and further the downstream processes are crucial.
Another factor to consider is the changes in the hydrodynamic size of the functionalized
polyplexes once suspended in the culture media. Any increase in the size beyond 341 nm
would significantly hamper the endocytosis.
Engineering the T cells is very important in the development of T cell therapeutics.
However, the maintenance of engineered T cells, their functional optimization, and potency
evaluation are crucial for developing a consistent therapeutic strategy. Due to the difficulty
and high costs in the maintenance of natural APCs, and the inconsistent activation profiles
of the engineered T cells offered by patients DCs, acellular artificial APCs (aaAPCs) are
being developed. aaAPCs are cheaper to produce and maintain in vitro. Besides, they can
offer consistent activation profiles of T cells besides providing an avenue to test the
potency of T cells by mimicking the tumor cells. In this dissertation, we developed
strategies to generate aaAPCs that resemble HER2-positive cancer cells. We report the
successful generation of HER2- and PD-L1- presenting aaAPCs by the use of the biotinstreptavidin

bioconjugation

technique

and

the

superparamagnetic

iron-oxide

microparticles of size 2.8 micron (M280). In this study, we generate varying densities of
HER2- and/or PD-L1- on M280 beads by simply controlling the amount of biotinylated
protein being supplied during the bioconjugation reactions. While the HER2 on aaAPCs
serves as the main antigen on HER2-positive cancer cells, PD-L1 serves as the ligand for
immune checkpoint protein receptor, PD1 on CAR-T cells. Together, the HER2-/ PD-L1-
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aaAPCs provide an artificial environment to test the potency and optimize the activation
levels of HER2-specific CAR-T cells.
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